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Abstract 
 
Urothelial cell carcinoma (UCC) of the bladder is a common malignancy worldwide, causing 
considerable morbidity and mortality.  It is unique among epithelial carcinomas in respect of 
the fact that it has divergent pathways of tumourigenesis.  Low-grade papillary tumours which 
frequently  recur,  but  seldom  convert  to  muscle  invasive  tumours  harbour  mutations  that 
activate the MAPK pathways, as a consequence of oncogenic mutations in FGFR3 or HRAS. 
However, in contrast, the high-grade muscle invasive tumours that readily metastasise have 
been shown to have defects in the p53 and retinoblastoma (RB) protein pathways  
Transgenic mice have allowed us to analyse the molecular basis of initiation, invasion and 
progression of many human cancers.  These mouse models increase our understanding of the 
disease process as well as providing targets for developing novel therapeutic approaches.  In 
UCC there has been a paucity of models that readily mimic the human disease.   
Although deregulation of the Wnt signalling pathway has been implicated in urothelial cell 
carcinoma (UCC), the functional significance is unknown. Recent studies have demonstrated 
the importance of this pathway in UCC progression, thus I endeavoured to test its importance 
both as a “driver” mutation, as well as a “progressor” mutation in more established UCC 
mutations. Thus I targeted expression of an activated form of β-catenin to the urothelium of 
transgenic mice using Cre-Lox technology.  Expression of this activated form of β-catenin led 
to the formation of localised hyperproliferative lesions by 3 months, which did not progress to 
malignancy.  Furthermore  expression  in  UroIICRE+  β-catenin
exon3/+  mice  showed  marked 
upregulation of the PTEN tumour suppressor protein that appears to be a direct consequence 
of activating Wnt signalling in the bladder.  I therefore combined PTEN deficiency with β-
catenin activation, which resulted in rapid formation of papillary UCC by 6 months. These 
tumours had increased pAKT signalling and were dependent on mTOR. Importantly in human 16 
 
UCC, there was a significant correlation between high levels of β-catenin and pAKT (and low 
levels of PTEN) (p<0.01, n=80).  Taken together, these data suggest that deregulated Wnt 
signalling plays a role in driving UCC, and human UCC that have high levels of Wnt and PI3 
kinase signalling may be responsive to mTOR inhibition. 
I next expressed oncogenic K-Ras or H-Ras in the urothelium alone, and in urothelial cells 
expressing  an  activated  β-catenin.  Although  Ras  activation  was  not  sufficient  to  drive 
tumourigenesis,  Ras  activation  combined  with  β-catenin  activation  in  UroIICRE
+  β-
catenin
exon3/exon3  K-Ras
G12D/+  and  UroIICRE
+  β-catenin
exon3/exon3  H-Ras
Q61L  mice  rapidly 
developed UCC. These tumours had upregulation of pERK1/2 with minimal levels of pAKT. 
Importantly in human UCC, there was a significant correlation between high levels of β-
catenin and pERK1/2 (p<0.01, n=80).  This data further supports the role of deregulated Wnt 
signalling and its co-operation with Ras in bladder carcinogenesis. 
I observed upregulated p21 expression in our UroIICRE+ β-catenin
exon3/+urothelial lesions 
and thus postulated that p21 may be acting as a block to tumourigenesis in the lesion. It was 
highly  relevant  to  observe  tumour  formation  in  the  double  mutant  UroIICRE+  β-
catenin
exon3/exon3 p21
-/- mice. 
FGFR3 gene is frequently mutated in superficial urothelial cell carcinoma (UCC).  To test the 
functional significance of FGFR3 mutations as a “driver” of UCC, expression of mutated 
Fgfr3  was  targeted  to  the  murine  urothelium  using  UroIICRE+  promoter.  These  FGFR3 
mutations (K644E and K644M) had no effect on bladder homeostasis or tumourigenesis up to 
18  months  of  ages.  Even  when  these  mutations  were  combined  with  β-Catenin  or  Ras 
activating mutations, no urothelial dysplasia/hyperplasia or UCC was observed. This suggests 
that other alterations are required that can cooperate with FGFR3 activation to cause UCC. 
Interestingly, however, due to sporadic ectopic Cre recombinase expression in the lung and 17 
 
skin  of  these  mice,  FGFR3  mutation  caused  skin  papilloma  and  promoted  lung 
tumourigenesis  in  cooperation  with  K-Ras  and  β-Catenin  activation,  respectively.  This 
confirmed that the mutant Fgfr3 was functional and that FGFR3 cooperates with other genetic 
events involving Ras and Wnt pathways to promote tumourigenesis in a context dependent 
manner and support the hypothesis that activation of FGFR signaling contributes to human 
cancer. 
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1. Introduction to Urothelial Cell Carcinoma 
1.1. Urothelial Cell Carcinoma Epidemiology 
 
Urothelial  cell  carcinoma  (UCC)  is  a  significant  health  problem  worldwide,  with  its 
prevalence continuing to rise.  In the U.K. it is the 4
th most common cancer in males, with 
7306 new cases in 2006. In comparison, there were only 2957 female cases, making it the 11
th 
most common female cancer. Worldwide there is an estimated 356600 new cases diagnosed 
yearly, and in terms of overall cancer frequency, it is ranked 9
th. (Cancer Research UK - 
http://info.cancerresearchuk.org/cancerstats/types/bladder/incidence/index.htm ). 
It is a relatively rare disease in under 50s, but the rates rise and peak in the oldest age group, 
where the male to female ratio becomes 3:1 (Figure 1.1). 
The highest incidence rates are found in industrially developed countries, particularly in the 
West, and in areas associated with endemic schistosomiasis such as Africa and the Middle 
East.  
Marked racial differences have been reported for bladder cancer incidence with higher rates in 
Caucasian populations (e.g. US rates in caucasians are double those for black men) (National 
Cancer Institute - http://seer.cancer.gov/csr/1975_2003/ ). 
Looking at the bladder cancer incidence rates over time, it is difficult to interpret because of 
changes  in  the  classification  of  muscle  invasive  disease  of  the  bladder.  In  spite  of  this 
difficulty Cancer Research UK have demonstrated that the age-standardised incidence rates 
per 100,000 population rose throughout the 1970s and 1980s to reach a peak of 32 in men and 
9 in women in the early 1990s and since then have fallen by around a third (Figure 1.2). This 
fall could be attributed to tighter regulation of occupational factors.  This trend will most 
probably continue since the passing of legislation banning cigarette smoking in public place, 
reducing active and passive smoking rates. 20 
 
 
 
 
Figure 1.1: Numbers of new cases and age-specific incidence rates, by sex, bladder 
cancer, UK 2006 
 (Source Cancer Research UK 
http://info.cancerresearchuk.org/cancerstats/types/bladder/incidence/index.htm)  
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Figure 1.2: Age standardised incidence rates, bladder cancer, by sex, UK, 1975-2006 
(Source Cancer Research UK 
http://info.cancerresearchuk.org/cancerstats/types/bladder/incidence/index.htm)  
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1.2 Pathophysiology of the Urothelium 
 
Urothelium, from which all UCC arise, is histologically a stratified and polarised epithelium 
(Khandelwal et al., 2009). It is composed of a single cell type, with differences in layers 
attributed to degrees of cellular differentiation.  It acts as a physiological and mechanical 
barrier between urine and blood. It acts to protect the underlying tissues from toxic urinary 
substances, as well as adjusting its surface area during bladder filling (Negrete et al., 1996). 
The  urothelium  is  extremely  stable,  with  cells  turning  over  very  slowly  (turnover  rate 
approximately every 200 days with a tritium-thymidine labelling index of less than 0.01%) 
(Hicks, 1975, Walker, 1960). 
Cells in the basal layer are the smallest in size and least differentiated. This is where the 
majority of proliferation occurs and where the stem cell niche may reside (Kurzrock et al., 
2008).    This  layer  is  the  only  urothelial  layer  to  express  appreciable  levels  of  epidermal 
growth factor (EGF) receptor, but this is protected from the high concentration of EGF in the 
urine due to the barrier afforded by the superficial urothelial layer (Messing, 1990, Messing, 
1992). Similarly, the basal (and presumed stem cells) are well protected from carcinogens, by 
a differentiated layer of intermediate cells (3-4 layers in humans, single in murine) (Wu et al., 
2009). 
The  superficial  urothelial  cells  facing  the  bladder  lumen,  also  called  umbrella  cells,  are 
distinctive large, terminally differentiated, polyhedral and bi-nucleated cells and are thought 
to be derived from intermediate cells through cell fusion (Koss, 1969). The umbrella cells 
contribute to form an asymmetrical membrane that lines over 95% of the luminal surface of 
the  urothelium.  Within  this  layer,  the  four  major  uroplakins  (Ia,  Ib,  II  and  IIIa),  luminal 
protein complexes restricted to the urothelium, are expressed (Wu et al., 2009).  23 
 
1.3. Classification of Urothelial Cell Carcinoma 
 
Clinical and pathological studies have found that development of UCC in humans arise from 
at  least  2  separate  mechanisms  (Wu,  2005,  Koss,  1992).  The  vast  majority  of  these  are 
transitional cell carcinomas (TCC). About 70% of the incidence is due to papillary, non-
invasive tumours (TaT1) (Table 1.1) that despite local excision tend to recur in over 30% of 
patients but progress to invasive disease in 10-20% of these cases (Knowles, 2001). In 2004, 
the  revised  classification  of  non-invasive  urothelial  tumours  was  proposed  by  the  World 
Health Organization (WHO) and the International Society of Urological Pathology (ISUP) 
(1998 WHO/ISUP classification) (Eble JN, 2004) (Table 1.1).  
Carcinoma in situ (CIS) is recognisable as flat, anaplastic epithelium. The urothelium lacks 
the  normal  cellular  polarity,  and  cells  contain  large,  irregular  hyperchromatic  nuclei  with 
prominent nucleoli. CIS may occur either close to or remote from an exophytic lesion or, 
rarely, it may occur as focal or diffuse lesions in a patient without macroscopic tumours. It 
has  a  variable  natural  history,  but  many  cases  progress  to  invasive  disease.  In  addition, 
exophytic lesions occurring with CIS are more likely to recur and invade than those without 
CIS.  The frequency of tumour invasion, recurrence, and progression is strongly correlated 
with tumour grade (Eble JN, 2004). 
 
 
 
 
 
 24 
 
 
 
 
 
 
 
Table 1.1: WHO grading in 1973 and in 2004 
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The majority of mortality is associated with patients with non-papillary, muscle invasive TCC 
(20-30% of all cases). These invasive tumours can penetrate deeply through the muscle wall 
of the bladder and 50% will relapse with metastases to distant sites despite radical therapy 
(Williams and Stein, 2004). Treatment fails in 95% of patients with advanced disease, and the 
5-year survival rate for metastatic bladder cancer is only 6% (Table 1.2 and Figure 1.3). 
 
 
Table 1.2: 2002 Tumour, Nodes, Metastases Classification (2002) 
The 2002 TNM classification has been approved by the Union Contre le Cancer (UICC) 
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Figure 1.3: T Staging of bladder cancer 
(Source Cancer Research UK 
http://info.cancerresearchuk.org/cancerstats/types/bladder/survival/index.htm )  
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1.4. Divergent Molecular Pathways of Urothelial Cell Carcinoma 
 
Both clinical and experimental evidence indicate that UCCs arise and progress along two 
distinctive pathways (Figure 1.4). The low-grade, superficial/papillary UCCs harbour frequent 
mutations in the HRAS gene (30–40%) and fibroblast growth factor receptor 3 (FGFR3) gene 
(~70%), indicating that RTK (Receptor Tyrosine Kinase)–Ras activation has an early and 
crucial role in this tumourigenesis pathway (Jebar et al., 2005). Deletions in the short arms of 
chromosomes 8 and 11 (8p– and 11p–) and long arms of chromosomes 13 and 14 (13q– and 
14q–) are often associated with the rare cases of progression to the muscle invasive stages of 
UCC (Wu, 2005).  
The high-grade muscle-invasive tumours can either originate from carcinoma in situ (CIS) or 
arise de novo. Over 50% of these tumours contain mutations in the tumour suppressors p53 
and/or the retinoblastoma protein (RB). Invasion and metastases are promoted by several 
factors that alter the tumour microenvironment, including the upregulation of N- cadherin (N-
Cad)  and  downregulation  of  E-cadherin  (E-cad),  matrix  metalloproteinases  (MMPs), 
angiogenic  factors  (e.g.  vascular  endothelial  growth  factor  (VEGF)),  and  antiangiogenic 
factors (e.g. thrombospondin 1 (TSP1)) and cyclooxygenase 2 (COX2) (Garcia del Muro et 
al., 2000, Shariat et al., 2001, Popov et al., 2000, Ribeiro-Filho et al., 2002, Zhang et al., 
2003, Rieger-Christ et al., 2004, Vihinen and Kahari, 2002, Kanayama, 2001, Izawa et al., 
2001, Slaton et al., 2001, Campbell et al., 1998, Grossfeld et al., 1997, Komhoff et al., 2000). 
Deletion  of  both  arms  of  chromosome  9  (9p–/9q–)  occurs  early  during  urothelial 
tumourigenesis in both tumour pathways (Chow et al., 2000, Obermann et al., 2003). Further 
elucidation of the genetic and epigenetic causes of the two distinctive pathways of UCC will 
have a great impact on the management of this disease condition. 
 28 
 
 
 
 
 
 
Figure 1.4: Important genetic and epigenetic defects that characterise the divergent 
pathways of UCC.   
Little work has been done on the PTEN and Wnt pathways in bladder cancer, thus their 
exclusion from this diagram.  
(Adapted from Wu, 2005) 
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Recent sequencing of human UCC by the Sanger institute in Cambridge has confirmed a 
number  of  these  mutations  are  indeed  present  in  human  UCC 
(http://www.sanger.ac.uk/perl/genetics/CGP/cosmic?action=byhist&ss=bladder&sn=urinary_t
ract&s=3) (Figure 1.5). 
  
 
 
 
Gene Name  Sample Number  Positive Samples  Percent Mutated 
FGFR3  3554  1668  47% 
CDKN2A  1241  189  15% 
HRAS  1166  135  12% 
PIK3CA  361  83  23% 
KRAS  470  19  4% 
Figure 1.5: Mutation profile of human UCC 
Unfortunately these sequenced tumours are a mixture of non-invasive and invasive UCC 
 
 
 
 30 
 
1.5. Risk Factors for Urothelial Cell Carcinoma  
1.5.1. Tobacco Smoking 
 
Tobacco smoking is the most well established risk factor for bladder cancer, causing about a 
half  of  male  cases  and  a  third  of  female  cases  (Brennan  et  al.,  2000).  The  carcinogenic 
contents  of  tobacco  smoke  include  arylamines  (particularly  4-aminobiphenyl),  polycyclic 
aromatic hydrocarbons (PAHs), N-nitroso compounds, heterocyclic amines and a variety of 
epoxides. The incidence of bladder cancer is related directly to the duration of smoking and 
number of cigarettes smoked per day (Brennan et al., 2000). There is also a higher risk of 
bladder  cancer  in  those  who  start  smoking  at  a  young  age  and  those  exposed  to  passive 
smoking during childhood (Bjerregaard et al., 2006). An immediate decrease in the risk of 
bladder cancer has been observed in those who quit smoking. This reduction was about 40% 
within 1-4 years of quitting smoking and reached 60% after 25 years of cessation (Brennan et 
al., 2000).  
 
1.5.2. Occupational Exposure to Chemicals 
 
Occupational  exposure  to  chemicals  is  the  second  most  important  risk  factor  for  bladder 
cancer. Work-related cases account for a quarter of all bladder cancer cases in several case 
series  (Pashos  et  al.,  2002,  Kogevinas  et  al.,  2003).  The  substances  implicated  include 
benzene derivatives and arylamines (2-naphthylamine, 4-ABP, 4, 4’-methylenedianiline and 
o-toluidine). At risk professions include those that use dyes, rubbers, textiles, paints, leathers 
and chemicals (Pashos et al., 2002). However due to the introduction of strict regulations in 
the West, these chemicals have had minimal contribution to the current incidence of bladder 
cancer. In fact, there has been a decrease in bladder cancer due to occupational exposure as 
reported in a pooled analysis of 11 European case control studies on bladder cancer conducted 
between 1976 and 1996 (Kogevinas et al., 2003). Another source of occupational exposure 31 
 
are the aromatic amines. A metabolic acetylation pathway can inactivate them and it had been 
hypothesised that patients with slow acetylation capability were more susceptible to bladder 
cancer  than  rapid  acetylators.    N-acetyltransferase  genes  1  and  2  (NAT1  and  NAT2)  are 
mapped to the short arm of human chromosome 8, are involved in amine inactivation. The 
presence of an NAT2 slow acetylation genotype has been related to a higher risk of bladder 
cancer (Garcia-Closas et al., 2005). Other risk factors include analgesic phenacetin. Some 
studies have suggested that the risk of bladder cancer due to phenacetin is dose-dependent; 
however,  the  data  is  controversial  concerning  its  metabolite  paracetamol  (acetaminophen) 
(Castelao et al., 2000). 
 
1.5.3. External beam radiation therapy 
 
Increased rates of “secondary” bladder carcinomas have been reported in the literature after 
external beam radiation therapy (EBRT) for gynaecological malignancies (Chrouser et al., 
2008, Chrouser et al., 2005). Similarly, in patients treated for prostate cancer by EBRT the 
rates of bladder malignancy were higher than those subjected to surgery alone (Boorjian et al., 
2007). 
 
1.5.4. Dietary factors 
 
To date, there is limited evidence of a causal relationship between bladder cancer and dietary 
factors. A meta-analysis of 38 articles reporting data on diet and bladder cancer supported the 
hypothesis  that  high  intake  of  vegetable  and  fruit  is  associated  with  reduced  the  risk  of 
bladder cancer (Steinmaus et al., 2000). 
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1.5.5. Chronic urinary tract infection 
 
Muscle-invasive squamous cell carcinoma (SCC) is directly related to the presence of chronic 
urinary  tract  infection.  Similarly  bladder  schistosomiasis  has  been  considered  a  definitive 
cause  of  urinary  bladder  cancer  with  an  associated  five-fold  risk.  Schistosomiasis  is  the 
second most common parasitic infection after malaria, with about 600 million people exposed 
to the infection in Africa, Asia, South America and the Caribbean (Johansson and Cohen, 
1997).  
Cyclophosphamide, an alkylating agent, has been correlated with development of posterior 
muscle-invasive  bladder  cancer  with  a  latency  period  of  6  to  13  years.  Acrolein  is  a 
metabolite of cyclophosphamide and is responsible for an increase in the incidence of bladder 
cancer and is independent of the occurrence of haemorrhagic cystitis related to the same 
treatment (Kaldor et al., 1995, Travis et al., 1995). 
 
1.5.6. Gender 
 
Differences  in  the  gender  prevalence  for  bladder  cancer  may  be  related  to  differences  in 
oestrogen and androgen levels between men and women (McGrath et al., 2006). 
Interestingly in radical cystectomy patients, it has been demonstrated that women are more 
likely to be diagnosed with primary muscle-invasive disease than men (85% vs. 51%) (Vaidya 
et al., 2001). It may be that women are likely to be older than men when diagnosed with a 
direct effect on their survival. This is however in direct contrast to Cancer Research UK 
figures (Section 1.1) where UCC is more prevalent in males. 
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1.6. Murine Models of Urothelial Cell Carcinoma 
 
Until very recently the murine models of UCC have been very limited.  One aim of this thesis 
is to create a better model of UCC.  Attempting to elucidate the molecular mechanisms behind 
UCC in cell lines/tissue culture is hampered by its artificial nature as well as the lack of 
stroma/microenvironment.  Murine  models  are  required  to  satisfy  our  desire  for  increased 
understanding of the molecular basis of UCC and to explore treatment regimes aimed to 
improve patient outcome. 
Although mice do not spontaneously develop bladder cancer, the murine models of human 
cancer have provided new tools for the investigation of bladder carcinogenesis.  In many other 
diseases murine models have provided invaluable information regarding pathogenesis and 
novel  disease  approaches  e.g.  cystic  fibrosis  (Guilbault  et  al.,  2007).    In  this  disease  the 
variety of models reflect that different aspects of the heterogenicity of phenotypes observed in 
humans; intestinal, pancreatic, hepatobilary and lung disease as well as ones reflecting the 
increased susceptibility to respiratory infections. 
In the past murine bladder cancer models included the orthotopic approach using primary or 
genetically  altered  cell  lines  derived  from  localised  and  metastatic  disease  and  chemical 
carcinogen techniques.  
 
1.6.1. Chemically induced carcinogenesis 
 
Spontaneous bladder cancers in mice (and rats) are very rare, thus intravesical installation of 
carcinogens  is  frequently  used.  The  most  commonly  used  carcinogens  are  N-butyl-N-(4-
hydroxybutyl)  nitrosamine  (BBN),  N-[4-(5-nitro-2-furyl)-2-thiazolyl]  formamide  (FANFT) 
and N-Methyl-N-nitosurea (MNU). They are used particularly for chemoprevention studies, 34 
 
although novel treatments can be tested and molecular mechanisms elucidated (Black and 
Dinney, 2007).   
BBN is the most widely studied of these agents, since the lesions closely resemble those 
found in human UCC. Recent work has attempted to profile the gene expression in these 
murine and rodent tumours and correlate them with human UCC (Williams et al., 2008).  
They  found  that  many  human  genes  homologous  to  those  differentially  expressed  in  the 
rodent  tumours  were  also  differentially  expressed  in  the  human  disease  and  were 
preferentially associated with progression from non-invasive to muscle invasive disease. They 
were predominantly cell cycle genes, as well as RAC GTPase-activating protein (RACGAP1) 
and N-myc downstream-regulated gene 2 (NDRG2).  Also interestingly they found that the 
overall gene expression profiles of rodent tumours corresponded more closely with those of 
muscle invasive tumours than the non-invasive ones. 
Advantages of chemically induced carcinogenesis include that these agents are specific to the 
urothelium, with 100% of mice developing carcinoma of the bladder. However the process of 
tumour induction takes 8-14 months and there are safety issues surrounding the exposure of 
lab/animal unit staff to carcinogens. 
 
1.6.2. Orthotopic Models 
 
There are two forms of orthotopic murine UCC (bladder) models utilised: 
1.  Orthotopic xenograft models (i.e. implantation of human bladder cancer cells into a 
nude mouse) 
2.  Orthotopic  syngeneic  models  (i.e.  implantation  of  murine  bladder  cancer  cells  in 
immunocompetent mice) 35 
 
1.6.1.1. Orthotopic xenograft models 
 
In  these  models  human  TCC  cells  are  implanted  into  the  immunodeficient  host  mouse. 
Several TCC cell lines have been used in this fashion including KU7, KU-19, T24 and UM-
UC3 cell lines. A major disadvantage of this technique is that the immune response, which is 
known  to  be  essential  to  allow  treatment  with  intravesical  agents  (that  is  agents  instilled 
directly into the bladder) such as Bacillus Calmette-Guerine (BCG) and mitomycin C cannot 
be assessed in these immuno-compromised mice. 
Dinney  and  colleagues  in  1995  established  the  first  reliable  orthotopic  model  of  bladder 
cancer by direct intravesical implantation of the human 253J TCC cells into the bladder of 
nude mice (Dinney et al., 1995). However many researchers continue to experiment with 
subcutaneous xenograft models, but as was demonstrated by Perrotte and colleagues results 
with ectopic tumour inoculation may not reflect what is found with orthotopic models. They 
used 253J-B-V cells and after 28 days of tumour growth found although tumour size was 
similar in the ectopic and orthotopic models, however only the orthotopic models developed 
metastasis to lymph nodes and lung. When these orthotopic models were analysed they found 
an  increase  in  microvessel  density  and  a  corresponding  increase  in  vascular  endothelial 
growth factor (VEGF) and fibroblast growth factor (FGF) expression and MMP-9 activity, 
demonstrating  the  importance  of  microenvironment  on  tumour  cells  and  their  ability  to 
metastasise. Again, however this is limited since the normal microenvironment of the murine 
bladder may not represent the normal (or indeed abnormal) microenvironment that is found in 
humans. In these studies single clones of tumours cells are used, when in reality human UCC 
is indeed a heterogenous condition. Multiple clonal subpopulations arise within the tumour, 
all of which have differential abilities to invade and metastasise as well as specific responses 
to treatments. 36 
 
Further refinements to these models have allowed tagging of these cell lines with either GFP 
or  luciferase  technologies  for  the  assessment  of  tumour  burden  and  ultimately  response 
(Tanaka et al., 2003, Hadaschik et al., 2007). 
 
1.6.1.2. Orthotopic syngeneic models 
 
In these syngenic models, bladder tumours are placed in mice of the same immune status from 
which the tumours cells were originally derived. The MB49 which contains a mutation in 
codon 12 of the K-Ras gene (from 7,12-dimethylenzanthacene-induced bladder tumour in 
C57BL/6 mouse) and MBT-2 which has lost p53 (from FANFT-induced bladder tumour in 
C3H/He mouse) cell lines are the most frequently used (Luo et al., 1999, Soloway, 1977, 
Summerhayes and Franks, 1979, Wada et al., 2001). 
One concern with this model (as in any orthotopic model) is that the ‘take’ rate of tumour 
implantation varies from as low as 30% up to 100% (Chan et al., 2009). Factors influencing 
tumour ‘take’ include tumourigenicity of tumour cells, number of cells implanted, duration 
implanted  for  and  pre-treatment  methods  (e.g.  traumatisation  of  urothelial  mucosa  before 
inoculation with cells) (Chan et al., 2009).  Furthermore multiple passages of these cells either 
in vitro or in vivo will result in numerous genetic events occurring in these cell lines. 
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1.7. Transgenic Models 
 
Transgenic murine bladder models have evolved into important tools for research into UCC, 
and  have  been  instrumental  in  elucidating  the  two  pathways  of  non-invasive  (superficial) 
papillary and muscle invasive bladder cancer (Wu, 2005). The mutations modelled in the 
mouse are those found in the human disease and have allowed researchers to further study the 
underlying molecular mechanisms. Such transgenic models allow researchers to study single 
and/or compound mutational events involving oncogenes and tumour suppressors in an organ 
specific temporal fashion. There are currently two approaches this can be achieved. 
Firstly, the traditional method has been a genome wide knock out of the gene in question 
(Capecchi, 1994).  The major problem is that it does not allow evaluation of the gene function 
if it results in embryonic lethality or premature death.  Also, since the gene is knocked out in 
all  cell  types,  it  is  difficult  to  prove  that  the  abnormal  phenotype  did  not  arise  from  a 
developmental defect (Copp, 1995).  Secondly one may use a conditional gene knock out 
technique that aims to overcome many of the above limitations.  The Cre-loxP recombination 
is  one  of  these  technologies,  which  allows  one  to  study  conditional  cell  type  and  tissue 
specific  deletion  of  genes  (Figure  1.5)  (Nagy,  2000).    The  bacterial  Cre-  (Cre:  Cause 
Recombination)  LOXP1  (locus  of  X-over  P1)  system  has  been  used  in  mammalian  cells 
(Sauer  and  Henderson,  1988).    This  system  relies  on  a  sequence  specific  DNA  cre 
recombinase  which mediates intramolecular recombination and deletion of DNA between 
loxP sequences. LoxP sequences are small sequences of DNA of 34 base pairs.  Using gene 
targeting  LoxP  flanked  alleles  have  been  generated,  allowing  deletion  of  genes  upon 
expression  of  cre  recombinase.    To  permit  gene  deletion  in  the  tissue  of  interest,  tissue 
specific Cre transgenes have been generated so that currently genes can be deleted in nearly 
every tissue of the mouse, including the bladder urothelium. 38 
 
In  addition  invasive  tumours  that  develop  metastasis  provide  an  excellent  platform  for 
investigating  specific  genetic  events  involved  in  the  metastatic  phenotype,  including  the 
contribution that stromal-epithelial interactions may have. 
Limitations  include  long  latency,  incomplete  penetrance  and  often  the  requirement  of  an 
artificial promoter (some models use knock-in endogenous alleles which mutate the allele in 
question, whilst others have overexpression of alleles to non-physiological levels).  Tumours 
developed in transgenic models tend to be less heterogeneous than in human bladder tumours, 
which may have an impact on tumour progression and distant spread. Given that no model has 
progressed  to  bone  metastases,  some  investigators  have  questioned  their  relevance  to  the 
human cancer. 
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Figure 1.6: The Cre-LoxP recombination system in transgenic mice 
The bacterial Cre- (Cre: Cause Recombination) LOXP1 (locus of X-over P1) system relies on 
a sequence specific DNA cre recombinase which mediates intramolecular recombination and 
deletion of DNA between loxP sequences. Using gene targeting LoxP flanked alleles have 
been generated, allowing deletion of genes upon expression of cre recombinase.  To permit 
gene deletion in the urothelium, urolthelial specific Cre transgenes have been generated. 
[Adapted from (Ahmad et al., 2008)] 
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1.7.1. Ras Pathway 
1.7.1.1. HRAS 
 
This was the first human oncogene isolated in human UCC, being mutated most often at 
either codon 12, 13 or 61 (Reddy et al., 1982). Mutation allows it to become constitutively 
active, as well as resulting in overexpression at the protein level (due to alternative splicing of 
the last intron). Despite the controversy regarding the reported mutation frequency rate recent 
studies indicate that HRAS mutation occurs in approximately in 30-40% of UCC (Bentley et 
al., 2009, Czerniak et al., 1992). 
Transgenic  models  have  provided  invaluable  information  regarding  the  molecular 
mechanisms behind H-RAS activation with much of this work largely being carried out by the 
Wu lab (Department of Urology, New York University School of Medicine) (Wu, 2005).  
They have utilised the mouse uroplakin II (UPII) promoter, which is expressed in the basal 
layer of the urothelium, within which the stem cell niche resides (Lin et al., 1995). In the first 
instance they targeted expression of a constitutively active rabbit H-Ras
Q61L to the urothelium 
using this promoter (Zhang et al., 2001).  Their rabbit H-Ras
Q61L mutant had been previously 
shown to share all the functional characteristics of codon 12 and 13 mutants and to be fully 
capable of transforming culture NIH 3T3 cells (Zhang et al., 2001). 
This induced early onset urothelial hyperplasia, with this hyperplasia progressing to low-
grade non-invasive papillary tumours. Interestingly tumour latency depended on transgene 
number. In the mice that had 1 or 2 copies of the rabbit H-Ras
Q61L transgene (low-copy), the 
tumour latency was almost 12 months. Histologically by 3-5 months the urothelial layer has 
become hyperplastic (from the usual 3 layers to 6-7 layers).  At 8 months the urothelium 
becomes more hyperplastic, forming areas of nodular hyperplasia.  From 10-26 months of age 
63% of mice developed superficial non-invasive UCC.  These lesions remained non-invasive 41 
 
during the 26-month follow-up period.  In contrast mice harbouring “high-copy” numbers of 
the HRAS
Q61L RAS transgene (30-48 copies) succumbed to death by 5 months of age. The 
mice  had  evidence  of  significantly  enlarged  bladder  and  associated  bladder  outflow 
obstruction (hydronephrosis and hydroureter). Again these tumours were of a papillary non-
invasive histology, with no evidence of muscle invasion or metastases.  
This fits with the human literature in which the Ras oncogene is shown to be frequently 
overexpressed. Quantification of the transcripts in paired tumour and adjacent normal tissue 
identified  a  40%  overexpression  of  H-RAS  (Vageli  et  al.,  1996).  Others  have  found 
overexpression of HRAS at the protein level in more than 50% of bladder tumours (Dunn et 
al., 1988, Ye et al., 1993). The fact that the bladder tumours in “low-copy” mice developed 
localised, superficial papillary tumours with a much longer latency, suggests, in the absence 
of overexpression, H-Ras, activation requires a secondary event, either genetic or epigenetic, 
to  fully  induce  bladder  tumours.  These  mice  have  been  instrumental  in  showing  the  Ras 
pathway activation is sufficient to lead to UCC along the low-grade/non-invasive papillary 
tumourigenesis  pathway.  They  have  also  suggested  that  these  results  indicate  urothelial 
hyperplasia may be an important precursor of papillary UCC. 
Subsequently the Wu group found upregulation of the senescent markers Ink4a/Arf in the 
mutant “low copy” HRAS urothelium, without histological evidence of senescence (Mo et al., 
2007).  Surprisingly, when the Ink4a/Arf locus in these mice was genetically knocked out, 
there was no evidence of acceleration of urothelial tumourigenesis. 
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1.7.2. Receptor Tyrosine Kinases 
1.7.2.1. Epidermal Growth Factor Receptor (EGFr) 
 
Epidermal growth factor receptor is overexpressed in 40-60% of human UCC at the mRNA 
and  protein  levels  (Neal  and  Mellon,  1992).  In  addition  EGFr  overexpression  has  been 
implicated in invasive UCC.  In chemical carcinogen models EGF significantly increased the 
frequency of heterotopically transplanted bladder tumours in rats (Fujimoto et al., 1996). 
The  Wu  lab  targeted  expression  of  functionally  active  EGFr  (demonstrated  auto-
phosphorylation  and  downstream  MAPK  activation)  to  the  urothelium  using  the  UPII 
promoter (Cheng et al., 2002).  The bladders developed hyperplasia, but did not progress to 
tumour. When combined with activated HRAS transgene there was no synergism in urothelial 
tumourigenesis, again strengthening the redundancy argument since they are both in the same 
signal  transduction  cascade.  Interestingly  they  found  that  EGFr  could  potentiate  with  the 
SV40 mouse (Simian virus 40, a polyomavirus that interacts SV40 Large T-antigen and SV40 
Small T-antigen, leading to defects in RB and p53) to accelerate CIS conversion into high 
grade UCC. 
 
1.7.2.2. Fibroblast Growth Factor Receptor 3 (FGFR3) 
 
In  urothelial  tumours,  over  70%  of  low-grade/non-invasive  papillary  tumours  exhibit 
mutations in FGFR3. However only 10-20% of invasive bladder tumours harbour mutations 
in this same locus, leading researchers to postulate that FGFR3 activation is one of the major 
genetic events that lead to low-grade/non-invasive papillary tumours (van Rhijn et al., 2004, 
van Rhijn et al., 2001).  Almost all the mutations have been identified as missense mutations.  
They  most  frequently  involve  the  receptor’s  extracellular  loop  and  affect  the  cysteine 
residues: either eliminating or creating a cysteine (Wu, 2005). This results in cysteine mis-43 
 
pairing, conformational change/misfolding and the failure of the mutated FGFR3 to exit the 
endoplasmic  reticulum.    Additionally  some  FGFR3  mutations  are  capable  of  undergoing 
ligand-independent activation, which lead to autophosphorylation of the intracellular kinase 
domain (Bakkar et al., 2003, Billerey et al., 2001). These mutated receptors exhibit increased 
stability and decreased translocation to the lysosomal degradative pathways (Cho et al., 2004, 
Monsonego-Ornan et al., 2000).  All these factors result in increased and prolonged activation 
of the receptor. 
As indicated earlier HRAS and FGFR3 mutations occur in up to 30% and 70% of clinical 
non-invasive UCC respectively, suggesting that the RTK-Ras pathway is responsible for these 
types  of  tumours.  Recent  studies  by  the  Knowles  lab  (University  of  Leeds)  suggest  that 
HRAS and FGFR3 mutations are unlikely to co-exist in the same tumours (Jebar et al., 2005). 
This  fits  with  data  from  other  tumours  types  such  as  malignant  melanoma,  in  which 
components from the same signaling pathway are rarely mutated simultaneously (NRAS and 
BRAF in melanoma), presumably since this offers no selective advantage to the tumour cells 
(Takata and Saida, 2006) (Figure 1.6). 
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Figure 1.7: Signalling cascades involved in UCC during FGFR3 and HRAS activation 
FGFR3  and  HRAS  gene  mutation  are  thought  to  share  the  same  downstream  signalling 
pathway.  FGFR3 consists of 3 extracellular (EC) immunoglobulin-like domains (IgI–III), a 
transmembrane  domain  (TM),  and  a  cytoplasmic  (CP)  tyrosine  kinase  domain  (TK1  and 
TK2). Mutations that affect the loop that connects the IgII and IgIII domains account for up to 
50-80% of all mutations, whereas those affecting the TM domain account for up to 15-40% 
and those affecting TK2 account for 5–10%. Loop and TM mutations often create a novel 
cysteine  and  might  be  responsible  for  receptor  dimerization  (*C–C*)  and 
autophosphorylation.  
FGFR3 phosphorylation triggers several signalling cascades, the most predominant of which 
is  the  Mitogen  Activated  Protein  Kinase  (MAPK)  pathway.    Phosphorylated  FGFR3  can 
activate the phosphatidylinositol 3-kinase (PI3K) and AKT pathway.  Lastly, the activated 
FGFR3 can directly or indirectly (through Janus-family kinases (JAKs)) trigger the signal 45 
 
transducer and activator of transcription (STAT) pathway. The activated FGFR3 can also 
interact  directly  with  proline-rich  tyrosine  kinase  2  (PYK2),  leading  to  STAT  pathway 
activation (Cappellen et al., 1999, Rieger-Christ et al., 2003, van Rhijn et al., 2004, Bakkar et 
al., 2003, van Rhijn et al., 2001, Billerey et al., 2001).  
Mutational activation of HRAS can trigger similar signalling pathways. 
(Adapted from Wu, 2005) 
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1.7.2.3. Sprouty (SPRY) 
 
SPRY proteins comprises of a family of well-conserved regulators of RTKs.  SPRY was 
originally  identified  in  Drosophila  as  an  antagonist  of  fibroblast  growth  factor  (FGF) 
mediated signalling (Hacohen et al., 1998).  Amongst the four mammalian SPRY orthologues 
(SPRY1-4), SPRY2 is the closest to Drosophila SPRY (dSPRY) and extensively studied as a 
RTK modulator.  SPRY2 has been shown to interact with a number of RTK downstream 
signalling components such as Grb2, Raf1, Shp2, c-Cbl and GAP1 (Kim and Bar-Sagi, 2004).  
As a consequence, SPRY2 can regulate both the intensity and duration of RTK mediated 
signalling.  The dSPRY can inhibit both FGF and epidermal growth factor (EGF) mediated 
signalling (Kramer et al., 1999).  However, SPRY2 has been shown to inhibit only FGF 
mediated signalling.  Interestingly, recent evidence indicate that SPRY2 exerts its negative 
and  positive  regulatory  roles  on  EGF  mediated  signalling  in  a  distinctive  manner  by 
interfering the trafficking and degradation of epidermal growth factor receptor (EGFR) (Kim 
and Bar-Sagi, 2004, Rubin et al., 2003, Fong et al., 2003). 
Using  Oncomine
TM  (http://www.oncomine.org/geneModule/differential/filterStore.jsp) 
Lindgren and colleagues have demonstrated that in FGFR3 mutant bladder cancer there is a 
downregulation of Sprouty 2 at the mRNA level (p=0.015) (Lindgren et al., 2006). In the 
same study they find that Sprouty2 mRNA levels are downregulated as the disease progresses 
from Grade 1 to 3 (p=0.015).  
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1.7.3. PTEN-PI3K-pAKT 
1.7.3.1. PTEN 
 
The phosphatase and tensin homology (PTEN), located on human chromosome 10, is a lipid 
phosphatase that dephosphorylates phosphoinositide-3,4,5-triphosphate (PI3P). As a result of 
this dephosphorylation, this 55-kDa protein antagonises the activity of PI3 kinase (PI3K), 
preventing it from activating downstream proliferation and survival signals, especially pAKT, 
leading to growth inhibition (Dahia, 2000). 
The PTEN/pAKT pathway has also been implicated in invasive UCC. Evidence suggests that 
restoration of PTEN function induces growth arrest in bladder cancer cell lines deficient in 
PTEN (Tanaka et al., 2000), and inhibition of PI3K may decrease the invasive potential of 
bladder tumours (Wu et al., 2004). 
Also deletion at the PTEN locus (3p, 5q, 10q) is rare in non-invasive, but occur frequently in 
invasive UCC (Puzio-Kuter et al., 2009). The reduction or loss of PTEN protein expression 
was observed in 42% of non-invasive and 94% of advanced UCC. This reduction in PTEN 
correlated with stage and grade (Tsuruta et al., 2006). 
Unfortunately the transgenic models that exist for Pten null mice have been inconsistent, 
possibly due to use of different Pten alleles and promoters, as well as differences in the 
background strains of the mice. 
Yoo and colleagues deleted exon 4-5 of the Pten gene using the Fabp-Cre system (which 
directs recombination in all the cell layers of the urothelium by embryonic day 16.5, as well 
as the intestinal epithelium) and were able to demonstrate urothelial hyperplasia and eventual 
UCC by 13.5 months of age (Yoo et al., 2006). 48 
 
Using a similar model, PTEN null mice (Fabp-Cre Pten
fl/fl) also developed non-invasive UCC 
in 10% of cases, after a long latency (>40 weeks) (Tsuruta et al., 2006).  The long latency and 
low tumour rate could be because of the slow proliferation rate of the urothelium and/or the 
requirement of secondary genetic events for urothelial carcinogenesis. 
More recently Qian and colleagues investigated the role of PTEN in UCC. In their Pten null 
mice (in this mouse exons 4-5 is flanked by the loxP sequences), using the Ksp-Cre promoter 
(expressed in renal tubules, collecting ducts and ureteric bud) they found renal pelvis UCC in 
57% of mice at 12 months (Qian et al., 2009). Interestingly they found upregulation of p-
mTOR in their tumours, suggesting a role for inhibitors of the pathway (i.e. rapamycin) as 
therapeutic agents. 
Surprisingly, another Pten
fl/fl bladder model did not have any urological phenotype when aged 
to  12  months  following  intravesical  administration  of  the  AdenoCre  (Puzio-Kuter  et  al., 
2009).   
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1.7.4. p53 
 
p53 is a nuclear phosphoprotein that acts as a key gatekeeper at the G1/S checkpoint of cell 
cycle  progression,  integral  in  controlling  urothelial  cell  growth  and  maintaining  genomic 
stability (Levine, 1997).  Mutation and deletion of the p53 tumour suppressor gene are among 
the most common genetic changes found in human UCC (Wu, 2005). Usually one allele is 
mutated and thus non-functional whilst the other is often deleted, suggesting that p53 is non 
functional in human UCC.  Consistent with these findings, p21 (also known as WAF), an 
important downstream target of p53, is downregulated in the majority of UCCs that harbour 
p53 loss/mutation (Lu et al., 2002, Stein et al., 1998).  Similar to the p53 data, loss of p21 
expression is also associated with disease progression (Stein et al., 1998). 
p53  abnormalities  are  much  more  prevalent  in  invasive  UCC  (>50%)  and  precursor  CIS 
lesions  when  compared  to  the  in  non-invasive  phenotype  (Cordon-Cardo  et  al.,  1994, 
Hartmann et al., 2002, Wagner et al., 1995, Spruck et al., 1994, Orntoft and Wolf, 1998). This 
suggests  that  p53  loss/mutation  may  be  responsible  for  the  formation  and  progression  of 
invasive UCC. 
The commonest site of p53 mutation was found in exon 5 and 8 (George et al., 2007).  90% of 
samples  with  exon  5  mutations  and  a  substantial  proportion  of  tumours  with  the  exon  8 
mutation demonstrate no nuclear p53 accumulation, suggesting loss of the protein and non-
functionality  of  the  mutation.    The  majority  of  these  were  point  mutations  G:C  to  C:G 
transversions.  Another study found p53 point mutations predominately in codons 280 (Arg to 
Thr) and 285.  These mutations are rare in other epithelial tumours, leading to speculation 
about the role of urothelial specific carcinogens (Feng et al., 2002, Berggren et al., 2001). 
Interestingly the association between smoking and UCC did not differ substantially between 
cases with and without p53 mutations, it was however more strongly associated with CpG 50 
 
G:C-A:T transitions than with other types of mutations (Spruck et al., 1993, Schroeder et al., 
2003).  Patients with p53 mutations have a far higher risk of disease progression and death 
than those without (George et al., 2007, Hartmann et al., 2002, Masters et al., 2003, Cordon-
Cardo, 1998).  
Nuclear accumulation of p53 (a sign of mutation) is significantly associated with a greater 
risk of UCC and decreased overall survival in patients with organ confined disease (Esrig et 
al., 1994).  Their multivariate analysis stratified according to grade, pathological stage and 
lymph node status demonstrated that nuclear p53 accumulation was an independent predictor 
of recurrence free and overall survival (p<0.001) (Esrig et al., 1994).  This is consistent with 
the theory that with models that promote progression of organ confined UCC have abnormal 
nuclear p53 function. 
However,  a  meta-analysis  based  on  43  studies  comprising  3764  patients  with  UCC 
demonstrated  considerable  variation  in  clinical  outcome,  different  immunohistochemistry 
protocols, patient selection and study design (Schmitz-Drager et al., 2000). 
Murine studies of UCC using the Trp53-knockout have been unsatisfactory since these mice 
develop fatal soft tissue sarcomas and thymic lymphomas by 7 months of age, at which stage 
the urothelium is still normal (Donehower et al., 1992). The heterozygous Trp53-knockout 
mice (which live longer) do not develop any urothelial abnormalities. 
Interestingly a mouse with dominant negative mutation of p53 (lacks DNA binding domain 
but  retains  the  tetramerization  domain)  targeted  to  the  urothelium  using  the  uroplakin 
promoter  develops  urothelial  hyperplasia  and  dysplasia  without  progression  to  frank 
carcinoma (Gao et al., 2004). Wu and colleagues studied the expression of activated H-Ras 
(again using the UPII promoter) in the absence of p53 (Gao et al., 2004).  They found absence 
of p53 accelerated the formation of the activated H-Ras induced high-grade UCC. However 51 
 
they were unable to prove that these tumours became invasive since the Trp53 null mice died 
of lymphomas by 7 months of age. 
When they repeated the experiment with p53 heterozygous mice they found this acceleration 
was negated and the mouse phenocopied the activated H-Ras mutant.  
Using  an  adenovirus  expressing  Cre  recombinase  delivered  directly  into  the  bladder, 
simultaneous p53 and Pten deletion (p53
fl/fl Pten
fl/fl) resulted in bladder tumours with 100% 
penetrance at 6 months, with metastasis to local lymph nodes and distant sites, including 
spleen, liver and diaphragm (60% by 4-6 months).  (Puzio-Kuter et al., 2009). The histology 
of these tumours closely resembled that of CIS and invasive tumours found in humans. 
Puzio-Kuter found that their p53
fl/fl Pten
fl/fl mice had highly upregulated p-mTOR, and when 
rapamycin was given to these mice tumour regression occurred (Puzio-Kuter et al., 2009, 
Seager  et  al.,  2009).  Interestingly  when  given  to  mice  at  the  CIS  stage,  the  rapamycin 
abrogated the progression to frank invasive tumourigenesis. 
Currently there are no murine studies looking at the effect of mutant p53 in the formation of 
UCC. 
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1.7.5. p21
 WAF/CIP1   
 
The cyclin-dependent kinase inhibitor p21
WAF/CIP1 (p21) was originally discovered as a key 
target of the p53 tumour suppressor gene following DNA damage. Induction of p21 by p53 
induced cell cycle arrest by a block in  G1 (Deng et al., 1995).  p21 has been shown to be 
induced in a p53 independent fashion, such as through oxidative stress, cytokines, tumour 
viruses and anti-cancer agents (Abbas and Dutta, 2009).  p21 is also implicated in protection 
from  p53-dependent  and  independent  apoptosis  (Weiss,  2003,  Gartel  and  Radhakrishnan, 
2005), and its overexpression was  sufficient to drive tumour cells into senescence (Fang et 
al.,  1999).  Moreover,  studies  have  shown  that  p21  is  key  in  the  induction  of  senescence 
following treatment with ant-cancer agents (Chang et al., 1999). 
p21 is downregulated in the majority of urothelial carcinomas that have p53 loss/mutation (Lu 
et al., 2002, Stein et al., 1998).  Similar to the literature on p53, loss of p21 expression is also 
associated  with  a  higher  recurrence  rate  and  lower  survival  rate  than  those  tumours  with 
maintained p21 expression levels, irrespective of tumour grade and pathological stage (Stein 
et al., 1998).  It was also noted that maintenance of p21 expression appeared to negate the 
effects of p53 alterations on UCC progression (Stein et al., 1998). 
Similarly,  Shariat  et  al  demonstrated  that  positive  p21  expression  was  independently 
associated with reduced UCC recurrence and progression in CIS (with no muscle-invasive 
disease), possibly by p53-independent modulation of p21 (Shariat et al., 2003).   
Although  no  models  of  p21  deletion  in  the  urothelium  have  been  published,  Yoo  and 
colleagues observed upregulation of p21 expression in the urothelium in their PTEN null 
mouse using the urothelial specific Fabp-Cre (Yoo et al., 2006).  In the urothelium of the 53 
 
newborn  mice,  cell  proliferation  is  initially  high,  but  within  days  is  inhibited  by  p21 
induction, suggesting a bladder specific compensatory mechanism. 
 
1.7.6. Retinoblastoma (RB) 
 
Recently it has been noticed that patients with germline mutations of RB1 have a higher risk 
of  developing  epithelial  carcinoma,  particularly  UCC  (Fletcher  et  al.,  2004).    Loss  of 
heterozygosity (LOH) of RB1 is also prevalent in invasive UCC (Cairns et al., 1991).  Either 
there is a lack of RB expression, or overexpression of a hyper-phosphorylated version of the 
protein  (Chatterjee  et  al.,  2004,  Logothetis  et  al.,  1992).  In  these  scenarios  RB  is 
dysfunctional and cannot inhibit E2F family of transcription factors, leading to an increase in 
cell  proliferation.  Transgenic  mice  with  RB1  ablated  in  all  tissues  die  embryonically 
(Donehower et al., 1992). 
Mutation of both p53 and RB occur in >50% of invasive UCC, with patients having increased 
rate  of  recurrence/progression  and  worse  overall  survival  than  patients  with  single  gene 
mutations (Grossman et al., 1998).  Fitting with this, mice with targeted urothelial expression 
of the simian virus 40 (SV40) large T-antigen, which inactivates both p53 and RB together, 
develop CIS and subsequent invasive tumours (Zhang et al., 1999, Grippo and Sandgren, 
2000).    Interestingly  the  CIS  evolved  to  high-grade  papillary  UCC  before  progressing  to 
muscle invasive disease.  Whether this is particular to the mouse has yet to be elucidated. 
Recently the Wu lab demonstrated that urothelial specific deletion of both copies of RB (UPII 
Cre)  failed  to  accelerate  urothelial  proliferation  (He  et  al.,  2009).  Instead  it  activated  a 
‘failsafe’  signature  by  profoundly  activating  the  p53  pathway  and  leading  to  apoptosis. 
Deletion of p53 in these RB null urothelial cells may therefore remove the tumourigenesis 
barrier.  However this resulted in nuclear atypia and only 2% of mice progressed to non-54 
 
invasive  papillary  tumours.    Interestingly,  mice  deficient  in  both  RB  and  p53  become 
extremely sensitive to chemically induced carcinogenesis (0.01% BBN for 10 weeks) and 
50% developed invasive UCC similar to the human condition. 
This suggests that loss of both p53 and RB is necessary, but insufficient to initiate UCC along 
the invasive pathway (Figure 1.7). It is presumed that other genetic alterations are required to 
trigger invasive UCC. 
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Figure 1.8: Collaborative effects between pRb family proteins and p53 in invasive UCC 
a) Ablation of pRb specifically in urothelium leads to E2F1 over-expression that in turn up-
regulates the p53 pathway and pRb family member p107 along with transcriptional repressor 
E2F4. These compensatory urothelial defences cause urothelial cells to undergo cell-cycle 
arrest and apoptosis. 
b) Additional ablation of p53 in urothelial cells lacking pRb effectively blunted apoptotic 
response, resulting in late-onset hyperplasia and nuclear atypia.  
c)  Treatment  of  urothelial  cells  lacking  both  pRb  and  p53  with  bladder  carcinogen  BBN 
down-regulates p107 and triggers invasive urothelial tumourigenesis. This model emphasizes 
the collaborative effects among pRb family proteins and p53 in invasive urothelial tumour 
initiation. (Adapted from He et al., 2009) 
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1.8 The Wnt signalling pathway 
 
The  Wnt  pathway  is  widely  conserved  throughout  many  species  including  C.elegans, 
Drosophila,  Xenopus  and  mammals.  The  Wnt  pathway  was  originally  discovered  in 
Drosophila  where  the  gene  wingless  (wg)  demonstrated  the  ability  to  influence  segment 
polarity during larval development (Nussleinvolhard and Wieschaus, 1980). Murine studies 
identified  a  gene  called  Wnt1  (originally  named  Int-1)  which  was  shown  to  be  a  proto-
oncogene in breast tumours induced by the mouse mammary tumour virus (MMTV) (Nusse 
and Varmus, 1982). Further studies went on to show that wingless (wg) was a fly homologue 
of the mouse Wnt1 gene (Rijsewijk et al., 1987). Thus the name Wnt, a compromise of wg, 
from the Drosophilia wingless gene and Int, the mouse homologue.  
The Wnt pathway is now known to control many events during embryonic development, and 
regulates homeostatic self-renewal in a number of adult tissues. As a result, mutations in this 
pathway are associated with the onset of various cancers, due to the influence of the Wnt 
pathway has on processes such as proliferation, motility and cell fate at the cellular level 
(Oving and Clevers, 2002, Polakis, 2000b). Wnt ligands are glycoproteins which interact with 
a  seven-transmembrane  frizzled  cell  surface  receptor,  leading  to  Wnt  pathway  activation. 
Three different pathways are believed to be activated upon receptor activation (the Wnt/Ca
2+ 
pathway, the non-canonical planar cell polarity pathway and the canonical pathway) (Clevers, 
2006).   
In  the  planar  cell  polarity  pathway  Wnt  signalling  through  frizzled  receptors  mediates 
asymmetric cytoskeletal organisation and the polarization of cells by inducing modifications 
to  the  actin  cytoskeleton.  Two  independent  pathways,  which  are  initiated  by  dishevelled, 
trigger the activation of the small GTPases Rho and Rac. Activation of Rho requires Daam-1 
and leads in turn to the activation of the Rho-associated kinase ROCK.  Rac activation is 57 
 
independent of Daam-1 and stimulates JNK activity (Huelsken and Behrens, 2002, Habas and 
Dawid, 2005).  
Wnt signalling via frizzled receptors can also lead to the release of intracellular calcium. 
Frizzled co-receptors, involved in this pathway include Knypek and Ror2. Other intracellular 
second  messengers  associated  with  this  pathway  include  heterotrimeric  G-proteins, 
phospholipase  C  (PLC)  and  protein  kinase  C  (PKC).  The  exact  genes  activated  by  the 
Wnt/Ca
2+ pathway are unknown, but NFAT appears to be involved, which is a transcription 
factor regulated by the calcium/calmodulin-dependent protein phosphatase, calcineurin. The 
Wnt/Ca
2+  pathway  is  important  for  cell  adhesion  and  cell  movements  during  gastrulation 
(Habas and Dawid, 2005, Kohn and Moon, 2005). 
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1.8.1. The Canonical Wnt Signalling Pathway  
 
The  canonical  Wnt  pathway  is  a  ligand  dependent  system  whereby  Wnt  proteins  bind  to 
frizzled  and  LPR  family  member  receptors  at  the  cell  surface.  This  in  turn  activates 
dishevelled family proteins and ultimately results in an increase in the amount of β-catenin 
that reaches the nucleus (Figure 1.8) (Reya and Clevers, 2005). Consequently β-catenin now 
complexes with TCF/LEF resulting in the transcriptional activation of Wnt target genes. In 
the presence of a Wnt ligand, Frizzled (Fz) proteins cooperate with a single pass transembrane 
molecule  called  LRP6  to  bind  the  ligand.  Upon  this  binding,  the  scaffold  protein  axin 
translocates to the membrane where it interacts with the intracellular tail of LRP5.  This 
results in the disassociation of the destruction complex comprising axin, GSK3β (glycogen 
synthase kinase), CK1 (casein kinase), Apc, and β-catenin (reviewed in Reya and Clevers, 
2005 and Clevers, 2006). Also, by an unknown mechanism, the binding of Wnt to Frizzled 
results  in  the  hyperphosphorylation  of  Dishevelled  (Dsh),  which  inhibits  the  activity  of  
GSK3β making it  unable to phosphorylate β-catenin (Mao et al., 2001, Yanagawa et al., 
1995).  In its unphosphorylated state, β-catenin is now not recognized by the F-box β-TRCP 
protein, a component of the E3 ubiquitin ligase and therefore is not degraded. Subsequently, 
β-catenin  is  now  free  to  translocate  to  the  nucleus,  where  it  binds  to  the  N  terminus  of 
LEF/TCF (lymphoid enhancer factor/T cell factor), and activates transcription of a number of 
Wnt target genes (Behrens et al., 1996, Molenaar et al., 1996, vandeWetering et al., 1997, 
Polakis, 2000b), including c-Myc (He et al., 1998), CD44 (Wielenga et al., 1999),  TCF-1 
(Roose et al., 1999), LEF-1 (Hovanes et al., 2001).  
Therefore,  during  inappropriate  Wnt  activation,  (caused  by  Apc/β-catenin  mutations), 
activation of key Wnt target genes such as c-Myc lead to uncontrolled bursts in proliferation. 
This once again, serves to highlight the important role that Apc plays as a key ‘gate keeper’ in 59 
 
controlling cell proliferation, particularly in the formation of colorectal cancer (Kinzler and 
Vogelstein, 1996).  
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Figure 1.9: Canonical Wnt Signaling 
a) In the absence of a WNT signal, the level of free intracellular β-catenin is minimised by 
sending  it  for  degradation  in  the  proteasome.  Free  cytoplasmic  β-catenin,  which  is  in 
equilibrium  with  β-catenin  at  adherens  junctions,  is  recruited  to  a  'destruction  complex' 
containing  APC,  axin/conductin  and  glycogen  synthase  kinase  3β  (GSK3β).  GSK3β 
phosphorylates β-catenin, allowing it to be recognized by an SCF complex containing the F-
box  protein  β-TrCP.  Other  proteins  in  the  SCF  complex  catalyse  the  addition  of  a 
polyubiquitin chain to β-catenin, allowing β-catenin to be recognized and degraded by the 
proteasome. Consequently, β-catenin cannot reach the nucleus, and cannot co-activate TCF-
responsive  genes.  Groucho,  a  corepressor,  also  prevents  the  activation  of  TCF/LEF-
responsive genes in the absence of β-catenin.  
b) In the presence of WNT, its receptor, Frizzled, in complex with LRP6, is activated. This 
leads to a poorly understood signalling cascade in which Dishevelled activates GBP — an 
inhibitor of GSK3β. Consequently, β-catenin cannot be targeted for destruction and is free to 
diffuse  into  the  nucleus,  where  it  acts  as  a  co-activator  for  TCF/LEF-responsive  genes.  
[Adapted from (Fodde et al., 2001)] 61 
 
1.8.2. The Role of Wnt Signalling in Cancer 
 
Germline mutations of the APC gene cause Familial adenomatous polypopsis (FAP).  This is 
an autosomal dominant disease that affects approximately 1/7000 people and is characterised 
by the development of hundreds of colorectal adenomas, often arising by the second decade of 
life (Kinzler and Vogelstein, 1996).  As the patient ages, a small proportion of adenomas 
progress  to  carcinomas,  with  100%  of  FAP  patients  developing  colorectal  cancer  by  the 
average age of forty years (Sancho et al., 2004). FAP patients can also develop other intestinal 
lesions including gastric fundic gland polyposis, duodenal adenomas, and gastric, pancreatic, 
bilary or distal small intestinal lesions. At much lower frequencies, FAP patients can also 
develop lesions out with the GI tract such as desmoids of the skin, retinal lesions, osteomas 
and brain tumours (Kinzler and Vogelstein, 1996).  
It  has  also  been  discovered  that  mutations  in  APC  occur  in  the  majority  of  all  sporadic 
colorectal tumours (Miyoshi et al., 1992, Powell et al., 1992). Given the high frequency of 
mutations in the APC gene, it has been proposed that APC acts as a key ‘gatekeeper’ gene of 
colonic homeostatsis, importantly controlling colonic epithelial cell proliferation. Therefore a 
mutation in this ‘gatekeeper’ gene results in uncontrolled cellular renewal and proliferation 
(Kinzler and Vogelstein, 1996). Although it is now widely accepted that mutations in APC 
initiate  the  neoplastic  process,  it  is  also  known  that  a  sequential  series  of  mutations  are 
necessary for tumour progression, 
The  Apc
Min+  (Multiple  Intestinal  Neoplasia)  mouse  was  the  first  murine  model  to 
phenotypically  recapitulate  FAP  (Moser  et  al.,  1990).  The  mice  demonstrated  signs  of 
anaemia  and  were  moribund  by  120  days.  Upon  necroscopy,  multiple  adenomas  were 
observed in the small intestine, which occasionally progressed to adenocarcinomas in older 
mice.  Each  mouse  presented  with  on  average  30  intestinal  adenomas,  hence  the  name 62 
 
Multiple  Intestinal  Neoplasia  (Moser  et  al.,  1990).  The  mutation  in  these  adenomas  was 
mapped to codon 850 of the murine homologue of the Apc protein, and was  similar to those 
observed  in  FAP  patients  (Su  et  al.,  1992).  Similar  to  FAP  patients  this  mutation  was 
characterised as a fully penetrant autosomal dominant disorder (Moser et al., 1990).  Despite 
similar  germline  mutations,  FAP  patients  predominantly  have  colorectal  adenomas  which 
routinely progress to invasive adenocarcinoms, in contrast to the small intestinal adenomas 
observed in the Apc
Min+ mouse.  This is possibly due to the fact that Apc
Min+ mice present with 
a high tumour burden, and as a consequence mice need to be sacrificed before tumours are 
able to progress to adenocarcinomas.  
Outwith colorectal cancer, mutations in the APC gene are much rarer.  In cancer such as 
hepatocellular  carcinoma  (HCC)  Wnt  pathway  activation  is  observed  through  β-catenin 
activating mutations or loss of negative regulators such as Axin or Axin2 (Satoh et al., 2000, 
Giles et al., 2003). Similarly activating/stabilising mutations of β-catenin have been observed 
in  melanoma,  ovarian  carcinomas,  childhood  hepatoblastomas  and  medulloblastomas, 
desmoid tumours and non-ductal solid pancreatic tumours (Giles et al., 2003). Interestingly in 
these cancers activating mutations of the Wnt pathways are not thought to be intitating event.  
Zhou et al proposed a role for Wnt signalling in renal carcinoma, since the key renal tumour 
suppressor protein (Von Hippal Lindal) VHL, acts through JADE, an E3 ubiquitin ligase to 
target β-catenin for degradation (Zhou et al., 2005). Therefore,  a mutation in VHL results in 
the stabilisation and activation of the oncogenic β-catenin pathway (Behrens, 2008). This link 
between the pathways explains why FAP patients, with a germline mutation of Apc rarely 
present with renal cell carcinoma, but mice with a renal specific deletion of Apc develop 
cancer similar to those wtih VHL mutations (Sansom et al., 2005). In addition, the promoter 
of the Apc gene is hypermethylated in up to 30% of renal carcinomas (Dulaimi et al., 2004), 63 
 
suggesting  Apc  loss/reduction  may  play  an  important  role  in  the  progression  of  renal 
carcinoma.  Indeed  using  the  AhCre  transgene  which  yields  sporadic  constitutive  Cre 
expression within all cell lineages of the kidney, only 1/3 of mice develop renal carcinoma, 
despite showing the presence of small premalignant lesions from 2 months of age (Sansom et 
al., 2005).  This suggests that Apc loss can predispose to renal carcinoma but Apc gene loss 
alone  is  a  very  poor  iniating  event.    In  contrast  deletion  of  Apc  within  the  intestinal 
epithelium rapidly leads to a marked ‘crypt-progenitor cell-like’ phenotype (Sansom et al., 
2004) and moreover, deletion of Apc within the LGR5
+ stem cell zones leads to adenoma 
formation in as little as 2 weeks, suggesting the importance of the cells that are targeted 
(Barker et al., 2009).  
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1.8.3. The Role of Wnt Signalling in Human UCC 
 
Germline  and  somatic  mutations  of  APC  are  found  in  the  majority  of  colorectal  cancers 
(Kinzler et al., 1991, Cottrell et al., 1992, Rubinfeld et al., 1993). However, in the case of 
bladder  carcinoma,  controversy  surrounds  the  occurrence  of  somatic  mutations  in  key 
components of the pathway; APC (Miyamoto et al., 1996, Bohm et al., 1997, Stoehr et al., 
2002, Urakami et al., 2006a) and β-catenin (Burger et al., 2008, Shiina et al., 2002, Shiina et 
al., 2001).  Miyamoto and colleagues found LOH of the APC locus in only 1 of 16 (6%) of 
UCCs (Miyamoto et al., 1996).  However another study reported LOH for the APC locus in 
50% of the 30 tumours (Bohm et al., 1997).  In a larger study Stoehr and colleagues found 
LOH in 10% of 72 tumours, but no APC mutations in 22 tumours and 4 cell lines, apart from 
a common SNP at codon 1493.  All of these studies, however included both non-invasive and 
invasive tumours, and utilised them as a single entity.  Recent human UCC sequencing by the 
Sanger institute in Cambridge has revealed APC mutation in 11 out of 93 (12%) samples 
(http://www.sanger.ac.uk/perl/genetics/CGP/cosmic?action=bycancer&ln=APC&sn=urinary_
tract&ss=bladder).  
Many of these studies have demonstrated immunohistochemical upregulation of β-catenin, the 
key protein in this pathway (Kashibuchi et al., 2006, Nakopoulou et al., 2000, Shimazui et al., 
1996,  Zhu  et  al.,  2000,  Garcia  et  al.,  2000).    Urakami  and  colleagues  showed  that  CpG 
hypermethylation  of  Wnt  inhibitory  factor-1  (Wif-1)  was  a  frequent  event  in  bladder 
tumourigenesis (Urakami et al., 2006b).  Most recently Kastritis and colleagues demonstrated 
APC missense (13%) and frameshift (3%) deletions adjacent to the β-catenin binding sites in 
bladder  tumours  (Kastritis  et  al.,  2009).    They  found  either  APC  mutations  or  β-catenin 
accumulation resulted in shorter disease free interval, and a shorter disease specific survival in 
multivariate analysis.  Similarly, epigenetic silencing of the four secreted frizzled receptor 65 
 
proteins (SFRP), antagonists of the Wnt signalling pathway, has been demonstrated as an 
independent predictor of invasive bladder cancer (Marsit et al., 2005).  In a cohort of 355 
patients, a linear relationship between the magnitude of the risk of invasive disease and the 
number of SFRP genes methylated was observed (p<0.0004) with a subsequent reduction in 
overall survival (p<0.0003). Therefore these studies suggest a key role of deregulation of Wnt 
signalling in bladder cancer, a finding that I tested in this thesis. 
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1.9. KEGG Pathway of UCC 
KEGG (Kyoto Encyclopaedia for Genes and Genome) is a bioinformatics resource that has 
been developed to attempt to link the common genetic mutations and pathways occurring in 
human cancer including UCC.  The pathways for UCC are reproduced below: 
 
Figure 1.10: KEGG Pathway of UCC 
(http://www.genome.jp/kegg/pathway/hsa/hsa05219.html) 
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1.10. Research in Progress and Outstanding Research Questions 
 
The  currently  available  models  have  provided  researchers  with  a  wealth  of  information 
regarding  potential  molecular  mechanisms  and  pathways  involved  in  bladder  cancer.  
However,  many  limitations  still  exist.    No  model  as  yet  demonstrated  metastasis  to  the 
skeletal  system.    A  transgenic  mouse  that  demonstrates  these  would  be  invaluable  in 
preclinical therapeutic models.  Why spontaneous osseous lesions have not been achieved 
remains to be elucidated, but may be due to a variety of reasons including the murine platform 
representing fundamental pathophysiological differences (e.g. pelvic venous drainage), the 
inability to accurately detect the metastasis or whether the genetic defects I created in our 
current models are not sufficient to initiate bone metastasis.   
As I have described there are a paucity of publications regarding therapeutic trials in murine 
models.    As  further  novel  genes  and  markers  are  identified  in  the  human  bladder 
carcinogenesis, it is essential that we base our murine models on these findings.  Newer 
models  will  mimic  human  bladder  tumourigenesis  more  closely  and  will  offer  attractive 
platforms for trials of novel agents. 
The  in  vivo  imaging  of  tumours  has  revolutionised  the  way  researchers  now  manipulate 
murine models of cancer.  The technology will allow one to follow disease progression as 
well  as  the  effects  of  therapeutic  interventions  in  a  model  system  comparable  to  that  of 
humans (Weissleder, 2002).  The two most widely available imaging modalities currently are 
bioluminescent enzyme firefly luciferase and green fluorescent protein (GFP).  GFP provides 
the benefit that one can directly monitor cells down to the single cell level, whilst luciferase 
only allows one to view derived pseudo-layered images.  GFP allow does not require injection 
of  a  substrate.    Despite  this  luciferase  is  much  more  sensitive  and  allows  one  to 
simultaneously monitor multiple mice (whereas GFP requires multiple excitation sources for 68 
 
multiple mice) (Massoud and Gambhir, 2003, Choy et al., 2003). One of the most applied 
techniques uses bioluminescent imaging to noninvasively monitor the growth of luciferase-
expressing  carcinoma  cells  in  vivo.  In  this  thesis  I  plan  to  utilise  both  ultrasound  and 
fluorescence based imaging techniques to image bladder tumours and assess their response to 
treatment. 
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1.11. Thesis Aims 
 
•  To investigate whether Wnt signaling is sufficient to drive tumourigenesis within the 
bladder urothelium 
 
•  To investigate the role of Wnt signaling within the bladder urothelium as a progressor 
mutation of UCC in the background of mutations to other key oncogenic/tumour 
suppressors (PTEN, Ras, p21, FGFR3) 
 
•  To utilise the above transgenic mice to develop better models of UCC 
 
 
Figure 1.11: Outline of research 
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Chapter 2:  Material and Methods 
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2.0. Material and Methods 
2.1. Statement of Contribution 
•  Choosing  which  mice  were  to  be  mated  to  give  genotypes  required  (animal  staff 
physically set up matings, carried out weanings and tail tippings) 
•  Tumour surveillance of mice (3 x weekly) 
•  Drug treatment of all mice 
•  Harvesting of organs 
•  Imaging of organs via US and OV100 
•  All immunohistochemistry 
•  All counting/scoring (double scored with Lukram Babloo Singh LBS) 
•  Extracting DNA and carrying out all PCR reactions at least once for each genotype 
(using published protocols for each mouse strain).  When reaction was confirmed as 
working, gel product sent to Transnetyx, Inc
TM (TN, USA) to allow them to sequence 
product  and  develop  qPCR  based  genotyping  assay  to  outsource  any  subsequent 
genotyping. 
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2.2. Generation of Mice colonies 
 
Mouse Experiments: All experiments were performed under the UK Home Office guidelines 
(project license 60/3947, personal license 60/11372). All mice were of a mixed background 
(derived predominantly from FVB/N [H-Ras
Q61L, Fgfr3 K644E, Fgfr3 K644M] and C57BL/6 
[Apc
fl/+, β-catenin 
exon3/+, GSK3αβ
fl/fl, K-Ras
G12D/+, p21
-/+, Pten
fl/+ and Z/EGFP] strains) mice) 
and  littermates  were  used  as  control  mice.  All  mice  were  maintained  under  non-barrier 
conditions and given a standard diet (Harlan) and water ad libitum.  The Biological services 
department at the Beatson Institute provided animal husbandry including setting up matings, 
weaning pups, and tail tipping for genotyping. 
The following cre were used: Uroplakin II (UroIICRE
+) (Zhang et al., 1999) and AhCreER
T 
mice (Kemp et al., 2004). 
They were intercrossed with the following alleles in this thesis: Apc
fl/+ (Shibata et al., 1997), 
β-catenin
exon3/+ (Harada et al., 1999), Fgfr3 K644E and Fgfr3 K644M (Iwata et al., 2000, 
Iwata et al., 2001), GSK3αβ
fl/fl (Patel et al., 2008, MacAulay et al., 2007), the rabbit H-Ras
Q61L 
transgene (Zhang et al., 2001), K-Ras 
G12D/+ (Jackson et al., 2001), p21
-/+ (Deng et al., 1995), 
Pten
fl/+ (Lesche et al., 2002) and the Z/EGFP allele (Novak et al., 2000) (Table 2.1). 
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Transgene  Description  Reference 
UroIICRE+  Uroplakin II is a protein expressed throughout the 
urothelial layers in mice. The 3.6-kb 5’-upstream 
sequence of mouse Uroplakin II promoter has 
been reported to successfully drive the expression 
of proteins including SV40 large T antigen and H-
Ras.  Previous studies (as well as ours) have 
shown that the UroIICRE
+ mice exhibit bladder 
specific recombination. 
(Zhang et al., 1999) 
Ah CreER
T  This is the cytochrome p450 inducible AhCreER
T 
transgene. Following administration of both β-
napthoflavone and tamoxifen, this yields cre-
mediated recombination within the urothelium of 
the bladder (as well as the intestine and liver). 
(Kemp et al., 2004) 
Apc
fl/+  loxP sites have been inserted into the introns 
around Apc exon 14, inducing a frameshift 
mutation at codon 580, resulting in the mutant 
allele (Apc 
580S) being introduced in a Cre specific 
manner. 
(Shibata et al., 1997) 
β-catenin
exon3/+  In this transgene the β-catenin gene has its exon3 
flanked by loxP sequences. On addition of Cre 
recombinase, exon3 is deleted. As this exon 
contains the residues that are phosphorylated by 
GSK3β, leading to β-catenin degradation, β-
catenin will therefore accumulate to drive Wnt 
signalling. 
(Harada et al., 1999) 
Fgfr3 K644E 
and K644M 
Both lines carry a neomycin resistant gene (neo) 
flanked by loxP sites in the intron approximate to 
the exon with the K644 mutations. This neo 
insertion is known to suppress the expression of 
Fgfr3 mutant allele in the absence of Cre 
recombination. In the presence of Cre, the neo 
gene is excised allowing expression of the mutant 
Fgfr3 protein, with a pattern and protein 
expression level similar to those of the age 
matched wildtype 
(Iwata et al., 2000, 
Iwata et al., 2001) 
GSK3αβ
fl/fl  GSK3α
fl/fl were generated with loxP sites flanking 
exon2 (by homologous recombination).  Cre 
recombination results in a loss of the protein. 
GSK3β
fl/fl were generated with loxP sites flanking 
exon2 (by homologous recombination).  Cre 
recombination results in transcription of a non-
functional protein form of GSK3β. 
 
(Patel et al., 2008, 
MacAulay et al., 2007) 74 
 
H-Ras
Q61L  Constitutively active rabbit H-Ras
Q61L mutant had 
been previously shown to share all the functional 
characteristics of codon 12 and 13 mutants and to 
be fully capable of transforming culture NIH 3T3 
cells.  Transgene drive by UPII promoter. Low 
copy number (2 copies) used in this thesis 
(Zhang et al., 2001) 
K-Ras 
G12D/+  A Lox–Stop–Lox K-Ras conditional mouse strain, 
in which expression of oncogenic K-Ras is 
controlled by a removable transcriptional 
termination Stop element.  The endogenous K-Ras 
locus is targeted in the LSL- K-Ras G12D strain 
and, therefore, endogenous levels of oncogenic K-
Ras G12D protein are expressed following 
removal of the Stop element.  
(Jackson et al., 2001) 
p21
-/+  This targeting construct p21
neo was used to delete 
exon 2 of the p21
CIP1/WAP1 gene. This exon 
encodes about 90% of coding sequence of the 
p21
CIP1/WAP1 protein, and Cre recombination 
results in loss of the protein. 
(Deng et al., 1995) 
Pten
fl/+  Conditional inactivatable Pten allele (where exon 
5 is flanked by loxP sites).  This encodes for the 
phosphatase domain of PTEN in which many 
tumor-associated mutations have been detected. 
(Lesche et al., 2002) 
Z/EGFP  The Z/EGFP transgene results in the expression of 
β-galactosidase by most tissues via a β-geo insert, 
which is flanked by loxP sites.  The presence of 
Cre recombinase results in the excision of the β-
geo, activating the constitutive expression of GFP. 
(Novak et al., 2000) 
 
Table 2.1: Description of transgenes used in this thesis 
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2.2.1. Mouse experiments for Chapter 3 (β-Catenin activation synergises with PTEN loss 
to cause bladder cancer formation) 
 
To achieve urothelial specific expression of activated β-catenin and PTEN loss, these mice 
were interbred with mice carrying the uroplakin II (UroIICRE+) Cre transgene to generate the 
following  cohorts  UroIICRE
+  β-catenin
+/+,  UroIICRE
+  β-catenin
exon3/+  and  UroIICRE
+  β-
catenin
exon3/exon3, UroIICRE
+ Pten
fl/+, UroIICRE
+ Pten
fl/fl, UroIICRE
+ β-catenin
exon3/+ Pten
fl/+, 
UroIICRE
+ β-catenin
exon3/exon3 Pten
fl/+, UroIICRE
+ β-catenin
exon3/exon3 Pten
fl/fl, β-catenin
exon3/+ 
Pten
fl/fl and UroIICRE
+ β-catenin
exon3/+ Pten
fl/+.  
I  also  bred  the  AhCreER
T  mice  to  Apc
fl/fl,  Pten
fl/fl  and  GSK3αβ
fl/fl  mice  to  generate  the 
following cohorts AhCreER
T Apc
fl/fl, AhCreER
T Apc 
fl/fl Pten
fl/fl and AhCreER
T GSK3αβ
fl/fl. 
For Cre induction, AhCreER
T mice were given 3 injections intra-peritoneally (IP) of 80mg/kg 
β-napthoflavone  and  Tamoxifen  in  a  single  day,  which  yields  nearly  100%  constitutive 
recombination in the murine small intestine (Marsh et al., 2008).  
Approximately a quarter of each cohort were also bred with the Z/EGFP allele (Novak et al., 
2000). This is a double reporter mouse line that expressed enhanced GFP upon Cre-mediated 
recombination. 
Tumourigenic cohorts (n>20 for each genotype) were aged, and examined three times a week 
by myself for signs of urinary tract disease. These included blood in the urine, hunching, and 
swollen kidneys; which was investigated through scruffing the mouse and gently feeling for 
an enlarged kidney, renal pelvis or urinary bladder that was indicative of a tumour.  This was 
the  criterion  for  sacrifice  of  the  animal.    Metastatic  disease  was  assessed  both  at  a 
macroscopic levels in organs (lung, liver, spleen, diaphragm and local lymph nodes) and at a 
microscopic level by looking at multiple sections through the organ of interest. 
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2.2.2. Mouse experiments for Chapter 4 (β-Catenin activation synergises with Ras 
activation to cause bladder cancer formation) 
 
Uroplakin II Cre mouse (UroIICRE
+) mice were intercrossed with mice harbouring Z/EGFP, 
β-catenin 
exon3/+,  K-Ras 
G12D/+,  the  H-Ras
Q61L  transgene  and  p21
-/-  in  the  following 
combinations UroIICRE
+K-Ras
G12D/+, H-Ras
Q61L, UroIICRE
+ β-catenin
exon3/exon3 K-Ras
G12D/+, 
UroIICRE
+ β-catenin
exon3/exon3 H-Ras
Q61L, UroIICRE
+ p21
-/- and UroIICRE
+ β-catenin
exon3/exon3 
p21
-/-. 
Approximately a quarter of mice from each cohort were also bred with the Z/EGFP allele 
carrying mice.   
Mice were assessed as per 2.2.1. 
 
2.2.3. Mouse experiments for Chapter 5 (The FGFR3 mutation cooperates with K-Ras 
and β-catenin mutations to promote skin and lung but not bladder tumour formation) 
 
UroIICre
+ mice were bred to lines carrying Fgfr3 K644E, Fgfr3 K644M, K-Ras 
G12D/+ and β-
catenin 
exon3/+  to  generate  the  following  cohorts  UroIICre
+Fgfr3
+/K644E  and 
UroIICre
+Fgfr3
+/K644M  UroIICre
+Fgfr3
+/K644EK-Ras
G12D/+  and  UroIICre
+Fgfr3
+/K644Eβ-
catenin
exon3/+. 
Approximately a quarter of mice from each cohort were also bred with the Z/EGFP allele 
carrying mice. 
Mice were assessed as per 2.2.1.  
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2.3. Tissue isolation 
 
For the analysis of urothelial cell carcinoma (UCC) cohorts, at the appropriate time, mice 
were culled and both kidneys, ureters and the urinary bladder were removed and fixed in 4% 
formalin, overnight at 4
oC for no more than 24 hours before processing and were then paraffin 
embedded. For senescence associated β-galactosidase staining, urinary bladder and kidney 
were placed on a cork disk and covered in OCT fixative before being submerged into liquid 
nitrogen.  
When  urinary  bladders  were  excised  they  were  all  emptied  of  urine.  All  bladders  were 
processed and cut in the same manner by a single histology technician (Mr. Colin Nixon) to 
aid standardisation. 
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2.4. Genotyping of mice 
 
When  I  started  at  the  Beatson,  genotyping  was  carried  out  in-house  by  the  Genotyping 
facility.  In 2009 this was outsourced to Transnetyx
TM (TN, USA) who genotype based on real 
time PCR techniques. 
  
2.4.1. DNA Extraction from tails 
 
DNA  was  extracted  from  tails  using  the  Purgene  DNA  Extraction  kit.    Tails  were  lysed 
overnight  in  500µl  of  cell  lysis  solution  (Puregene)  and  10µl  of  proteinase  K  (20mg/ml, 
Sigma), shaken at 37ºC.   Tails were then left to cool at room temperature; 200µl of protein 
precipitation  solution  (Puregene)  was  added  to  each  tube.    These  were  vortexed  and 
centrifuged at top speed for 5 minutes in a microfuge. 
The supernatant was removed into a clean tube containing 500µl of isopropanol, vortexed and 
centrifuged at top speed for 5 minutes.   The supernatant was poured off and the DNA pellet 
was  left  to  dry  overnight.    DNA  was  resuspended  in  500µl  DNA  hydration  solution 
(Puregene). 
 
2.4.2. Genotyping of Mice via PCR 
 
Initially all genotyping of mice was done by genomic PCR (Polymerase Chain Reaction) from 
DNA extracted from tails (2.2.1) by the in-house genotyping facility.  All PCR were done in 
50µl volumes using 2.5µl of the tail DNA preparation.  The groups that created the mice 
developed these protocols. 
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Apc
fl PCR Protocol 
PCR mix 
              µl 
5x Colorless GoTaq Flexi Buffer*    10 
MgCl2  (25mM)        5 
dNTPs   (10mM)        0.4 
Primer   (100µM)        0.2 (of each) 
Go Taq*            0.2 
H2O to final volume of 47.5 µl 
*GoTaq Flexi DNA Polymerase from Promega.  
 
Primers 
APC F = 5’ GTT  CTG TAT CAT GGA AAG ATA GGT GGT C 3’ 
APC R = 5’ CAC TCA AAA CGC TTT TGA GGG TTG 3’ 
 
PCR Program: 95°C, 3min (95°C, 30s; 60°C, 30s; 72°C 1min) 30 72°C, 5min. 4°C, hold. 
PCR products were run on a 2% gel. 
Bands  FLOX = 314bp 
WT = 226bp  
 
 
Figure 2.1: Apc
fl PCR 
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β-catenin
exon3 PCR Protocol 
PCR mix 
              µl 
5x Colorless GoTaq Flexi Buffer*    10 
MgCl2  (25mM)        5 
dNTPs   (10mM)        0.4 
Primer   (100µM)        0.2 (of each) 
Go Taq*            0.2 
H2O to final volume of 47.5 µl 
*GoTaq Flexi DNA Polymerase from Promega.  
 
Primers  
β-catenin act F = 5’ CTG CGT GGA CAA TGG CTA CT 3’ 
β-catenin act R = 5’ TCC ATC AGG TCA GCT GTA AAA A 3’ 
 
PCR Program: 94°C, 2.5min (94°C, 30s; 60°C, 30s; 72°C 1min) 34 72°C, 10min. 4°C, hold. 
Products run on a 2% gel 
Bands  WT = 324bp 
Dominant stable = ~500bp 
 
Figure 2.2: β-catenin
exon3 PCR 
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Cre PCR Protocol 
PCR mix 
              µl 
5x Colorless GoTaq Flexi Buffer*    10 
MgCl2  (25mM)        5 
dNTPs   (10mM)        0.4 
Primer   (100µM)        0.2 (of each) 
Go Taq*            0.2 
H2O to final volume of 47.5 µl 
*GoTaq Flexi DNA Polymerase from Promega.  
 
Primers 
CRE F = 5’ TGA CCG TAC ACC AAA ATT TG 3’ 
CRE R = 5’ ATT GCC CCT GTT TCA CTA TC 3’ 
 
PCR Program: 95°C, 3min (95°C, 30s; 55°C, 30s; 72°C 1min) 30,72°C, 5min. 15°C, hold. 
Bands  CRE = 1000bp 
 
Figure 2.3: Cre
 PCR 
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Fgfr3 K644 Protocol  
PCR Mix 
        µl 
Buffer      5 
MgCl2  (50mM)  2.5 
dNTPs   (10mM)  0.4 
Primer   (100µM)  0.1 (of each) 
Platinum Taq    0.2 
H2O to final volume of  47.5 
 
Primers 
F = 5’ GGG TGA TGC TTT GCC TGA GC 3’   
R = 5’ TTC AGA TCT CCC TAC CCC CAT 3’ 
 
PCR Program: 94°C, 3min (94°C, 1min; 60°C, 1min; 72°C 1min) 30, 72°C, 7min. 15°C, hold. 
PCR product was digested with BbsI 
Bands  WT = Double band of ~120bp  
+/K644 = Two bands of ~120bp and 350bp 
K644/K644 =Band of 350bp only 
 
Figure 2.4: Fgfr3 K644
 PCR 
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GSK3α PCR Protocol 
PCR Mix 
        µl 
Buffer      10 
MgCl2  (50mM)  5 
dNTPs   (10mM)  0.4 
Primer   (100µM)  0.2 (of each) 
Go Taq      0.2 
H2O to final volume of  47.5 
 
Primers 
GSK3α F = 5’ CCC CCA CCA AGT GAT TTC ACT GCT A 3’  
GSK3α R = 5’ AAC ATG AAA TTC CGG GCT CCA ACT CTA T 3’  
 
PCR Program: 94°C 2mins (94°C, 30s;56°C, 30s; 68°C 1min)35, 68°C 7 min; 15°C, hold. 
Bands  (NULL = 250bp) 
WT = 600bp 
FLOX= 750bp  
 
 
Figure 2.5: GSK3α PCR 
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GSK3β PCR Protocol 
PCR Mix 
        µl 
Buffer      10 
MgCl2  (50mM)  5 
dNTPs   (10mM)  0.4 
Primer   (100µM)  0.2 (of each) 
Go Taq      0.2 
H2O to final volume of  47.5 
 
Primers 
GSK3βfl F = 5’ GGG GCA ACC TTA ATT TCA TT 3’ 
GSK3βfl R = 5’ TCT GGG CTA TAG CTA TCT AGT AAC G 3’ 
 
PCR Program: 94°C 2mins (94°C, 30s;56.5°C, 30s; 68°C 1min)35, 68°C 7 min; 15°C, hold. 
Bands  WT = 600bp 
FLOX= 1100bp  
 
Figure 2.6: GSK3β PCR 
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Rabbit H-Ras
Q61L Transgene PCR Protocol 
PCR mix 
              µl 
5x Colorless GoTaq Flexi Buffer*    10 
MgCl2  (25mM)        5 
dNTPs   (10mM)        0.4 
Primer   (100µM)        0.2 (of each) 
Go Taq*            0.2 
H2O to final volume of 47.5 µl 
*GoTaq Flexi DNA Polymerase from Promega.  
 
Primers 
RABBIT HRAS F  =  5’  CGGCGGTGTAGGCAAGAGCGC 3’ 
RABBIT HRAS R  =  5’ TCTTGGCCGAGGTCTCGATA 3’ 
 
PCR Program: 94°C, 5min (94°C, 1 min; 64°C, 30s; 72°C 1min)35, 72°C, 8min. 4°C, hold. 
Bands  RABBIT HRAS = ~500bp 
Only HET should have a band here 
 
Figure 2.7: Rabbit H-Ras
Q61L PCR 
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K-Ras G12D PCR Protocol (Split PCR) 
PCR Mix 
        µl 
Buffer      5 
MgCl2  (50mM)  2.5 
dNTPs   (10mM)  0.4 
Primer   (100µM)  0.1 (of each) 
Platinum Taq    0.2 
H2O to final volume of  47.5 
 
Note: This is a duplex PCR  
WT Reaction use primers KRasG12D WT and KRasG12D Universal 
LSL Reaction use primers KRasG12D Mut and KRasG12D Universal 
 
Primers 
KRasG12D WT = 5’ GTC GAC AAG CTC ATG CGG GTG 3’ 
KRasG12D Universal = 5’ CCT TTA CAA GCG CAC GCA GAC TGT AGA 3’ 
KRasG12D Mut = 5’ AGC TAG CCA CCA TGG CTT GAG TAA GTC TGC A 3’ 
 
PCR Program: 94°C 3min (94°C, 30s; 60°C, 1min 30; 72°C 1min) 35, 72°C, 5min. 4°C hold. 
Bands  WT = 500bp 
LSL = 550bp  
 
Figure 2.8: K-Ras G12D PCR 87 
 
Pten
fl PCR Protocol 
PCR Mix 
        µl 
Buffer      5 
MgCl2  (50mM)  2.5 
dNTPs   (10mM)  0.4 
Primer   (100µM)  0.1 (of each) 
Platinum Taq    0.2 
H2O to final volume of  47.5 
 
Primers 
PTEN Fl F = 5’ CTC CTC TAC TCC ATT CTT CCC 3’ 
PTEN Fl R = 5’ ACT CCC ACC AAT GAA CAA AC 3’ 
 
PCR Program: 95°C, 2min 30s (94°C, 1min; 58°C, 1min; 72°C 1min)35, 72°C, 10min. 15°C, 
hold. 
Bands  WT = 228bp 
Flox = 335bp  
 
Figure 2.9: Pten PCR 
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p21 PCR Protocol (Split PCR) 
PCR Mix 
        µl 
Buffer      5 
MgCl2  (50mM)  2.5 
dNTPs   (10mM)  0.4 
Primer   (100µM)  0.1 (of each) 
Platinum Taq    0.2 
H2O to final volume of  47.5 
 
Note: This is a duplex PCR  
WT Reaction use primers p21F and p21R 
Mutant Reaction use primers p21-5 and R1N-1A 
 
Primers 
P21 F = 5’ TCT TGT GTT TCA GCC ACA GGC  3’ 
P21 R = 5’ TGT CAG GCT GGT CTG CCT CC 3’ 
P21-5. =  5’ ATT TTC CAG GGA TCT GAC TC 3’ 
R1N-1A =  5’ CCA GAC TGC CTT GGG AAA AGC 3’ 
PCR Program: 95ºC, 2min (95ºC, 30s; 59ºC, 30s; 72ºC, 1min) 35, 72ºC, 3min. 4ºC hold. 
Bands  WT = 430bp 
NULL = 150bp  
 
Figure 2.10: p21 PCR 89 
 
Z/EGFP (GFP) PCR Protocol 
PCR Mix 
              µl 
5x Colorless GoTaq Flexi Buffer*    10 
MgCl2  (25mM)        5 
dNTPs   (10mM)        0.4 
Primer   (100µM)        0.2 (of each) 
Go Taq*            0.2 
H2O to final volume of 47.5 µl 
 
*GoTaq Flexi DNA Polymerase from Promega.  
 
Primers 
Bry-GFP F = 5’ ACG TAA ACG GCC ACA AGT TC 3’ 
Bry-GFP R = 5’ AAG TCG TGC TGC TTC ATG TG 3’ 
 
PCR Program: 95°C, 3min (95°C, 30s; 58°C, 45s; 72°C 1min) 40 72°C, 5min. 4°C, hold. 
 
Band  GFP = 187bp 
 
 
Figure 2.11: Z/EGFP PCR 90 
 
2.4.3. Summary of PCR reactions 
 
PCR  Primer Sequences 
(5' to 3') 
PCR Program  Expected 
Products 
Apc Flox  APC F = GTT  CTG TAT CAT GGA AAG ATA GGT GGT C 
APC R = CAC TCA AAA CGC TTT TGA GGG TTG ATT C 
 
95°C,  3min  (95°C,  30s; 
60°C, 30s; 72°C 1min)  30 
72°C, 5min. 4°C, hold. 
FLOX  = 
314bp 
WT  = 
226bp 
 
β-catenin 
exon3 
β-catenin F = CTG CGT GGA CAA TGG CTA CT 
β-catenin R = AAA AAT GTC GAC TGG ACT ACC T 
94°C, 2.5min (94°C, 30s; 
60°C, 30s; 72°C 1min)  34 
72°C, 10min. 4°C, hold. 
WT  = 
324bp 
Dominant 
stable  = 
~500bp 
Cre   CRE F   = TGA CCG TAC ACC AAA ATT TG 
CRE R  = ATT GCC CCT GTT TCA CTA TC 
 
95°C,  3min  (95°C,  30s; 
55°C, 30s; 72°C 1min) 30 
72°C, 5min. 15°C, hold. 
 
CRE  = 
~1000bp 
 
FGFR3 
K644 
F = GGG TGA TGC TTT GCC TGA GC    
R = TTC AGA TCT CCC TAC CCC CAT 
 
94°C,  3min  (94°C,  1min; 
60°C,  1min;  72°C  1min) 
30 
72°C, 7min. 15°C, hold. 
 
Double 
band  of 
~120bp  
+/K644  = 
Two  bands 
of  ~120bp 
and 350bp 
K644/K644 
=Band  of 
350bp only 
GSK3α 
null 
GSK3α F = CCC CCA CCA AGT GAT TTC ACT GCT A  
GSK3α R = AAC ATG AAA TTC CGG GCT CCA ACT CTA 
T  
 
94°C 2mins (94°C, 30s; 
56°C, 30s; 68°C 1min)35 
68°C 7 min 
WT  = 
600bp 
NULL  = 
250bp 
GSK3βfl    GSK3βflF = GGG GCA ACC TTA ATT TCA TT 
GSK3βflR = TCT GGG CTA TAG CTA TCT AGT AAC G 
 
94°C,  2min  30s  (94°C, 
30s;  56.5°C,  30s;  68°C, 
1min, 25s) 30  
68°C, 7min.  
FLOX  = 
1100bp 
WT  = 
895bp 91 
 
Rabbit  H-
Rqw 
Transgene 
RABBIT HRAS F  = CGGCGGTGTAGGCAAGAGCGC 
RABBIT HRAS R  = TCTTGGCCGAGGTCTCGATA 
 
94°C, 5min (94°C, 1 min; 
64°C, 30s; 72°C 1min) for 
35 cycles, 
72°C, 8min. 4°C, hold. 
 
RABBIT 
HRAS  = 
~500bp 
 
K-Ras
G12D 
(Duplex 
PCR) 
 
KRasG12D WT = GTC GAC AAG CTC ATG CGG G 
KRasG12D Universal = CGC AGA CTG TAG AGC AGC G 
KRasG12D Mut = CCA TGG CTT GAG TAA GTC TGC 
 
94ºC,  3min  (94ºC,  30s; 
60ºC, 1.5min; 72ºC, 1min) 
35 
72ºC, 5min. 4ºC hold. 
WT  = 
~500bp 
LSL  = 
~550bp 
p21 Null 
(Duplex 
PCR) 
 
P21 F = TCT TGT GTT TCA GCC ACA GGC  
P21 R = TGT CAG GCT GGT CTG CCT CC  
(WT PCR) 
95ºC,  2min  (95ºC,  30s; 
59ºC, 30s; 72ºC, 1min) 35  
72ºC, 3min. 4ºC hold. 
WT  = 
430bp  
 
  P21-5.  =  ATT TTC CAG GGA TCT GAC TC 3’ 
R1N-1A =  CCA GAC TGC CTT GGG AAA AGC 3’ 
(P21 interrupted PCR) 
95ºC,  2min  (95ºC,  30s; 
59ºC, 30s; 72ºC, 1min) 35  
72ºC, 3min. 4ºC hold. 
NULL  = 
150bp  
 
Pten Flox  PTEN F = CTC CTC TAC TCC ATT CTT CCC 
PTEN-R = ACT CCC ACC AAT GAA CAA AC 
 
95°C,  2min  30s  (94°C, 
1min;  58°C,  1min;  72°C 
1min) 35  
72°C, 10min. 15°C, hold. 
WT  = 
228bp 
Flox  = 
335bp 
Z/EGFP  GFP F = ACG TAA ACG GCC ACA AGT TC  
GFP R = AAG TCG TGC TGC TTC ATG TG 
 
95°C, 3min (95°C, 30s; 
58°C, 45s; 72°C 1min) 
40  72°C,  5min.  4°C, 
hold. 
 
GFP  = 
187bp 
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2.5. Rapamycin Treatment 
 
Mice were also treated with either Rapamycin (LC laboratories, Woburn, MA) or vehicle 
treatment. This was provided once daily via intraperitoneal (i.p.) at 10mg/kg in vivo for 4 
weeks. The i.p. solution was prepared as an aqueous solution with a final concentration of 4% 
ethanol, 5% polyethylene glycol and 5% Tween 80 immediately before injection (Namba et 
al., 2006). 
 
2.6. Assaying urothelial lesions in vivo 
 
At each indicated time point, a minimum of three animals were killed and the urinary bladder 
was removed.  Urine was removed and the bladder was fixed overnight in 4% formalin before 
processing.  Haematoxylin and Eosin (H&E) stained sections were made and the number of 
lesions were counted using the Olympus BX51 microscope.  At least 3 sections were counted 
from each mouse and the number of lesions was averaged over these 3 slides to give an 
average lesion count for that mouse. For each genotype, 3 age-matched mice were used.  
Statistics (Mann Whitney tests) were performed using Minitab v.15.  In Boxplots the thick bar 
represents median, and the box represents the inter-quartile range. 
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2.6.1. Assaying proliferation in vivo  
 
In  order  to  examine  levels  of  proliferation  mice  were  injected  with  250ul  of 
bromodeoxyuridine  (BrdU)  (Amersham)  two  hours  prior  to  being  sacrificed  (50mg/kg). 
Immunohistochemical staining for BrdU was then performed using an anti-BrdU antibody 
(BD 1:50). At least 3 mice were used for each genotype and timepoint. To examine levels of 
proliferation, following a two-hour BrdU pulse chase, total numbers of BrdU positive cells 
per lesion/tumour were counted.  
To quantify levels of proliferation between different cohorts of mice, at least 3 mice of each 
genotype  were  injected  with  BrdU  two  hours  prior  to  being  sacrificed.  BrdU 
immunohistochemistry was then performed on paraffin embedded urinary bladder sections of 
these mice.  
Statistics (Mann Whitney tests) were performed using Minitab v.15.  In Boxplots the thick bar 
represents median, and the box represents the inter-quartile range. 
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2.7. Immunohistochemistry 
 
2.7.1. Immunohistochemistry on frozen sections: 
 
Senescence associated β-galactosidase: 
Frozen sections of either kidney or urinary bladder were cut into 3µm sections on Poly-L-
lysine slides (Sigma). Sections were then thawed at room temperature for 30 minutes. The 
senescence β-galactosidase staining kit from Cell signalling (# 9860) was used. Slides were 
then fixed with 1x fixative solution from the kit for 10 minutes at room temperature. Slides 
were then washed 2x in dH20. A 1x staining solution from the kit was then prepared and the 
pH was adjusted to 5.5. Slides were incubated with the staining solution overnight at 37
oC. A 
small piece of parafilm was applied to each slide to ensure that the staining solution did not 
evaporate off. The following day excess staining solution was removed from the slides and 
the slides were counter stained with nuclear fast red for 5 minutes. Slides were then washed in 
dH20 for 5 minutes. Slides were mounted using DPX mounting medium.  
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2.7.2. Immunohistochemistry on paraffin sections: 
 
For all immunohistochemistry on paraffin sections, except for β-catenin, antigen retrieval was 
performed with citrate buffer either in the microwave or in the water bath (protocols below)  
 
Microwave antigen retrieval: 
Solution A (0.1M): 
10.5g of Citric Acid (molecular weight 192.12g: 10.5g/192.12g/mole = 0.055 moles)  
500 mls dH20 (M = 0.055 moles/0.500 L = 0.110M = 0.1M) 
Solution B (0.5M):  
29.4g Sodium Citrate (molecular weight = 58.44g: 29.4g/58.44g/mole = 0.503 moles) 
1 litre dH20 (M = 0.503 moles/1.000 L = 0.503M= 0.5M) 
 
To make a 1.5L solution: 27mls of solution A ([27mlx0.1M]/1500ml = 1.8mM) was mixed 
with 123mls of solution B ([123x0.1M]/1500ml = 8.2mM) and made up to 1.5L with dH20 
and adjusted to pH 6.0. The 1.5 L solution was placed in a pressure cooker and microwaved 
for 20 minutes or until the solution was boiling.  Slides were added and microwaved until the 
cooker was pressurised and then boiled for another 3-4 minutes. 
The pressure cooker was then removed and placed into a sink filled with cold water. Slides 
were removed and allowed to cool in solution for 20 minutes. 
 
Water Bath antigen retrieval: 
 
Citrate  Buffer  (Labvision)  was  diluted  1/10  in  distilled  water  and  50ml  of  diluted  citrate 
buffer solution was placed into a glass coplin jar. The coplin jar was immersed into a water 
bath and pre-heated to 99.9
oC. Slides were immersed into a preheated solution and boiled for 96 
 
20 minutes. The coplin jar was removed from the water bath and allowed to cool for 30 
minutes at room temperature in the solution. 
 
2.7.3. Immunohistochemistry for p21:  
 
The  staining  was  done  on  paraffin  embedded,  ‘quick  fixed’  samples.    This  entailed  the 
specimens being placed in a formalin fixative for less than 24 hours. 3um sections of tissue 
were cut onto Poly-L-lysine slides (Sigma).  Sections were dewaxed by placing into xylene 
for 20 minutes.  They were rehydrated through graded ethanol solutions (absolute alcohol, 
70% ethanol) and then into water. Antigen retrieval was performed as per the microwave 
method. Slides were washed 3x5 minutes in PBS. They were then blocked for 30 minutes 
with 5% goat serum in PBS.  Again they were washed 3x5 minutes with PBS. Slides were 
then incubated with Santa Cruz anti-p21 (M-19) (rabbit polyclonal) diluted 1/500 in 5% goat 
serum /PBS for 1 hour at room temperature. After this slides were washed again 3x5 minutes 
with PBS.  Slides were then incubated for 30 minutes with biotinylated secondary antibody 
from  rabbit  ABC  kit  (Vector  Laboratories).    Slides  were  washed  3x5  minutes  with  PBS. 
Slides were then incubated with ABC solution for 30 minutes; 2 drops of solution A + 2 drops 
of solution B in 5 ml 5% goat serum/PBS. (made up 30 minutes earlier). DAB reagents were 
then mixed in the ratio 1ml substrate buffer to 1 drops chromogen. This was applied to slides 
and  incubated  for  5-10mins.  Slides  were  wash  3x5  minutes  with  PBS.  Slides  were  then 
transferred to dH2O.  
Slides  were  then  counterstained  in  Haematoxylin  for  approximately  60  seconds  before 
washing in running tap water for 5 minutes. Slides were dehydrated by washing in increasing 
concentrations of alcohols (1x5 minute wash in 70% alcohol, 2x5 minute washes in 100% 97 
 
alcohol) before being placed in xylene for 2x10 minute washes. Slides were then mounted 
using DPX mounting medium.  
 
2.7.4. Immunohistochemistry for p16: 
 
Immunohistochemistry was performed as in 2.7.3. Exceptions: Slides were incubated with 
primary antibody to p16 (Santa Cruz M-156) 1/25 in 5% goat serum PBS for 1 hour at room 
temperature. Slides were then incubated for 30 minutes with biotinylated secondary antibody 
from rabbit ABC kit (Vector Laboratories).  
 
2.7.5. Immunohistochemistry for p19: 
 
Immunohistochemistry  was  performed  as  in  2.7.3.  Exceptions:  Antigen  retrieval  was 
performed  as  per  the  water  bath  method.  Slides  were  incubated  with  primary  antibody 
p19/ARF 1/300 (Upstate) in 5% goat serum PBS overnight at 4
0C. Slides were then incubated 
for  30  minutes  with  biotinylated  secondary  antibody  from  rabbit  ABC  kit  (Vector 
Laboratories).  
 
2.7.6: β-Catenin Immunohistochemistry: 
 
Slides were cut and rehydrated as in 2.7.3. Slides were blocked for 30-45 minutes in the 
following block; 1 litre stock = 4.16g citric acid, 10.76g Na2HPO4 (DiSodium Hydrogen 
Phosphate  2  hydrate),  1g  NaAz  (Sodium  Azide);  add  fresh  H2O2  to  1.5%.  For  antigen 
retrieval, slides were boiled in a water bath for 50 minutes in Tris EDTA; 1 litre stock = 242g 
Tris, 18.6g EDTA. (10mM Tris Base, 1mM EDTA Solution).  For working solution, 30ml 
stock was diluted in 1500ml dH2O, adjusted to pH to 8.0 with HCl. Slides were allowed to 98 
 
cool for 1 hour. Slides were then blocked for 30 minutes in 1% BSA in PBS. Slides were then 
incubated with β-catenin antibody (mouse monoclonal; C19220, Transduction Laboratories) 
1/50 in 1%BSA/PBS for 2 hours at room temperature. Then slides were washed 3x in PBS. 
Incubate slides with HRP-labelled polymer from Mouse Envision+ system (Dako systems) for 
1 hour at room temperature. Washed slides 3x in PBS. Slides were then developed with DAB, 
rehydrated and mounted as 2.6.3. 
 
2.7.7. BrdU Immunohistochemistry:  
 
Slides were cut and rehydrated as in 2.7.3. Antigen retrieval was performed as per the water 
bath method for 20 minutes. Slides were allowed to cool for 30 minutes at room temperature 
in solution. Slides were then rinsed in dH20. For prevention of endogenous staining, slides 
were blocked for 15 minutes in 1.5% H202 solution in dH20. Slides were then blocked for 30 
minutes in 1%BSA in PBS. Slides were then incubated with a 1/500 dilution of mouse anti-
BrdU (BD:cat N 347 580) diluted in PBS/1%BSA overnight at 4
0C. Slides were then washed 
3x  in  PBS  and  incubated  with  secondary  polymer  HRP-conjugated  Envision+  (Mouse 
Envision+ system Dako Systems) for 1 hour at room temperature. Slides were then washed 3x 
5 minutes in PBS. Slides were then developed with DAB, rehydrated and mounted as in 2.6.3. 
 
2.7.8. p53 Immunohistochemistry:  
 
Slides were cut and rehydrated as in 2.7.3. For epitope retrieval slides were steamed for 40-45 
minutes in 10mM sodium citrate (pH 6.0), and cooled slowly at room temperature for 30 
minutes. Slides were then incubated in methanol/ H2O2 (180 mL meth. /20 mL 30% H2O2) 
for 20 minutes at room temp. They were then rinsed profusely with H2O. Slides were then 
blocked for 30 minutes at room temperature in normal serum from VECTASTAIN kit (4 99 
 
drops  serum/10  mL  1X  PBS-0.1%  Tween-20).  Slides  were  then  incubated  with  primary 
antibody diluted in blocking solution for 1-2 hours at room temperature (anti-p53 (CM5 from 
Vector laboratories) at 1:200 dilution), followed by 3x in PBS washes, and then incubated 
with secondary antibody from Vectastain Universal kit (1 drop/10 mL blocking solution) at 
room temperature for 30 minutes. 
Slides were washed 3x in PBS and then incubated slides with ABC solution for 30 minutes (2 
drops of solution A + 2 drops of solution B in 5 ml 5% goat serum/ PBS). Slides were then 
developed with DAB, rehydrated and mounted as in 2.6.3. 
 
2.7.9. MCM2 Immunohistochemistry: 
 
Slides  were  cut  and  rehydrated  as  in  2.7.3.  Antigen  retrieval  was  performed  as  per  the 
microwave method. Slides were then blocked in 10% H2O2 made with dH2O for 10 minutes 
at room temperature. Slides were then washed with PBS 3x5 minutes, before being blocked in 
5% goat serum PBS for 30 minutes. Incubated slides with MCM2 (Cell signalling # 4007) 
rabbit polyclonal antibody at 1/200 with 5% goat serum PBS. Incubated overnight at 4
oC. 
Washed slides with PBS 3x 5 minutes. Slides were then incubated with secondary polymer 
HRP-conjugated Envision+ (Rabbit Envision+ system Dako Systems) for 1 hour at room 
temperature. Slides were then washed 3x 5 minutes in PBS. Slides were then developed with 
DAB, rehydrated and mounted as in 2.6.3. 
 
2.7.10. Ki67 Immunohistochemistry: 
 
IHC was performed as per MCM2 IHC. Incubate with primary antibody: (Thermo; RM-9106) 
1/250 in 5% goat serum PBS for 1 hour at room temperature. Wash slides with PBS 3x5 100 
 
minutes.  Slides  were  then  incubated  with  secondary  polymer  HRP-conjugated  Envision+ 
(Rabbit Envision+ system Dako Systems) for 1 hour at room temperature. Slides were then 
washed 3x5 minutes in PBS. Slides were then developed with DAB, rehydrated and mounted 
as in 2.6.3. 
 
2.7.11. PTEN Immunohistochemistry 
 
Slide were cut and rehydrated as per 2.7.3. Antigen retrieval was performed as per the water 
bath method. Slides were then blocked in 3% H2O2 made with dH2O for 20 minutes at room 
temperature. Slides were then washed 2x5 minutes in dH2O, then 1x 5min TBS/T. Slides were 
then blocked for 45mins in 5% Goat Serum diluted in TBS/T at room temperature, followed 
by incubation in PTEN (Cell signalling # 9559) rabbit monoclonal antibody at 1/100 with  5% 
goat serum TBS/T overnight at 4
oC. Washed slides with TBS/T 3x5 minutes, and incubated 
with secondary biotinylated goat anti-rabbit secondary Ab (DAKO) diluted 1/200 in 5% Goat 
Serum  in  TBS/T  for  30mins  at  room  temperature.  Unbound  secondary  antibodies  were 
washed off by 3x5 minutes TBS/T and signal reported with ABC solution for 30 minutes. 
Slides were washed slides 3x in PBS. Slides were then developed with DAB, rehydrated and 
mounted as in 2.6.3. 
 
2.7.12. p-AKT (Ser473) Immunohistochemistry 
 
Immunohistochemistry as per 2.7.10 except slides were then incubated with p-AKT (Ser473) 
(Cell signalling # 3787) rabbit monoclonal antibody at 1/100 with 5% goat serum TBS/T. 
Incubated overnight at 4
oC.  
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2.7.13. p-mTOR (Ser2448) Immunohistochemistry 
 
Immunohistochemistry  as  per  2.7.10  except  slides  were  then  incubated  with  p-mTOR 
(Ser2448) (Cell signalling # 2976) rabbit polyclonal antibody at 1/100 with 5% goat serum 
TBS/T. Incubated overnight at 4
oC.  
 
2.7.14. pERK1/2 Immunohistochemistry 
 
Immunohistochemistry as per 2.7.10 except slides were then incubated with p-ERK1/2 (Cell 
signalling # 9001) rabbit polyclonal antibody at 1/100 with 5% goat serum TBS/T. Incubated 
overnight at 4
oC.  
 
2.7.15. pMEK1/2 Immunohistochemistry 
 
Immunohistochemistry as per 2.7.10 except slides were then incubated with p-MEK1/2 (Cell 
signalling # 2338) rabbit polyclonal antibody at 1/125 with 5% goat serum TBS/T. Incubated 
overnight at 4
oC.  
 
2.7.16. p-S6 Kinase Immunohistochemistry 
 
Immunohistochemistry  as  per  2.7.10  except  slides  were  then  incubated  with  p-S6  Kinase 
(Thr421/Ser424) (Cell signalling # 9204) rabbit polyclonal antibody at 1/100 with 5% goat 
serum TBS/T. Incubated overnight at 4
oC.  
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2.7.17. Active-Rac1 Immunohistochemistry 
 
Immunohistochemistry  as  per  2.7.10  except  slides  were  then  incubated  with  Active-Rac1 
(NewEast  Biosciences  #  26903)  rabbit  polyclonal  antibody  at  1/400  with  5%  goat  serum 
TBS/T. Incubated overnight at 4
oC.  
 
2.7.18. GFP Immunohistochemistry 
 
Slide  were  cut  and  rehydrated  as  per  2.7.3.  Antigen  retrieval  was  performed  as  per  the 
microwave method. Slides were then blocked in 3% H2O2 made with dH2O for 15 minutes at 
room temperature. Slides were then washed 3x 5min TBS/T. Slides were then blocked for 1 
hour in 5% Goat Serum diluted in TBS/T at room temperature. Slides were then incubated 
with GFP (AbCam #abcam6556) rabbit polyclonal antibody at 1/1000 with  5% goat serum 
TBS/T overnight at 37
oC humidified. Slides were then washed with TBS/T 3x5 minutes, 
before being incubated with secondary antibody from Vectastain Universal kit (1 drop/10 mL 
blocking solution) at room temperature for 30 minutes. 
Slides were washed 3x in PBS. Incubated slides with ABC solution for 30 minutes; 2 drops of 
solution A + 2 drops of solution B in 5 ml 5% goat serum/ PBS. Washed slides 3x in PBS. 
Slides were then developed with DAB, rehydrated and mounted as in 2.6.3. 
 
2.7.19. Sprouty2 Immunohistochemistry 
 
Immunohistochemistry  as  per  2.7.15  except  slides  were  then  incubated  with  Sprouty2 
(AbCam # ab60719) mouse monoclonal antibody at 1/300 with 1%BSA/PBS overnight at 
4
oC.  
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2.7.20. FGFR3 Immunohistochemistry 
 
Slide were cut and rehydrated as per 2.7.3. No antigen retrieval was performed. Slides were 
then blocked in 3% H2O2 made with dH2O for 20 minutes at room temperature. Slides were 
then washed 2x in 5min dH2O, then 1x 5min TBS/T. Slides were then blocked for 45mins in 
5%  Goat  Serum  diluted  in  TBS/T  at  room  temperature.  Slides  were  then  incubated  with 
FGFR3 (Santa Cruz c-15) rabbit polyclonal antibody at 1/20 with  5% goat serum TBS/T 
overnight at 4
oC.  Slides were then washed with TBS/T 3x5 minutes before being incubated 
with secondary biotinylated goat anti-rabbit secondary Ab (DAKO) diluted 1/200 in 5% Goat 
Serum in TBS/T for 30mins at room temperature. Washed 3x 5mins TBS/T.  Slides incubated 
with ABC solution for 30 minutes; 2 drops of solution A + 2 drops of solution B in 5 ml 5% 
goat serum/ PBS. Slides were then washed 3x in PBS. Slides were then developed with DAB, 
rehydrated and mounted as in 2.7.3. 
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2.8. Imaging 
 
2.8.1 Microscopy 
 
Light microscopy was carried out using the Olympus BX51.  All images were taken at 20x 
magnification, unless otherwise stated in the figure legends.  
For GFP in vivo imaging we used the Olympus OV100 system.  Mice were anesthetised by 
inhalation anaesthetic, using a mixture of O2 and isoflurane.  Imaging was also performed on 
mice post-mortem with both skin intact and removed. 
 
2.8.2. Ultrasound Scanning  
 
This was performed on live mice using Visualsonic’s Vevo 770 (Visulasonics Inc, Toronto, 
Canada).  For  all  abdominal  imaging  mice  were  anaesthetised  using 
hypnorm(fentanyl)/hypnovel(midazolam)  10ml/kg  i.p.    To  improve  resolution  an  ascites 
protocol using an i.p. injection of 5ml of PBS was utilised.  
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2.9. Human Tissue Microarray (TMA) 
 
This was purchased from Folio biosciences (OH, USA) and consists of 60 cancer and 20 
benign bladder cancer cases with data on patient sex, age and tumour grade. Slides were 
scanned using the Aperio slide scanner (Pathology department, Western Infirmary). 
Protein expression levels were scored by two independent observers (Imran Ahmad and 
Lukram Babloo Singh, Research technician, The Beatson Insitute for Cancer Research), 
blinded to clinical parameters, using a weighted histoscore method, also known as the H-
score, at magnification ×40. Each cellular location (membranes, cytoplasm, and nuclei) was 
scored separately. The weighted histoscore method assesses the staining intensity and the 
percentage of cells stained with that intensity for the full slide. It is calculated by (1 × % cells 
staining weakly positive) + (2 × % cells staining moderately positive) + (3 × % cells staining 
strongly positive). This provides a semiquantitative classification of staining intensity, with 
the maximum score being 300 (if 100% of cells stain strongly positive) and minimum score 
being 0 (if 100% or cells are negative). The weighted histoscore method is a well-established 
method for scoring tissue that has heterogeneous staining.  Inter-observer agreement between 
the scorers was excellent with interclass correlation scores >0.80. 
I classified upregulation as a score ≥100 and downregulation as <100 (Kirkegaard et al., 
2006).  Correlation coefficient was calculated using SPSS v.15).  Multiple testing was taken 
into account (Bonferroni principle). 
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Chapter 3: β-Catenin activation synergises with PTEN loss to cause bladder 
cancer formation 
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3.1. Introduction 
 
A number of genetic and epigenetic alterations involved in bladder tumourigenesis have been 
identified, including activating mutations in FGFR3, and RAS family genes, amplification of 
ERBB2, and loss of the TP53, RB1 and PTEN tumour suppressors (Cordon-Cardo, 2008, Diaz 
et al., 2008, Luis et al., 2007, Schulz, 2006). However the role of the Wnt pathway in UCC 
has yet to be resolved. 
The  Wnt/  β-catenin  signalling  pathway  plays  a  crucial  role  in  embryogenesis,  cell 
differentiation  and  tumourigenesis.  Wnts  are  secreted  glycoproteins  that  act  as  ligands  to 
stimulate  receptor-mediated  signal  transduction  pathways  in  both  vertebrates  and 
invertebrates (Moon et al., 2004).  In the absence of a Wnt signal, cytoplasmic β-catenin is 
phosphorylated  and  degraded  in  a  complex  of  proteins.  The  complex  which  causes  the 
phosphorylation of β-catenin and thus targets it for degradation is a multi-protein scaffolding 
complex,  consisting  of  adenomatous  polyposis  coli  (APC),  glycogen  synthase  kinase  3β 
(GSK-3β), CK1 (casein kinase 1) and axin.  Following Wnt pathway activation (through the 
binding of a Wnt ligand to the frizzled transmembrane receptor), GSK3 is inactivated and β-
catenin  is  no  longer  phosphorylated  and  targeted  for  degradation.    As  a  result  β-catenin 
accumulates  in  the  cytoplasm  and  enters  the  nucleus,  where  it  binds  to  TCF/LEF  family 
members and transcriptionally regulates Wnt target genes which include cyclin D1 and c-myc 
(canonical Wnt signalling pathway) (Bienz and Clevers, 2000, He et al., 1998, Tetsu and 
McCormick, 1999, Polakis, 2000a). 
Mutations of the tumour suppressor PTEN have been described in many tumours (Salmena et 
al., 2008), including deletion of the locus in bladder cancers (Aveyard et al., 1999, Teng et al., 
1997, Tsuruta et al., 2006).  These deletions are absent/rare in superficial tumours, but occur 
frequently in invasive bladder cancers.  Previously published models of inactivation of PTEN 108 
 
in the murine urothelium have shown widely conflicting phenotypes from benign epithelium 
to widespread hyperplasia whilst some demonstrate UCC after a long latency and with an 
incomplete penetrance (Puzio-Kuter et al., 2009, Tsuruta et al., 2006, Yoo et al., 2006, Qian et 
al.,  2009).    This  may  be  in  part  related  to  the  different  promoters,  PTEN  alleles  and 
backgrounds of the mice used.  Recently it has been demonstrated that combined deletion of 
Pten and Trp53 in the murine urothelium results in aggressive UCC, which is dependent on 
mTOR signalling (Puzio-Kuter et al., 2009).  
In this study, I tested whether activation of Wnt signalling pathway may cooperate with loss 
of PTEN function to drive UCC in vivo. 
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3.2. Results 
 
3.2.1 β-catenin overexpression leads to benign hyperproliferation of the urothelium 
 
In order to drive deregulated Wnt signalling, I used mice that carry a dominant allele of the β-
catenin gene in which exon3 is flanked by loxP sequences (Harada et al., 1999). On addition 
of  Cre  recombinase,  exon3  is  deleted.  As  this  exon  contains  the  residues  that  are 
phosphorylated  by  GSK3β,  leading  to  β-catenin  degradation,  β-catenin  will  therefore 
accumulate  to  drive  Wnt  signalling  (Moon  et  al.,  2004).  To  achieve  urothelial  specific 
expression of activated β-catenin, these mice were interbred with mice carrying an uroplakin 
II (UroII) CRE transgene (He et al., 2009, Mo et al., 2005). UroII is a protein localised at the 
apical surface of the urothelium and is important for its permeability barrier function (Zhang 
et al., 1999).  It is expressed throughout the urothelial layers in mice (Mo et al., 2005). The 
UroII promoter has been reported to successfully drive the expression of proteins including 
SV40 large T antigen and H-Ras (Zhang et al., 2001, Mo et al., 2007).  Previous studies have 
shown that the UroIICRE
+ mice exhibit bladder specific recombination (Zhang et al., 1999). 
To confirm this and to report levels of recombination, UroIICRE
+ mice were intercrossed 
with  mice  carrying  the  Z/EGFP  reporter  transgene  (Novak  et  al.,  2000).  In  the  Z/EGFP 
reporter mouse, the Z/EGFP transgene results in the expression of β-galactosidase by most 
tissues via a β-geo insert, which is flanked by lox-P sites.  The presence of Cre recombinase 
results  in  the  excision  of  the  β-geo,  activating  the  constitutive  expression  of  GFP.    Both 
immunohistochemistry and OV100 imaging for GFP shows the expression of eGFP in the 
urothelial lining of the bladder and ureters (Figure 3.1) (Novak et al., 2000). 
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Figure 3.1: GFP Expression of UroIICRE
+ Z/EGFP mice 
IHC  for  Green  Fluorescent  Protein  (GFP)  in  wildtype  (A)  and  12-month  old  UroIICre
+ 
Z/EGFP bladder (B).  Black bar measures 200µm (20x magnification). GFP visualised by 
OV100 shows evidence of Cre mediated recombination in the urothelium of 12-month old 
UroIICre
+ Z/EGFP bladder (C). Imaging was performed ex-vivo after urine had been drained. 
Magnification at 14x.   
(At least 3 samples from each cohort stained and representative images are shown above). 
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Firstly, I used mice carrying one or two copies of the β-catenin exon3 allele to test whether 
the amplitude of the Wnt deregulation was important, as levels of deregulated Wnt signalling 
have been shown to be key in other organs such as the mammary gland (Howe and Brown, 
2004).  To  investigate  the  phenotype  of  β-catenin  activation  within  the  bladder  I  aged 
UroIICRE
+ β-catenin
+/+, UroIICRE
+ β-catenin
exon3/+ and UroIICRE
+ β-catenin
exon3/exon3 mice 
to 3 months of age. In mice carrying one or two copies of the β-catenin exon3 allele there was 
a clear phenotype in the bladder epithelium, with all mice developing areas of urothelial 
hyperplasia (Figure 3.2 A,C,E).  To confirm that this was due to the activation of β-catenin, I 
performed IHC for β-catenin and saw a marked upregulated of nuclear β-catenin compared to 
wildtype (Figure 3.2 B,D,F) as well as Wnt target gene c-Myc (Figure 3.3 A,D). To confirm 
the  lesions  were  hyperproliferative  I  then  stained  for  the  proliferation  markers  Ki67  and 
BrdU,  both  of  which  I  found  to  be  upregulated  (Figure  3.3  B,C,E,F).  No  differences  in 
proliferation as assessed by BrdU positivity were observed in mice carrying either one or two 
copies of the β-catenin exon3 allele (data not shown).   
Given  that  mice  formed  hyperproliferative  lesions  I  wished  to  test  whether  these  mice 
developed UCC as they aged. Therefore UroIICRE
+ β-catenin
+/+, UroIICRE
+ β-catenin
exon3/+ 
and UroIICRE
+ β-catenin
exon3/exon3 mice were aged to 18 months old. Remarkably, no mice 
developed UCC within this time course and when bladders from these 18-month-old mice 
were  examined  they  appeared  equivalent  to  those  at  3  months  with  a  number  of 
hyperproliferative lesions that had not progressed to cancer.  There was however a small yet 
significant  increase  in  the  numbers  of  lesions  in  bladders  for  each  group  of  aged  mice 
(p<0.001) (Figure 3.4). Interestingly given the paucity of lesions in the mutant bladders this 
suggests that secondary mutations are required in the recombined cells to allow these lesions 
to  form,  whilst  the  majority  of  singly  β-catenin  mutant  cells  that  do  not  possess  these 
additional mutations are being selected against. 112 
 
The lack of invasive progression among these lesions highlights that β-catenin activation is 
not  sufficient  to  drive  UCC  formation  and  potentially  explains  why  subjects  that  carry 
germline mutations of APC do not develop UCC.  Similarly the lesions are composed of 
numerous proliferating cells, but never progress to tumours/overrun the urothelium.  This 
suggests that either there is a concordant high rate of apoptosis or the somehow these cells 
despite  exhibiting  markers  of  proliferation  are  not  actually  dividing  (suggestive  by 
upregulation of markers of senescence (Figure 3.5). 
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Figure 3.2: UroIICRE
+ β-catenin
exon3/exon3 urothelium demonstrates upregulation of 
nuclear β-catenin 
Histology from 12-month-old Wildtype and UroIICRE
+ β-catenin
exon3/exon3 mice. H&E reveals 
development of hyperplastic lesions in the mutant urothelium (black/red arrows) (A&C), of 
which  a  close  up  (red  arrows)  is  seen  in  (E).  Immunohistochemistry  shows  strong 
upregulation of nuclear β-catenin (B,D,F) compared to wildtype. Red bar measures 1000 µm 
(4x magnification), black bar measures 200µm (20x magnification).  Red box outline in (A) 
and (B) highlights the picture for (C) and (D). 
(At least 3 samples from each cohort stained and representative images are shown above). 114 
 
 
 
 
 
 
Figure 3.3: UroIICRE
+ β-catenin
exon3/exon3 urothelium demonstrates upregulation of Wnt 
target genes and proliferative markers 
IHC from 12-month-old Wildtype and UroIICRE
+ β-catenin
exon3/exon3 urothelium demonstrates 
strong upregulation Wnt target gene c-Myc (A&D), as well as upregulation of markers of 
proliferation; BrdU (B&E) and Ki-67 (C&F) in the mutant urothelia. Black bar measures 
200µm (20x magnification). 
(At least 3 samples from each cohort stained and representative images are shown above). 
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Figure 3.4: Box plot of lesion numbers in the wildtype, UroIICRE
+ β-catenin
exon3/+ and 
UroIICRE
+ β-catenin
exon3/exon3 
Box plot of lesion numbers in the wildtype, UroIICRE
+ β-catenin
exon3/+ and UroIICRE
+ β-
catenin
exon3/exon3 cohorts at 3, 12 and 18 months of age (n=3).  I showed that at 3, 12 and 18 
months the number of lesions in the UroIICRE
+ β-catenin
exon3/+ (e3/+) and UroIICRE
+ β-
catenin
exon3/exon3 (e3/e3) are significantly higher than the corresponding wildtype (WT) time 
point (*, p<0.001, Mann Whitney Test).  Similarly lesions at both 12 and 18 months in the 
UroIICRE
+ β-catenin
exon3/+ and UroIICRE
+ β-catenin
exon3/exon3 cohorts are significantly higher 
than the corresponding cohort at 3 months (
#, p<0.001, Mann Whitney Test).  Thick bar 
represents median, and the box represents the inter-quartile range. 
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3.2.2. The PTEN tumour suppressor pathway is activated in the bladder lesions  
 
I next investigated the pathways that were constraining tumour progression within the areas of 
urothelial hyperplasia. UCC can be broadly separated into two molecular pathways (Luis et 
al., 2007, Wu, 2005).  In one pathway where patients have either FGFR3 or HRAS mutations, 
they develop superficial papillary disease, which often carries a good prognosis.  The other 
tumour subtype has a more aggressive phenotype, leading to muscle invasion and ultimately 
metastatic disease.  These tumours have often lost p53 and/or have an activation of the PI3-
kinase signalling pathway. Indeed, a recent study has shown that low PTEN levels correlate 
with a poor prognosis in human bladder cancer (Puzio-Kuter et al., 2009). This has recently 
been modelled in the mouse using adenoviral Cre infections into the bladder. Mice either 
singly mutant for Pten or Trp53 did not develop tumours, however double knockout mice 
developed metastatic urothelial cancer. Thus I next investigated the expression of candidate 
molecules  from  the  p53  and  PTEN  tumour  suppressor  pathways  within  lesions  from  the 
UroIICRE
+ β-catenin
exon3/exon3 mice. Within the lesions, there were very high levels of the 
PTEN  tumour  suppressor  protein  expression  (Figure  3.5  A&B)  with  associated  minimal 
pAKT,  p-mTOR  and  pS6  Kinase  staining  (Figure  3.5  D,F,H)  suggesting  that  the  PTEN 
tumour  suppressor  was  potentially  blocking  tumour  progression.  In  contrast  to  a  large 
increase in PTEN, there was only a modest increase in the levels of nuclear p53 although one 
of its targets p21 was highly upregulated within the lesions of the mice (Figure 3.5 J&L).  
There  was  strong  upregulation  of  p19
ARF  (Figure  3.6  N),  another  p53  related  tumour 
suppressor.    Similarly  I  noticed  upregulation  of  senescence-associated  β-galactosidase 
(Saβgal)  (Figure 3.5 P). 
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Figure 3.5: UroIICRE
+ β-catenin
exon3/exon3 urothelium demonstrates upregulation of 
PTEN, p53, p21 and p19ARF 
IHC from 12 month old Wildtype and UroIICRE
+ β-catenin
exon3/exon3 urothelium demonstrates 
strong upregulation PTEN (A&B), with minimal pAkt(Ser473) (C&D) and p-mTOR (E&F) 
signal. I also noticed significant upregulation of p-S6 Kinase, p21, p19ARF, p53 and Saβgal 
(G-P).  Red  bar  measures  1000  µm  (4x  magnification),  black  bar  measures  200µm  (20x 
magnification). 
(At least 3 samples from each cohort stained and representative images are shown above). 
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3.2.3. PTEN upregulation acts to block β-catenin driven urothelial proliferation 
 
As the uroplakin II cre recombinase is expressed throughout development of the urothelium, 
it is difficult to assess whether the upregulation of PTEN is a direct consequence of β-catenin 
accumulation.  Therefore  I  next  investigated  the  consequence  of  inducibly  activating  Wnt 
signaling in the adult urothelium. To do this mice carrying the cytochrome p450 inducible 
AhCreER
T  transgene  were  used.  Following  administration  of  both  β-napthoflavone  and 
tamoxifen, this yields cre-mediated recombination within the urothelium of the bladder (as 
well  as  the  intestine)  (Marsh  et  al.,  2008).  Figure  3.6  demonstrate  recombination  in  the 
bladder as evidenced by GFP signalling identified by OV100 imaging (ex-vivo) and IHC for 
GFP  in  AhCreER
T  Z/EGFP  reporter  mice  7  days  following  induction.  To  investigate  the 
impact of acutely activating Wnt signalling in the adult bladder I intercrossed AhCreER
T mice 
to mice carrying the inducible knockout Apc
580S allele (from here on known as Apc
fl) in which 
loxp sites are inserted into the introns around exon 14 (Shibata et al., 1997). Remarkably, 
examination  of  the  bladders  from  AhCreER
T  Apc
fl/fl  mice  seven  days  following  induction 
revealed development of urothelial lesions which phenocopied those from our UroIICRE
+ β-
catenin
exon3/exon3 mice (Figure 3.7 A). Indeed there were more lesions in the AhCreER
T Apc
fl/fl 
urothelia suggesting a greater recombination frequency than the UroIICRE
+.  Consistent with 
the activation of Wnt signalling, lesions demonstrated a high level of nuclear β-catenin and 
again an upregulation in BrdU incorporation compared to the surrounding urothelium (Figure 
3.7 B&C). Importantly, once again very high levels of PTEN were seen within these lesions 
(Figure 3.7 D) with minimal upregulation of pAKT (Figure 3.7 E). To confirm this was due to 
increased levels of Wnt signalling, I also activated Wnt signalling by deleting both copies of 
GSK3α and GSK3β.  Bladders from induced AhCreER
T GSK3αβ
fl/fl mice displayed similar 
lesions to the AhCreER
T Apc
fl/fl mice, with the accumulation of nuclear β-catenin, BrdU and 
PTEN (Figure 3.8 A-D) (MacAulay et al., 2007, Patel et al., 2008, Kemp et al., 2004). Using 121 
 
this induction regime, mice developed hyperplastic intestinal epithelium, which precluded 
long term tumour experiments, however in mice aged up to 4 months bladder lesions still 
remained small and did not progress to cancer, suggesting PTEN was once again blocking 
tumourigenesis. 
 
 
Figure 3.6: GFP expression in AhCreER
T Z/EGFP mice 7 days post induction 
Bladders from AhCreER
T Z/EGFP mice reveal recombination in the bladder as evidenced by 
GFP signalling, identified by IHC for GFP (B) compared to wildtype (A). OV100 imaging 
(ex-vivo) (C). 
(At least 3 samples from each cohort stained and representative images are shown above). 
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Figure 3.7: Histology of AhCreER
T Apc 
fl/fl 7 days post induction 
Bladders  from  AhCreER
T  Apc
fl/fl  mice  reveal  similar  hyperproliferative  lesions  to  our 
UroIICRE
+  β-catenin
exon3/exon3  (A),  which  demonstrate  proliferation  (C)  as  well  as 
upregulation of nuclear β-catenin and PTEN staining with minimal pAKT expression (B,D,E). 
Black bar measures 200µm (20x magnification). 
(At least 3 samples from each cohort stained and representative images are shown above). 
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Figure 3.8: Histology of AhCreER
T GSK3αβ 
fl/fl mice 7 days post induction 
AhCreER
T GSK3αβ 
fl/fl mice reveal bladder lesions (A), which demonstrate proliferation as 
well as accumulation of nuclear β-catenin and PTEN (B-D). Black bar measures 200µm (20x 
magnification). 
(At least 3 samples from each cohort stained and representative images are shown above). 
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To  test  the  role  PTEN  was  having  immediately  following  Apc  loss  in  the  urothelium  I 
generated AhCreER
T APC 
fl/fl PTEN 
fl/fl mice. Seven days following induction, the mice again 
developed urothelial lesions that were much larger than in AhCreER
T Apc
fl/fl Pten
+/+ mice 
(Figure  3.9  A).  These  lesions  showed  an  accumulation  of  nuclear  β-catenin,  high  BrdU 
expression and consistent with PTEN deletion, a complete absence of PTEN staining in the 
lesions (Figure 3.9 B-D), and showed strong pAKT(Ser473) upregulation (Figure 3.9 E) To 
investigate  whether  the  reason  for  the  enlarged  lesions  was  due  to  hyperproliferation,  I 
examined  the  number  of  BrdU  positive  cells  per  lesion  in  both  AhCreER
T  Apc
fl/fl  and 
AhCreER
T  Apc
fl/fl  Pten
fl/fl  mice  and  demonstrated  a  statistically  significantly  increase  in 
proliferation when PTEN is lost (p<0.05, Mann Whitney Test) (Figure 3.10).  Thus PTEN 
accumulation  following  β-catenin  activation  is  acting  to  limit  proliferation.    I  was  again 
unable to further analyse the AhCreER
T Apc
fl/fl Pten
fl/fl mice as these mice became ill rapidly 
after induction due to intestinal disease at day 8. 
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Figure 3.9: Histology of AhCreER
T Apc
fl/fl Pten
fl/fl 
Bladders  from  AhCreER
T  Apc
fl/fl  Pten
fl/fl  mice  reveal  larger  lesions  (A)  that  show  further 
proliferation (B), nuclear β-catenin (C), but this time the absence of PTEN staining in the 
lesions  (D).  These  lesions  demonstrate  significant  upregulation  of  pAKT  (E).  Black  bar 
measures 200µm (20x magnification). 
(At least 3 samples from each cohort stained and representative images are shown above). 
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Figure 3.10: Box plot of average number of BrdU positive cells per lesion in both 
AhCreER
T Apc
fl/fl  and AhCreER
T Apc
fl/fl Pten
fl/fl mice. 
Urothelium assessed at 7 days after first induction (n=3) (p<0.001, Mann Whitney test). Total 
number of positive cells from lesions (n=3) counted from 3 mice (total lesions n=9), with 
median, inter-quartile range and range represented above. 
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3.2.4. PTEN loss cooperates with β-catenin activation to drive UCC formation  
 
To  test  whether  this  block  of  proliferation  by  PTEN  was  suppressing  tumourigenesis  I 
intercrossed  UroIICRE
+  β-catenin
exon3/exon3  mice  with  mice  carrying  a  conditional 
inactivatable Pten allele (where exon 5 is flanked by lox p sites) (Lesche et al., 2002). A 
recent study using adenoviral Cre delivery to the bladder has shown that deletion of Pten 
alone in the murine urothelium is not sufficient to promote bladder cancer formation (Puzio-
Kuter  et  al.,  2009).  I  have  confirmed  this  result  here,  as  neither  UroIICRE
+  Pten
fl/+  nor 
UroIICRE
+ Pten
fl/fl mice developed cancer when aged until 18 months (n=20).  Indeed, no 
phenotypic changes (dysplasia, hyperplasia or tumourigenesis) were observed in urothelium 
between UroIICRE
+ Pten
fl/fl and wildtype mice (Figure 3.11 A-B). To confirm that Pten was 
deleted in these mice I stained for PTEN levels by IHC and found a downregulation of the 
PTEN protein in bladders from UroIICRE
+ Pten
fl/fl  (Figure 3.11 C-D) and only a modest 
upregulation of pAKT(Ser473) staining  (Figure 3.11 E-F). These data are consistent with 
previous studies within the intestinal epithelium where Pten deletion was not sufficient to 
drive tumourigenesis and only modestly affected the levels of pAKT (Marsh et al., 2008).  
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Figure 3.11: Histology of UroIICRE
+Pten
fl/fl mice 
Comparison  of  12-month-old  wildtype  and  UroIICRE
+Pten
fl/fl  urothelium.    The  H&E 
demonstrates that the urothelium of UroIICRE
+Pten
fl/fl (B) is comparable to wildtype (A) with 
no  hyperplasia,  dysplasia  or  tumour  formation.    Lower  levels  of  PTEN  in  the 
UroIICRE
+Pten
fl/fl urothelium (D) when compared to wildtype (C) and slightly elevated levels 
of pAkt(Ser473) (E,F) were observed.  Black bar measures 200µm (20x magnification). 
(At least 3 samples from each cohort stained and representative images are shown above). 
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To study the simultaneous activation of β-catenin and PTEN loss, the following cohorts were 
generated:  UroIICRE
+  β-catenin
exon3/+Pten
fl/+,  UroIICRE
+  β-catenin
exon3/exon3Pten
fl/+, 
UroIICRE
+ β-catenin
exon3/+Pten
fl/fl, and UroIICRE
+ β-catenin
exon3/exon3Pten
fl/fl (n= 20, 16, 24, 21 
respectively).  A cohort of these mice was harvested at 3 months of age and the bladder 
phenotypes  were  analysed.    A  second  cohort  of  mice  was  allowed  to  age  until  clinical 
evidence of tumour development, or when animals were required to be sacrificed per project 
license  guidelines.    At  3  months  of  age,  hyperplastic  lesions  (scored  from  3  H&E  cross 
sections of each mouse, with 3 mice in each cohort) were observed at an increased frequency 
in doubly mutant mice compared with mice carrying only β-catenin mutation (Figure 3.12).   
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Figure 3:12 Tumour burden of UroIICRE
+ β-catenin
exon3/exon3 Pten
fl/fl mice
 
Box plot of number of lesions found in urothelium of each cohort at 3 and 12 months (n=3). 
Cohorts denoted by * demonstrate significantly elevated levels of lesions in comparison to 12 
month old UroIICRE
+ β-catenin
exon3/exon3 (p<0.05, Mann Whitney Test).  Abbreviations: e3/e3 
(UroIICRE
+  β-catenin
exon3/exon3),  e3/+  fl/+  (UroIICRE
+  β-catenin
exon3/+  Pten
fl/+),  e3/e3  fl/+ 
(UroIICRE
+  β-catenin
exon3/exon3  Pten
fl/+),  e3/+  fl/fl
  (UroIICRE
+  β-catenin
exon3/+  Pten
fl/fl)  and 
e3/e3 fl/fl (UroIICRE
+ β-catenin
exon3/exon3Pten
fl/fl). Thick bar represents median, and the box 
represents the inter-quartile range. 
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In contrast to the UroIICRE
+ β-catenin
exon3/+Pten
fl/+ and UroIICRE
+ β-catenin
exon3/exon3Pten
fl/+ 
mice,  the  UroIICRE
+  β-catenin
exon3/exon3Pten
fl/fl  mice  and  UroIICRE
+  β-catenin
exon3/+Pten
fl/fl 
mice rapidly developed symptoms of bladder tumour; abdominal swelling, haematuria (blood 
in  the  urine)  and  hunching  (Figure  3.13  &  3.14).  Mice  with  loss  of  both  copies  of  Pten 
succumbed to bladder tumours 100 days earlier than those with single copy loss.   
On  necropsy,  the  presence  of  bladder  tumour  was  confirmed,  which  showed  histological 
progression to papillary carcinoma (Figure 3.15 A&B). I found no evidence of metastasis in 
any of the models studied (both at macroscopic and microscopic level, with multiple sections 
taken through the lung, liver, spleen, diaphragm, kidneys and local lymph nodes). Consistent 
with Pten deletion, the tumours that developed showed complete loss of PTEN protein and 
now displayed strong activation of pAKT(Ser473) (Figure 3.15 C&D). Tumours also showed 
a nuclear upregulation of β-catenin and Ki-67 (Figure 3.15 E&F).   
These data are consistent with tumour formation in the bladder being synergistically promoted 
by Wnt and PI3 kinase signalling. This scenario fits with our previous studies in the intestinal 
epithelium where Wnt activation or Pten loss alone, were not sufficient to induce high levels 
of pAKT and presumably PI3 kinase signalling (Marsh et al., 2008). However in our bladder 
model, combination of deregulated Wnt signalling and PTEN loss caused a dramatic increase 
in pAKT that presumably drives tumour formation.  Of the targets downstream of pAKT, I 
also  saw  a  dramatic  increase  in  p-mTOR
2448  (Figure  3.15  G),  suggesting  that  mTOR 
activation is a key component of tumourigenesis in this model.  A recent chemoprevention 
study  by  Puzio-Kuter
  has  shown  that  mTOR  inhibition  using  Rapamycin  suppresses 
tumourigenesis in Trp53/Pten double knockout tumours (Puzio-Kuter et al., 2009). Consistent 
with our tumours being dependent on PI3-kinase signalling, there was no upregulation of 
pERK1/2 in the tumours (Figure 3.15 H).  There was minimal upregulation of p53 and p21 132 
 
(Figure 3.15 J&K).  By 12 months of age, a small subset of the UroIICRE+ β-catenin
exon3/exon3 
Pten
fl/+ mice and UroIICRE+ β-catenin
exon3/+Pten
fl/+ mice had developed tumours. This was 
presumably due to the loss of the remaining Pten allele, as staining for PTEN was absent from 
the tumours (Figure 3.15 I). There has been much debate over the crosstalk between the Wnt 
and PI3 kinase pathways and it is often proposed that the inhibitory phosphorylation of GSK3 
by AKT/PKB may allow the activation of Wnt signalling. If this was the case one would 
argue that PTEN loss alone should be sufficient to activate Wnt signalling and numerous 
studies have shown that this is not the case (including our present study) (Salmena et al., 
2008).  Moreover two key studies suggest that the phosphorylation of GSK3 by AKT does not 
affect  Wnt  signalling.  First  ‘knock-in’  mice  where  the  AKT  phosphorylation  sites  on 
GSK3alpha (Ser21) and GSK3beta (Ser9) were converted to alanine did not elevate Wnt 
signalling (McManus et al., 2005). Second a recent study has shown that the Wnt pool of 
GSK3 is physically distinct from the AKT pool (Ng et al., 2009).  Our data here shows it is 
only  in  the  complete  genetic  absence  of  both  GSK3α  and  GSK3β  that  Wnt  signalling  is 
deregulated (Figure 3.8). 
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Figure 3:13 Survival of UroIICRE
+ β-catenin
exon3/exon3 Pten
fl/fl mice
 
Kaplan  Meier  curves  of  tumour  free  survival  of  respective  double  mutant  cohorts. 
Abbreviations:  e3/+  fl/+  (UroIICRE
+  β-catenin
exon3/+  Pten
fl/+),  e3/e3  fl/+  (UroIICRE
+  β-
catenin
exon3/exon3  Pten
fl/+),  e3/+  fl/fl
  (UroIICRE
+  β-catenin
exon3/+  Pten
fl/fl)  and  e3/e3  fl/fl 
(UroIICRE
+ β-catenin
exon3/exon3 Pten
fl/fl).  Log rank test indicates significant difference between 
e3/+fl/+ / e3/e3 fl/+ and e3/+ fl/fl
 / e3/e3 fl/fl cohorts (p<0.001). 
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Figure 3:14 Photograph of UroIICRE
+ β-catenin
exon3/exon3 Pten
fl/fl bladder tumour 
The whole bladder here has been replaced by tumour, creating the solid mass seen above. 
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Figure 3.15: Histology of a UroIICRE
+ β-catenin
exon3/exon3 Pten
fl/fl mice 
Histology of a UroIICRE
+ β-catenin
exon3/exon3 Pten
fl/fl mice reveals urothelial bladder tumour 
(A,B) with loss of PTEN (C) and upregulation of pAKT(Ser473) in these tumours (D).  There 
is also upregulation of nuclear β-catenin (E), Ki67 (F) and mTOR(Ser2448) (G).   I noticed no 
upregulation in pERK1/2 in these tumours (H).  By 12 months of age, a small subset of the 
UroIICRE+ β-catenin
exon3/exon3 Pten
fl/+ mice and UroIICRE+ β-catenin
exon3/+ Pten
fl/+ mice had 
developed tumours, presumably due to the loss of the remaining Pten allele (I). Tumours 
demonstrate minimal upregulation of p53 (J) and p21 (K).  There is significant upregulation 
of  p-S6  Kinase  (L).  Red  bar  measures  1000  µm  (4x  magnification),  black  bar  measures 
100µm (40x magnification). 
(At least 3 samples from each cohort stained and representative images are shown above). 136 
 
3.2.5. UroIICRE
+ β-catenin
exon3/exon3 Pten
fl/fl UCCs are mTOR dependent 
 
Given mTOR is one of the key tumour promoting pathways downstream of PTEN loss, I next 
investigated whether tumours from UroIICRE
+ β-catenin
exon3/exon3 Pten
fl/fl mice would remain 
dependent on mTOR even if they were fully established. Therefore I treated UroIICRE
+ β-
catenin
exon3/exon3  Pten
fl/fl  mice  at  6  months  of  age  with  Rapamycin  (10mg/kg  i.p.  daily),  a 
potent  inhibitor  of  mTOR,  or  vehicle  (n=3)  when  mice  had  a  detectable  tumour  using 
Visualsonic’s  Vevo  770  ultrasound.  Remarkably  I  was  able  to  demonstrate  regression  of 
tumour bulk between initiation and the end of treatment (Figure 3.16 A-D). All mice on 
treatment survived the 4-week experiment, however in the vehicle treated mice cohort, 2 mice 
had to be sacrificed early (7 and 11 days) because of tumour burden.  IHC for p-mTOR
2448 
revealed  significant  upregulation  of  this  pathway  in  UroIICRE
+  β-catenin
exon3/exon3  Pten
fl/fl 
mice.  However when treated with 4 weeks of Rapamycin I noticed regression of the lesions 
and downregulation of the protein staining, as well as downstream targets p-S6 kinase and p-
4EBP1 (Figure 3.16 E&F and 3.17). I noticed a statistically significant reduction in the BrdU 
positive  cells  in  the  tumours  from  the  Rapamycin  treated  mice  compared  to  the  vehicle 
controls (p<0.05, Mann Whitney Test) (Figure 3.18). 
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Figure 3.16: UroIICRE
+ β-catenin
exon3/exon3 Pten
fl/fl mice treated with Rapamycin 
Analysis  of  UroIICRE
+  β-catenin
exon3/exon3  Pten
fl/fl  mice  treated  with  4  weeks  of  daily  IP 
injections of Rapamycin (10mg/kg). Ultrasound imaging reveals shrinking of the tumour in 
the treated mice bladders between initiation (A) and end of treatment (B) regimes. I saw 
regression of tumour formation (C) from non-treated controls.  Boxplot shows that bladders of 
treated  mice  have  less  tumour  bulk  p<0.05,  Mann  Whitney  Test)  (D).  IHC  for  p-mTOR 
reveals significant upregulation of this pathway in UroIICRE
+ β-catenin
exon3/exon3 Pten
fl/fl mice 
(E).  However when treated with 4 weeks of Rapamycin I noticed regression of the lesions 
and  downregulation  of  the  protein  staining  (F).  Black  bar  represents  100µm  (all 
magnifications at 40x). 138 
 
 
Figure 3.17: UroIICRE
+ β-catenin
exon3/exon3 Pten
fl/fl mice treated with Rapamycin 
Additional  IHC  for  p-mTOR  reveals  significant  downregulation  of  this  pathway  in 
UroIICRE
+ β-catenin
exon3/exon3 Pten
fl/fl mice after treatment with Rapamycin (A,B).  Similarly I 
also demonstrate that p-4EBP1 and p-S6 Kinase, a known target of the mTOR pathway, is 
downregulated after treatment (C-F).  Black bar represents 100µm (40x objective). 
(At least 3 samples from each cohort stained and representative images are shown above). 
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Figure 3.18: Proliferation of tumours in Rapamycin treated mice versus vehicle control 
Boxplot indicating reduction of BrdU positive cells per 20x field view of bladder tumours 
treated with Rapamycin versus those treated with vehicle control (p<0.05, Mann Whitney 
Test).  At least 3 areas scored from each slide (n=3).  Thick lines represents median, box 
represents inter-quartile range and whiskers the range. 
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3.2.6. Human UCC demonstrate correlation between Wnt activation and PTEN loss 
 
In human urothelial cancer, a number of studies have suggested Wnt signalling is important. 
Of  particular  note  is  the  demonstration  that  nuclear  β-catenin  is  associated  with  a  poor 
prognosis, and methylation of the genes encoding inhibitors of Wnt signalling, the SRFPs, act 
as markers of a bad prognosis (Marsit et al., 2005, Urakami et al., 2006a, Urakami et al., 
2006b). Indeed the methylation of these genes has been suggested as a marker of invasive 
bladder carcinoma.   
A tissue microarray of human bladder UCC containing 80 cases, 60 UCC (transitional cell 
carcinomas [TCC]) and 20 benign controls (Folio biosciences, OH, USA), was studied. Using 
the histoscore technique to quantitate immunoreactivity, upregulation of β-catenin expression 
and  loss  of  PTEN  signal  were  found  to  be  significantly  associated  (n=36/56,  cc=0.314, 
p<0.01,  SPSS  v15).  Upregulated  expression  of  β-Catenin  and  pAKT
Ser473  were  similarly 
associated (n=30/56, cc=0.471, p<0.001, SPSSv15) (Figure 3.19 and 3.20). Taken together, 
loss  of  PTEN  and  resulting  upregulation  of  pAKT  is  essential  for  Wnt  driven  UCC  to 
progress.  
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Figure 3.19: Human Bladder UCC TMA 
IHC  of  3  human  bladder  transitional  cell  carcinoma  cases  (A-C,  D-F  and  G-I)  revealing 
upregulation of β-catenin (A&D), loss of corresponding PTEN signal (B&E) and upregulation 
of pAKT
Ser473 (C&F). Conversely a few samples showed upregulation of PTEN (H) with 
minimal β-catenin and pAKT
Ser473 signal (G&I). 
Each core size is 1.5mm 142 
 
 
 
 
Figure 3.20: Correlation between β-catenin and PTEN/pAKT in Human Bladder UCC 
TMA 
Table demonstrating proportions of cores that show combinations of up- and downregulation 
of  β-catenin  and  PTEN/pAKT  (Upregulation  is  classified  as  ≥100  and  downregulation  as 
<100 using the histoscore technique) (A). Scatterplot demonstrating correlation between β-
catenin and pAKT (B).  
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3.3. Discussion 
 
Data presented in this chapter suggests that activation of Wnt signalling cooperates with other 
mutations such as loss of PTEN/activation of pAKT to drive bladder carcinogenesis. This 
may  indicate  that  the  significance  of  Wnt  signalling  in  human  bladder  cancer  has  been 
underestimated,  due  to  the  relatively  rare  nature  of  APC  and  β-catenin  mutations. 
Traditionally  up  to  a  quarter  of  bladder  tumours  are  thought  to  exhibit  nuclear  β-catenin 
(Kastritis et al., 2009). Instead the Wnt signalling pathway may be involved by epigenetic 
inactivation or mutations in other components of the pathway (e.g. secreted frizzled related 
proteins). Patients with Wnt dependent tumours may be identified by IHC for proteins such as 
β-catenin or downstream proteins such as c-Myc.  Unfortunately the active epitope for β-
catenin rapidly degrades unless the samples are processed and embedded within 24 hours, 
which is not always practical for clinical samples.  Thus there is a need to identify more 
robust biomarkers for Wnt pathway activation that we can transfer to the clinic. 
Indeed our studies would suggest in those patients where tumours had high levels of β-catenin 
and  p-AKT,  the  combination  of  mTOR  and  Wnt  inhibition  might  be  an  attractive 
combination.  My TMA results are exciting, but still very preliminary, since they are carried 
out on a relatively small cohort of patients (n=80).  I am currently repeating these studies on 
larger powered cohorts. 
Recently, antibody-based therapies have also been developed that target molecules of the Wnt 
pathway (such as Wnts and Frizzleds) that are over-expressed in disease (Nagayama et al., 
2005, You et al., 2004).  These tumours may be responsive to antibodies that inhibit Wnt 
signalling through blocking ligand binding such as Frizzled8CRD-hFc (DeAlmeida et al., 
2007).  These are currently being developed and tested in preclinical tumour models. 144 
 
X-ray structure analysis of components of the Wnt pathway (β-catenin, Axins, APC, TCFs, 
Dishevelled,  BCL9  and  their  complexes)  will  allow  future  design  and  testing  of  novel 
compounds targeting this pathway, and a number of high-throughput screening programmes 
to discover such compounds are currently underway (Klaus and Birchmeier, 2008).  Future 
evaluation of combined inhibition of the mTOR and Wnt pathways is desirable.  This would 
indeed  be  the  first  steps  towards  “personalised”  medicine,  in  which  each  tumour  has  its 
molecular signature analysed and subsequent treatment regimes are based on these finding.  
So it would not be unreasonable to suggest our subset of UCC patients with upregulation of 
the Wnt and PI3K pathways may receive a combination of Wnt and PI3K inhibitors for their 
tumours. 
Taken  together,  I  showed  original  data  supporting  a  causative  role  for  β-catenin  in  the 
formation of UCC in vivo and provide definitive evidence that activating mutations in the Wnt 
pathway promote UCC when combined with loss of PTEN/activation of the PI3K pathway. 
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Chapter 4: Ras mutation cooperates with β-catenin activation to drive 
bladder tumorigenesis 
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4.1. Introduction 
 
In  the  previous  experimental  chapter,  I  explored  the  causative  role  of  β-catenin  in  the 
formation of UCC in vivo, and showed that activating mutations in the Wnt pathway promote 
UCC when combined with loss of PTEN/activation of the PI3K pathway.  
H-Ras was the first human oncogene isolated in human UCC, being mutated most often at 
codon  12,  13  and  61  (Reddy  et  al.,  1982).  As  well  as  becoming  constitutively  active, 
overexpression of the protein due to alternative splicing of the last intron can also occur. 
Despite the controversy regarding the reported mutation frequency rate recent studies indicate 
that  HRAS  mutation  occurs  in  approximately  in  30-40%  of  UCC  (Kompier  et  al.,  2010).  
Transgenic  models  have  provided  invaluable  information  regarding  the  molecular 
mechanisms behind HRAS activation (See section 1.6.1.1.). 
Conversely few studies have looked at K-Ras mutations in human bladder cancer, although 
those that have suggest a wide variation in frequency (4-29%) (Ayan et al., 2001, Uchida et 
al., 1995, Olderoy et al., 1998).  Interestingly a study by Vageli and colleagues demonstrated 
the K-Ras oncogene was overexpressed in 15 of the 26 (58%) samples (Vageli et al., 1996).  
Unfortunately, as with many of these studies there was no segregation of samples into non-
invasive and muscle invasive tumours.  
As I have outlined previously the human data regarding Wnt pathway activation is highly 
controversial.  It is now becoming clear that the pathway is activated in a proportion of UCCs, 
but  whether  these  are  segregated  to  the  non-invasive,  papillary  pathway  or  the  muscle 
invasive pathway is yet to be fully elucidated.    
I have previously shown that UroIICRE
+ β-catenin
exon3/exon3 mice develop hyperproliferative 
lesions that do not progress to invasive UCC despite aging. As demonstarted the HRAS mice 
(low-copy)  develop  tumours  only  after  a  very  long  latency  (up  to  26  months)  with  an 147 
 
incomplete penetrance (63%), despite demonstrating significant hyperproliferation at an early 
stage (Zhang et al., 2001).  This is suggestive that additional mutations may be required to 
drive the non-invasive, papillary, UCC phenotype.  Despite K-Ras being implicated in human 
UCC, there are no murine models as yet published. 
Thus the aim of this part of my project was to test the effect of Ras overexpression or its 
mutation on the murine urothelium in vivo to promote carcinogenesis, and its interaction with 
a background of upregulated Wnt signalling. 
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4.2. Results 
 
4.2.1. Ras activation alone does not lead to UCC in the mouse  
 
To  test  whether  oncogenic  Ras  mutation  would  lead  to  UCC,  UroIICRE
+  mice  were 
intercrossed to mice carrying either oncogenic K-Ras G12D allele (Jackson et al., 2001) or 
constitutively active H-Ras oncogene (“low-copy”) (Zhang et al., 2001). I demonstrated that 
neither UroIICRE
+K-Ras
G12D/+ nor H-Ras
Q61L mice developed cancer when aged to 12 months 
of  age  (n=20).    Indeed,  no  phenotypic  abnormalities  were  observed  in  the  urothelium  of 
UroIICRE
+K-Ras
G12D/+ mice (Figure 4.1 A&B). There was minimal proliferation as observed 
by Ki67 staining (Figure 4.1 D&E), with significant upregulation of pERK1/2 compared to 
wildtype (Figure 4.1 G&H). I noticed no upregulation of pAKT, p21, pMEK, Active-Rac1 or 
β-catenin (Figure 4.1 J-K, M-N, Q-P, S-T, and V-W). 
In comparison, as previously published, I noticed global hyperplasia of the 12 month old H-
Ras
Q61L urothelium compared to wildtype (Figure 4.2 C) (Zhang et al., 2001). These “low 
copy”  mice  have  2  copies  of  the  oncogenic  rabbit  transgene.    Although  Zhang  et  al 
demonstrated tumour latency from 10-26 months of age; no tumours were observed in our H-
Ras
Q61L mice cohort at sacrifice (12 months of age). These aged mice again demonstrated 
strong upregulation of pERK1/2 with upregulation of Ki67 and p21 (Figure 4.1 F, I, O), 
without evidence of any upregulation of pAKT signal (Figure 4.1 L).  There was minimal 
upregulation of pMEK and Active-Rac1, although there is some β-catenin staining, there is 
only the occasional sporadic cell that exhibited nuclear staining (Figure 4.1 R,U,X).  This may 
be due to partial Wnt pathway activation by upregulation of the MAPK pathway in the H-
Ras
Q61L mutant urothelium. 
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Figure 4.1: Histology from 12-month-old Wildtype, UroIICRE+K-Ras
G12D/+ and H-
Ras
Q61L mice 
Wildtype,  UroIICRE
+  K-Ras
G12D/+  (oncogenic  point  mutation,  endogenous  levels)  and  H-
Ras
Q61L  (rabbit  transgene,  multiple  copies)  urothelia  H&E  (A-C),  Ki67  (D-F),  perk  (G-I), 
pAKT (J-L), p21(M-O), β-catenin (P-R), pMEK (S-U) and Active-Rac1 (V-X). 
Black bar measures 200µm (20x magnification). 
(At least 3 samples from each cohort stained and representative images are shown above). 
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Thus I next investigated the expression of candidate molecules from the FGFR3 and RAS 
oncogenic pathways within lesions from the UroIICRE
+ β -catenin
exon3/exon3 mice. Within the 
lesions I saw minimal levels of STAT3 signalling (Figure 4.2 C), though very high levels of 
pERK1/2 staining was present (Figure 4.2 D) suggesting a role of the Ras signalling pathway.  
 
 
 
 
 
Figure 4.2: Histology from 12 month old UroIICRE
+ β-catenin
exon3/exon3 mice.  
Within  these  urothelial  lesions  I  see  comparable  (minimal)  STAT3  staining  to  wildtype 
(A&C) with significant upregulation of pERK1/2 compared to wildtype (B&D) signal.  
Black bar measures 200µm (20x magnification). 
(At least 3 samples from each cohort stained and representative images are shown above). 
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4.2.2. Ras activation cooperates with β-catenin to drive UCC formation  
 
To test the cooperation of β-catenin and Ras activation I next generated the following cohorts: 
UroIICRE
+ β-catenin
exon3/exon3 K-Ras
G12D/+ and UroIICRE
+ β-catenin
exon3/exon3 H-Ras
Q61L (n= 
25 and 29 respectively).  Two cohorts were studied, with mice sacrificed at 3 months of age or 
aged mice until tumour development, and then bladder phenotypes were characterised.  In 
contrast  to  the  singly  mutant  mice,  the  UroIICRE
+  β-catenin
exon3/exon3  K-Ras
G12D/+  (mean 
survival  185  days,  median  200  days)  and  UroIICRE
+  β-catenin
exon3/exon3  H-Ras
Q61L  (mean 
survival  231  days,  median  236  days)  mice  rapidly  developed  symptoms  of  bladder 
tumourigenesis, namely abdominal swelling, haematuria (blood in the urine) and hunching 
(Figure 4.3). On necropsy, I observed bladder tumours with histological progression to non-
invasive papillary carcinomas (Figure 4.4 A&B). I found no evidence of metastasis in any of 
our  models.  Unfortunately  a  proportion  of  our  UroIICRE
+  β-catenin
exon3/exon3  K-Ras
G12D/+ 
mice developed lung tumours.  These mice were excluded from this analysis and will be 
discussed in more detail in section 5.2.3. 
Tumours from both models showed a nuclear upregulation of β-catenin and Ki-67 (Figure 4.4 
C-F).  The numbers of proliferating cells within tumours (identified by Ki-67 and BrdU IHC) 
were  much  higher  than  in  the  UroIICRE
+  β-catenin
exon3/exon3  mice  (Figure  4.5),  possibly 
explaining  why  lesions  do  not  progress  in  the  single  mutant.  I  observed  significant 
upregulation of pERK1/2 (Figure 4.4 G-H), with minimal levels of pAKT (Figure 4.4 I&J), 
similar to what was observed in the single β-catenin and Ras mutant mice.  The PTEN signal 
is  still  intact  in  these  tumours  (Figure  4.4  K&L).  In  both  sets  of  tumours  I  noticed 
upregulation  of  the  tumour  suppressor  p21  (Figure  4.4  M&N).    This  upregulation  is 
particularly marked in the UroIICRE
+ β-catenin
exon3/exon3 K-Ras
G12D/+ mutants since the K-Ras 
single mutants have minimal p21 staining.  Interestingly when I quantified the p21 positive 
cells  (per  field  view)  between  H-Ras
Q61L  and  the  UroIICRE
+  β-catenin
exon3/exon3 H-Ras
Q61L 153 
 
mice I noticed a significant drop in positivity in the tumours compared to the hyperplastic 
urothelium of the single mutant (Figure 4.6). 
These data are consistent with tumour formation in the bladder being synergistically promoted 
by Wnt and MAPK signalling.  
 
 
 
 
Figure 4.3: Kaplan Meier curves of tumour free survival of respective mutant cohorts 
Abbreviations: WT (wildtype), U K-Ras (UroIICRE
+K-Ras
G12D/+), U H-Ras (H-Ras
Q61L), UB 
K-Ras (UroIICRE
+ β-catenin
exon3/exon3K-Ras
G12D/+), UB H-Ras (UroIICRE
+ β-catenin
exon3/exon3 
H-Ras
Q61L).  Log rank test reveals significant reduction in survival of UB K-Ras and UB-H-
Ras compared to WT/U K-RAS/U H-Ras (p<0.001). 
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Figure 4.4: Histology of UroIICRE+ β-catenin
exon3/exon3K-RasG12D/+ and UroIICRE+ β-
catenin
exon3/exon3 H-Ras
Q61L mice: 
Reveals  urothelial  bladder  tumours  (A&B).  I  stained  for  Ki67  (C&D),  β-catenin  (E&F), 
pERK1/2 (G&H), pMEK (O&P), pAKT (I&J) and PTEN (K&L). Black bar measures 200µm 
(20x magnification). 
(At least 3 samples from each cohort stained and representative images are shown above). 
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Figure 4.5: Boxplot comparing Ki67 positivity between UroIICRE+ β-catenin
exon3/exon3, 
UroIICRE+ β-catenin
exon3/exon3 H-Ras
Q61L and UroIICRE+ β-catenin
exon3/exon3K-Ras mice 
Boxplot indicating increase of Ki67 positive cells between the 3 cohorts of mice (p<0.001, 
Mann Whitney Test).  At least 3 areas from each slide scored (3 mice per cohort). Thick line 
represents median, box represents inter-quartile range and whiskers represent range. 
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Figure 4.6: Boxplot comparing p21 positivity between H-Ras
Q61L and UroIICRE+ β-
catenin
exon3/exon3 H-Ras
Q61L mice 
Boxplot indicating reduction of p21 positive cells between the 2 cohorts of mice (p<0.001, 
Mann Whitney Test). At least 3 areas from each slide scored (3 mice per cohort). Thick line 
represents median, box represents inter-quartile range and whiskers represent range. 
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4.2.3. p21 upregulation blocks β-catenin driven UCC 
 
As I have shown p21 levels are upregulated in the H-Ras
Q61L hyperplastic urothelium, but in 
the  UroIICRE
+  β-catenin
exon3/exon3  H-Ras
Q61L  tumours  I  noticed  a  significant  drop  in  p21 
positivity.  This is a similar picture to the UroIICRE
+ β-catenin
exon3/exon3 urothelium, where I 
see significant upregulation of p21 in the lesions, but this disappears in the UroIICRE
+ β-
catenin
exon3/exon3Pten
fl/fl  tumours.    In  both  cases  there  appears  to  be  a  bladder-specific 
upregulation  of  p21,  associated  with  blocked  tumourigenesis  of  the  H-Ras  and  β-catenin 
mutants.    Thus,  I  next  tested  if  the  p21  compensatory  mechanism  is  lost,  will  β-catenin 
activation result in progression to frank UCC.  
I  generated  the  following  cohorts:  UroIICRE
+p21
-/-  and  UroIICRE
+β-catenin
exon3/exon3p21
-/- 
(n= 6 and 16 respectively).  I then aged mice until tumour development. The UroIICRE
+β-
catenin
exon3/exon3p21
-/- mice rapidly developed urothelial tumours (mean 237, median 238 days) 
in  comparison  to  the  UroIICRE
+  p21
-/-  that  were  aged  to  18  months  with  no  urothelial 
phenotype (Figure 4.7). 
Indeed consistent with previous studies these tumours demonstrated evidence of proliferation 
by Ki67 staining as well as high levels of nuclear β-catenin and pERK1/2 (Figure 4.8 A-D). 
This time the lesions did not demonstrate any significant level of nuclear p53 or p21 (Figure 
4.8 E-F). This suggests that p21 plays a role in blocking β-catenin induced UCC. 
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Figure 4.7: Kaplan Meier curves of tumour free survival of UroIICRE
+p21
-/- (U p21) and 
UroIICRE
+β-catenin
exon3/exon3p21
-/ (UB p21) cohorts 
Log Rank test p<0.0001 
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Figure 4.8: Histology of UroIICRE
+ β-catenin
exon3/exon3p21
-/- mouse.  
H&E reveals bladder tumour (A) with upregulation of Ki67, β-catenin and pERK1/2 (B-D). 
There  is  minimal  upregulation  of  p53  and  p21  (E&F).  Black  bar  measures  200µm  (20x 
magnification). 
(At least 3 samples from each cohort stained and representative images are shown above). 
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4.2.4. Human UCC demonstrate correlation between Wnt and Ras activation 
 
In human urothelial cancer, a number of studies have suggested Wnt signalling is important. 
Of  particular  note  is  the  demonstration  that  nuclear  β-catenin  is  associated  with  a  poor 
prognosis, and methylation of the genes encoding inhibitors of Wnt signalling, the SRFPs, act 
as markers of a bad prognosis (Marsit et al., 2005, Urakami et al., 2006a, Urakami et al., 
2006b). Indeed the methylation of these genes has been suggested as a marker of invasive 
bladder carcinoma.   
I  next  looked  at  human  bladder  UCC  using  a  tissue  microarray  of  80  cases,  60  UCC 
(transitional cell carcinomas [TCC]) and 20 benign controls (Folio biosciences, OH, USA). 
Using the histoscore technique I was able to demonstrate a significant correlation between 
upregulation  of  β-catenin  and  activation  of  pERK1/2  (n=24/56,  cc=0.333,  p=0.012,  SPSS 
v15) (Figure 4.9 & Figure 4.10). This is further indication that activation of the Ras pathway 
is essential for Wnt driven UCC to progress.  
The presence of nuclear p21 was observed in a third of the tumour samples (20 out of 60), 
which did not show significant association with tumour grade, probably due to the small 
cohort size.  I next wanted to look at correlation between upregulation of β-catenin and loss of 
p21 (Figure 4.9). However I found no evidence for any correlation between the 2 groups 
(cc=0.174,  p=0.199).  Interestingly,  there  was  an  expected  significant  correlation  between 
upregulation of pERK1/2 and p21 loss (cc=0.369, p=0.005).   
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Figure 4.9: Human Bladder UCC TMA 
IHC of human bladder transitional cell carcinoma revealing upregulation of β-catenin (A&D), 
and corresponding upregulation of pERK1/2 (B&E), with minimal expression of p21 (C&F) 
compared to wildtype.  
Each core size is 1.5mm. 
 
 
 
 
 
 163 
 
 
 
 
 
 
 
 
Figure 4.10: Correlation between β-catenin and pERK1/2 in Human Bladder UCC TMA 
Scatterplot demonstrating correlation between β-catenin and pERK1/2. 
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4.3. Discussion 
I have shown that activation of the Ras pathway alone is not enough to drive UCC.  However, 
activation  of  Wnt  signalling  strongly  cooperates  with  other  genetic  events  that  occur  in 
bladder cancer such as activation of Ras to drive carcinoma formation.  Our tumours never 
became invasive, suggesting co-operation of both mutations along the non-invasive/papillary 
UCC pathway.  It must be noted that both our Ras mice are different in respect to knock-
in/overexpression  status.    I  utilised  the  Lox-Stop-Lox  K-Ras  conditional  mouse  strain,  in 
which  expression  of  oncogenic  K-Ras  G12D  is  controlled  by  a  removable  transcriptional 
termination  Stop  element  (Jackson  et  al.,  2001).    Since  the  endogenous  K-Ras  locus  is 
targeted in the K-Ras G12D strain, only endogenous levels of oncogenic K-Ras G12D are 
expressed (not overexpression).  In contrast, the H-Ras model is an overexpression of the 
oncogenic rabbit transgene (point mutation at codon 61 of the second exon converting CAG 
(encoding glutamine) to CTG (leucine) (Zhang et al., 2001).  Transgene copy number varied 
from 2 copies (low copy, UCC from 10-26 months of age) to 48 copies (high copy, UCC from 
4 months of age).  This may account for the difference in phenotypes, namely no phenotype in 
the  UroIICRE
+K-Ras
G12D/+  and  pronounced  hyperplasia  in  the  overexpression  H-Ras
Q61L 
model.  However it is difficult to make any definitive conclusions since we are dealing with 
different Ras alleles.  In anticipation I am currently repeating these experiments with a Lox-
Stop-Lox  H-Ras  G12V  conditional  mouse  strain,  which  will  allow  us  to  make  direct 
comparisons.   
Interestingly, despite modelling all these mutations in the murine urothelium, these tumours 
remain non-invasive and do not metastasis despite extended follow-up.  Again this may be 
due to our tumours not being “aggressive” enough, and by inserting p53 mutations these 
tumours  may  become  locally  invasive  and  ultimately  metastatic,  as  has  been  previously 
outlined in the colon by our group (Muller et al., 2009).  These experiments have been set up 165 
 
and I am currently ageing these mice to demonstrate whether these mice develop muscle 
invasive UCC.  
Given the experimental data from this chapter, it appears p21 acts as a bladder specific block 
to  proliferation  (and  tumourigenesis)  in  the  UroIICRE
+  β-catenin
exon3/exon3  and  H-Ras
Q61L 
mice.  This indeed confirmed to be the case since when p21 was knocked out in these bladder 
lesions they rapidly progressed to UCC. The human UCC correlations of loss of p21 must be 
viewed with a critical eye since, as I have demonstrated that p21 is upregulated early, as a 
bladder specific compensatory mechanism to block proliferation and tumourigenesis.  Our 
TMA’s  cohort  of  tumours  is  of  varying  grades  and  does  not  differentiate  between  non-
invasive and muscle invasive disease.  It will be important to interrogate a larger cohort with 
both  early  and  late  disease.    My  working  hypothesis  is  that  p21  upregulation  would  be 
observed early in precursor lesion (CIS) and low grade tumours, whilst the more aggressive 
and muscle invasive tumours will show loss of their compensatory mechanism and p21 will 
not be expressed at the protein level. 
It will be interesting to treat these mice with an ERK inhibitor in order to investigate whether 
pERK  formation  is  required  for  UCC  formation  in  the  double  mutants.    It  will  also  be 
particularly interesting to look at the UroIICRE
+ β-catenin
exon3/exon3 H-Ras
Q61L lesions to see 
whether the fall in pERK1/2 is accompanied by a fall in p21 
Taken together, I demonstrated the causative role of β-catenin in the formation of UCC in 
vivo and provide evidence that activating mutations in the Wnt pathway promote UCC when 
combined with other oncogenic mutations (Ras) and loss of tumour suppressors (p21).  
 
 
 
 166 
 
 
 
 
 
 
 
Chapter 5: The FGFR3 mutation cooperates with K-Ras and β-Catenin 
mutations to promote skin and lung but not bladder tumour formation 
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5.1. Introduction 
 
In the last chapter I investigated whether Ras mutations were sufficient to drive the murine 
urothelium to develop non-invasive papillary UCC, as is seen with the human disease.  I was 
able to demonstrate that in the case of K-Ras G12D point mutation no tumour forms unless 
this is combined with Wnt pathway upregulation.  In the case of the overexpressing H-Ras 
oncogene, I found that Wnt pathway activation greatly reduced the tumour latency.  I have 
also  previously  demonstrated  that  mice  with  β-catenin  overexpression  co-operates  with 
PTEN/p21 loss to drive tumourigenesis along the non-invasive papillary pathway.   
Thus the aim of this final chapter was to investigate the role of oncogenic FGFR3 mutation on 
the murine urothelium in vivo.  Given our previous experiments, I also wished to test this on 
the background of Wnt pathway upregulation. 
Somatic mutations in Fibroblast Growth Factor Receptor 3 (FGFR3) have been identified at a 
high frequency in the superficial UCC (70%) (Knowles, 2007). FGFR3 is a receptor tyrosine 
kinase  that  is  known  to  mediate  the  effects  of  fibroblast  growth  factors  (FGFs).  Several 
studies have shown that mutations of FGFR3 in the bladder is strongly associated with a low 
tumor grade and stage
 (Billerey et al., 2001, Lamy et al., 2006, Jebar et al., 2005, Lindgren et 
al., 2006). When these activating mutations occur in the germ-line, they are known to cause 
several autosomal dominant human skeletal dysplasia syndromes (Muenke and Schell, 1995).  
Although human studies strongly suggest the importance of FGFR3 mutations in cancer, thus 
far they have been uninformative on the precise mechanistic role of FGFR3 mutations in 
tumour formation and progression. Generation of relevant mouse model is essential not only 
for the investigation of mechanism but also for testing potential therapeutic approaches. In 
this study, I assessed the role of two potent, activating mutations of FGFR3 found in UCC in 168 
 
the initiation and development of bladder cancer in vivo as a sole driver, and in synergy with 
β-catenin and K-Ras mutations. 
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5.2. Results 
5.2.1. Targeting of the Fgfr3 mutations in the bladder 
 
I bred UroIICRE
+ mice to lines carrying Fgfr3 K644E and Fgfr3 K644M mutations (murine 
equivalent of human K652E and K652M, respectively) (Iwata et al., 2000, Iwata et al., 2001). 
Both  lines  carry  a  neomycin  resistant  gene  (neo)  flanked  by  loxP  sites  in  the  intron  5’-
upstream  of  the  exon  harboring  the  K644  mutations.  This  exogenous  gene  insertion  was 
designed  to  suppress  the  expression  of  Fgfr3  mutant  allele  in  the  absence  of  Cre 
recombination. In the presence of Cre, the neo gene is excised allowing expression of the 
mutant Fgfr3 protein. In the offspring of UroIICRE
+Fgfr3
+/K644E and UroIICRE
+Fgfr3
+/K644M, 
pattern and approximate levels of the Fgfr3 protein expression were similar to those of the age 
matched  wildtype  (Figure  5.1  A,B,E  &  Figure  5.2).  In  wildtype  mice,  Fgfr3  expression 
revealed occasional scattered cells in the urothelium at P2 (Postnatal day 2) and 5 months; 
whilst at 12 months its expression was uniformly detected in the urothelium (Figure 5.1 D-F).  
I did not notice any difference in staining expression at earlier 3-month timepoint in the 
UroIICRE
+Fgfr3
+/K644E  and  UroIICRE
+Fgfr3
+/K644M  mice  compared  to  the  12-month 
timepoint. 
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Figure 5.1 Cre recombination and expression of Fgfr3 in the urothelium 
Immunohistochemistry  (IHC)  for  Fgfr3  (arrowhead)  in  the  urothelium  of 
UroIICRE
+Fgfr3
+/K644E (A), UroIICRE
+Fgfr3
+/K644M (B), as well as P2 (postnatal day 2) (C), 5 
month (D) and 12 month-old (E) wildtype urothelium. This revealed that expression levels 
and location of Fgfr3 were comparable in the mutant and wildtype at 12 month. Scale bar 
represents 200 µm in B-F. 
(At least 3 samples from each cohort stained and representative images are shown above). 
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Figure 5.2 FGFR3 positive cells in 12 month old Wildtype, UroIICRE+Fgfr3
+/K644E and 
UroIICRE+Fgfr3
+/K644M   
20x magnification, 3 fields per murine bladder, 3 mice for each cohort sampled. 
Thick  line  represents  median,  box  represents  inter-quartile  range  and  whiskers  represent 
range. 
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5.2.2. Fgfr3 mutation alone does not drive tumourigenesis of the bladder 
 
To  investigate  the  role  of  Fgfr3  mutations  as  a  driver  of  UCC,  I  aged  the 
UroIICRE
+Fgfr3
+/K644E and UroIICRE
+Fgfr3
+/K644M mutant mice to 18 months (n=20 each 
genotype). No mouse developed urothelial hyperplasia, dysplasia or carcinoma when aged to 
18 months of age (Figure 5.3 & 5.4 A,E,I). 
Upon 2 hours of in vivo incorporation of BrdU in our 12 month old cohort, no apparent 
positivity  was  observed  by  IHC  with  anti-BrdU  antibody,  indicating  that  little  or  no  cell 
proliferation took place in the urothelium either in the wildtype or in the mutant cohorts 
(Figure  5.4  B,F,J).  I  next  examined  the  known  core  signalling  pathways  downstream  of 
FGFR. A strong upregulation of pERK1/2 was observed in both UroIICRE
+Fgfr3
+/K644E and 
UroIICRE
+Fgfr3
+/K644M mutants compared to wildtype (Figure 5.4 C,J,K & Figure 5.5). This 
was accompanied by an upregulation of Sprouty2 levels (Figure 5.4 H,L & Figure 5.5). No 
significant  pAKT  (Ser473)  or  p-mTOR  staining  was  present  in  the  Fgfr3  mutant  cohorts 
similar to wildtype (Figure 5.6). 
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Figure 5.3 Bladder H&Es from 12 month old Wildtype, UroIICRE
+Fgfr3
+/K644E and 
UroIICRE
+Fgfr3
+/K644M mice 
(At least 3 samples from each cohort stained and representative images are shown above). 
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Figure 5.4 Fgfr3 mutation is not the sole driver of tumourigenesis in the bladder.  
The  samples  are  from  12-month  old  Wildtype  (A-D),  UroIICRE
+Fgfr3
+/K644E  (E-H)  and, 
UroIICRE
+Fgfr3
+/K644M (I-L). Haematoxylin and eosin (H&E) staining showed no apparent 
lesions in the urothelium in all Fgfr3 mutants (A,E,I). No significant cell proliferation was 
observed (as assessed by 2 hours of in vivo BrdU incorporation) (B,F,J). Upregulation of 
pERK1/2  (J,K)  and  Sprouty2  (H,L)  were  observed  in  Fgfr3  mutant  mice,  comparing  to 
Wildtype (C,D). Scale bar represents 200 µm in all panels.  
(At least 3 samples from each cohort stained and representative images are shown above). 
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Figure 5.5 Further images showing upregulation of pERK1/2 and Sprouty2: 
In 12-month-old UroIICRE+Fgfr3+/K644E (D-F, M-O), UroIICRE+Fgfr3+/K644M (G-I, P-
R) compared to wildtype bladders (A-C, J-L). Scale bar represents 200 µm in all panels.  
(At least 3 samples from each cohort stained and representative images are shown above). 176 
 
 
 
 
Figure 5.6 Role of the AKT-mTOR pathway in mutant models 
The  samples  are  from  12-month  old  Wildtype  (A-B),  UroIICRE
+Fgfr3
+/K644E  (C-D), 
UroIICRE
+Fgfr3
+/K644M  (E-F),  UroIICRE
+Fgfr3
+/K644EK-Ras
G12D/+  (G-H),  and 
UroIICRE
+Fgfr3
+/K644Eβ-catenin
exon3/+  (I-J).  Minimal  upregulation  of  pAKT  and  p-mTOR 
was observed in all mutant cohorts compared to wildtype. Red arrowhead in (I) indicates the 
area of hyperproliferation. Scale bar represents 200 µm in all panels.  
(At least 3 samples from each cohort stained and representative images are shown above). 177 
 
 
Given  our  previous  experimental  work  I  next  examined  the  role  of  β-catenin  activating 
mutations in the context of FGFR3 mutation, UroIICRE
+Fgfr3
+/K644Eβ-catenin
exon3/+ (n=27) 
(Harada et al., 1999).  In order to drive deregulated Wnt signalling, I again used mice that 
carry a dominant allele of the β-catenin gene in which exon3 is flanked by loxP sequences 
(Harada et al., 1999). Although areas of hyperproliferation were observed in the bladders of 
UroIICRE
+Fgfr3
+/K644Eβ-catenin
exon3/+ from approximately 3 months of age in 100% of mice 
(n=20), equivalent lesions were found in the UroIICRE
+β-catenin
exon3/+ urothelium. In both 
groups these lesions never progressed further upon examination up to 12 months (Figure 5.7 
E); however they did show incorporation of BrdU (Figure 5.7F). Similar to above described 
single and double mutants, upregulation of pERK1/2 and Sprouty2 was also observed (Figure 
5.7 G,H). The areas of hyperproliferation that were observed in UroIICRE
+β-catenin
exon3/+ 
mice had comparable levels of upregulation of BrdU, pERK1/2 and Sprouty2 in the lesions 
(data not shown), indicating that Fgfr3 mutations are not contributing to urothelial hyperplasia 
in  UroIICRE
+Fgfr3
+/K644Eβ-catenin
exon3/+  mice.  I  did  not  observe  any  upregulation  of 
pAKT(Ser473)  or  p-mTOR  (Figure  5.6).  Taken  together,  these  data  suggest  that  FGFR3 
mutation does not cooperate with activation of Wnt signaling to drive UCC.   
 
I  next  examined  the  role  of  oncogenic  K-Ras  G12D  (Jackson  et  al.,  2001)  in 
UroIICRE
+Fgfr3
+/K644EK-Ras
G12D/+  (n=23).    Upon  aging  to  12  months,  no 
UroIICRE
+Fgfr3
+/K644EK-Ras
G12D/+  mice  developed  urothelial  hyperplasia,  dysplasia  or 
carcinoma (Figure 5.7 A) and no apparent changes in BrdU incorporation were observed 
(Figure 5.7 B). Similar to the single mutants, a strong upregulation of pERK1/2 (Figure 5.7 C) 
as well as an accompanying upregulation of Sprouty2 was observed (Figure 5.7 D). Similar 
levels of upregulation of pERK1/2 and Sprouty2 were observed in the UroIICRE
+K-Ras
G12D/+ 178 
 
urothelium (data not shown). I observed minimal levels of upregulation of pAKT(Ser473) and 
p-mTOR in the UroIICRE
+Fgfr3
+/K644EK-Ras
G12D/+ cohorts (Figure 5.6). 
 
 
 
 
 
Figure 5.7 Fgfr3 mutation in combination does not lead to tumourigenesis in the bladder 
The  samples  are  from  12-month  old  UroIICRE
+Fgfr3
+/K644EK-Ras
G12D/+  (A-D),  and 
UroIICRE
+Fgfr3
+/K644Eβ-catenin
exon3/+  (E-H).  Haematoxylin  and  eosin  (H&E)  staining 
showed no apparent lesions in the urothelium in UroIICRE
+Fgfr3
+/K644EK-Ras
G12D/+ mice (A) 
except for the compound model with β-catenin
exon3/+ (E) where hyperplasia was observed (red 
arrowhead, also in G,H). No significant cell proliferation was observed (as assessed by 2 
hours  of  in  vivo  BrdU  incorporation)  (B)  except  for  the  area  of  hyperplastic  lesion  in 
UroIICRE
+Fgfr3
+/K644Eβ-catenin
exon3/+ (arrowhead) (F). Upregulation of pERK1/2 (C,G) and 
Sprouty2  (D,H)  were  observed  in  Fgfr3  mutant  mice,  comparing  to  Wildtype.  Scale  bar 
represents 200 µm in all panels.  
(At least 3 samples from each cohort stained and representative images are shown above). 
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5.2.3. Formation of lung tumors in the UroIICre
+Fgfr3
+/K644Eβ-catenin
exon3/+ mice 
 
In contrast to observations in the urothelium, 28% (8/28) of the UroIICRE
+Fgfr3
+/K644Eβ-
catenin
exon3/+ mice by 1 year of age developed lung tumours (Figure 5.8). Imaging with the 
OV100  microscope  showed  a  strong  GFP  signal  in  the  lung  tumor,  indicating  that  the 
UroIICRE-driven recombination occurred in these tumors (Figure 5.9 A). I did not see any 
signal in the normal lung tissue. These tumors resembled most closely solitary fibrous tumour 
(SFT) of the lung (Figure 5.9 B). Up to a third of SFTs exhibit nuclear β-catenin consistent 
with our murine models (Andino et al., 2006).  Solitary fibrous tumours (SFTs) were termed 
hemangiopericytomas  (HPCs)  in  the  past.  According  to  the  World  Health  Organization 
(WHO),  these  tumours  are  mesenchymal  neoplasms  of  subendothelial  origin  that  can  be 
found mostly in the pleura but also in extraserosal sites, such as lung, mediastinum, liver, 
head and neck, and deep soft tissues of the extremities. Most SFTs behave as slowly growing, 
painless masses (Kouki et al., 2008). In our murine tumours strong BrdU positivity indicated 
rapid cell proliferation (Figure 5.9 C). In addition tumors showed high levels of nuclear β-
catenin by IHC, consistent with the activation of β-catenin due to Cre mediated excision of 
exon 3 (Figure 5.9 D). No lung tumors were observed in the UroIICRE
+β-catenin
exon3/+ mice 
aged up to 18 months (n=20); therefore the FGFR3 mutation is cooperating with β-catenin 
activation to drive lung tumourigenesis. 
Increased levels of pAKT (Ser473) and p-mTOR were observed (Figure 5.9 E,F), suggesting 
the involvement of AKT pathway in tumourigenesis. However, I found minimal upregulation 
of pERK in these tumors with accompanying upregulation of Sprouty2 (Figure 5.9 G,H). 
I  compared  these  tumors  to  phenotypically  similar  lung  tumours  found  in  UroIICRE
+β-
catenin
exon3/+K-Ras
G12D/+ mice. In these tumors, I found that rather than having high levels by 
the pAKT pathway, they was dramatic upregulation of pERK1/2, with corresponding fall in 
Sprouty2 expression (Figure 5.9 I-L). When I measured staining intensity using a weighted 180 
 
Histoscore  technique,  I  found  statistically  significant  increases  in  both  nuclear  and 
cytoplasmic pERK1/2 staining in the UroIICRE
+β-catenin
exon3/+K-Ras
G12D/+ cohort compared 
to the UroIICRE
+Fgfr3
+/K644Eβ-catenin
exon3/+ mice (p<0.001, Figure 5.10 A,B) (Kirkegaard et 
al., 2006). Conversely, I found much higher levels of pAKT(Ser473) staining in lung tumors 
of  the  UroIICRE
+Fgfr3
+/K644Eβ-catenin
exon3/+  mice  in  comparison  to  UroIICRE
+β-
catenin
exon3/+K-Ras
G12D/+ mice (p<0.001, Figure 5.10 C,D).  Consistent with this, p-mTOR 
staining was also upregulated in UroIICRE
+Fgfr3
+/K644Eβ-catenin
exon3/+ mice.  As observed 
with the IHC, when quantified I observed increased levels of membranous and cytoplasmic 
Sprouty2  staining  in  the  UroIICRE
+Fgfr3
+/K644Eβ-catenin
exon3/+  mice  in  comparison  to 
UroIICRE
+β-catenin
exon3/+K-Ras
G12D/+ (p<0.05) (Figure 5.10 E&F). 
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Figure 5.8 Kaplan-Meier curve of UroIICRE
+Fgfr3
+/K644Eβ-catenin
exon3/+ (Fgfr3 β-Cat) 
mice 
UroIICRE
+Fgfr3
+/K644Eβ-catenin
exon3/+ (Fgfr3 β-Cat) cohorts showed accelerated lethality due 
to  tumour  formation  comparing  to,  UroIICRE
+β-catenin 
exon3/+(B-cat),  and 
UroIICRE
+Fgfr3
+/K644E (Fgfr3). Long rank test reveals significant reduction in survival in 
Fgfr3 B-cat colony compare to Fgfr3/B-cat colonies (p<0001). 
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Figure 5.9 Formation of lung tumor in the UroIICRE
+Fgfr3
+/K644Eβ-catenin
exon3/+ model. 
Ex-vivo GFP imaging by OV100 (Olympus) demonstrated Cre-mediated recombination in the 
lung  tumors  of  UroIICRE
+Fgfr3
+/K644Eβ-catenin
exon3/+  (A).  H&E  staining  shows  the  lung 
tumour (B), in which BrdU staining indicates high cell proliferation in the lesion (C).  Strong 
nuclear staining indicates the activation of β-Catenin in the tumour (D). pAKT(Ser473) (E), 
p-mTOR(Ser2448)  (F)  and  Sprouty2  (H)  were  all  upregulated  in  the  lung  tumor  in 
UroIICRE
+Fgfr3
+/K644Eβ-catenin
exon3/+, with minimal pERK (G) staining. In comparison, lung 
tumors in UroIICRE
+β-catenin
exon3/+K-Ras
G12D/+ show minimal upregulation of pAKT (I) and 
p-mTOR (J), but strong upregulation of pERK (K) with very little Sprouty2 increase (L). 
Scale bar represents 200 µm. 
(At least 3 samples from each cohort stained and representative images are shown above). 
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Figure 5.10 Box plots quantifying immunostaining of pERK1/2, pAKT(Ser473) and 
Sprouty2 in lung tumors of UroIICRE
+β-catenin
exon3/+K-Ras
G12D/+ and 
UroIICRE
+Fgfr3
+/K644Eβ-catenin
exon3/+ mice   
For  each  tissue  section  (n=5),  the  percentage  of  immunoreactivities  in  the  nucleus  and 
cytoplasm was evaluated at × 40 magnification. Staining intensity was categorized into the 
percentage of cells with 0, 1, 2 and 3, denoting negative, weak, moderate and strong staining, 
respectively. The final histoscore was calculated from the sum of (1 × % weakly positive 
tumour cells) + (2 × % moderately positive tumour cells) + (3 × % strongly positive tumour 
cells) positive tumour cells with a maximum histoscore of 300.  Statistics were performed 
using the Mann Whitney test. 184 
 
5.2.4. Skin Papilloma formation in UroIICre
+Fgfr3
+/K644EK-Ras
G12D/+ mice 
 
By  1  year  of  age,  10/21  (48%)  of  UroIICre
+Fgfr3
+/K644EK-Ras
G12D/+  cohort  developed 
papilloma (Figure 5.11, Figure 5.12 A,C). These tumours reached 1 cm of size by a median of 
220  days  (mean  249  days).  To  ensure  the  tumour  formation  was  due  to  sporadic  Cre 
recombination, I crossed the UroIICRE
+Fgfr3
+/K644EK-Ras
G12D/+ mice to Z/EGFP reporter. I 
observed  a  strong  GFP  signal  within  these  papillomas,  indicating  the  Cre  recombination 
(Figure 5.12 E), with no expression in normal skin. In contrast, no papilloma formation was 
observed in the UroIICRE
+K-Ras
G12D/+ cohort aged up to 18 months (n=20), indicating that 
Fgfr3 mutation cooperates with K-Ras mutation to drive papilloma formation. The papillomas 
in  the  UroIICRE
+Fgfr3
+/K644EK-Ras
G12D/+  cohort  incorporated  BrdU  (Figure  5.13  A), 
indicating the increase in cell proliferation. Mechanistically, tumour formation was associated 
with a robust activation of pERK1/2 (Figure 5.13 C). Distinct from the observation in the 
urothelium of these mice, an increased level of Sprouty2 was not observed (Figure 5.13 E), 
which either suggests that the negative feedback counteracting oncogenic MAPK pathway has 
not occurred in this line or that all the Sprouty2 has been lost (e.g. hypermethylation in the 
tumours).  Levels  of  pAKT  (Ser473)  and  p-mTOR  were  unchanged  (Figure  5.13  G,I).  I 
noticed upregulation of p21 and pMEK (Figure 5.13 K,M)  
I  compared  this  phenotype  to  UroIICRE
+K-Ras
G12D/+Pten
fl/+  mice  that  regularly  develop 
papillomas (8/19 or 42%) (Figure 5.12 B,D). I found a similar increase in BrdU incorporation, 
but this time with much lower levels of nuclear pERK1/2 observed in the lesion (Figure 5.13 
B,D). Sprouty2 was upregulated (Figure 5.13 F) similar to urothelium phenotype of Fgfr3 
mutant models, while elevated levels of pAKT (Ser473) and p-mTOR were also observed 
(Figure 5.13 H,J).  Similarly I observed upregulation of p21 and pMEK (Figure 5.13 L,N).  I 
also measured staining intensity using a modified Histoscore in the papillomas from each 
cohort  (n=5).  I  found  statistically  significant  increases  in  both  nuclear  and  cytoplasmic 185 
 
pERK1/2 staining in the UroIICRE
+Fgfr3
+/K644EK-Ras
G12D/+ compared to the UroIICRE
+K-
Ras
G12D/+Pten
fl/+  mice  (p<0.001/0.05  respectively,  Figure  5.14  A,B).  Conversely,  I  found 
much  higher  levels  of  pAKT(Ser473)  staining  in  papillomas  of  the  UroIICRE
+K-
Ras
G12D/+Pten
fl/+   mice in comparison to UroIICRE
+Fgfr3
+/K644EK-Ras
G12D/+ mice (p<0.001, 
Figure  5.14  C,D).  These  results  indicate  that  although  Sprouty-mediated  suppression  of 
MAPK signaling is intact, activation of AKT pathway may contribute to tumourigenesis in 
this model.  
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Figure 5.11 Kaplan-Meier curve of UroIICRE
+Fgfr3
+/K644EK-Ras
G12D/+ (Fgfr3 K–Ras) 
mice 
UroIICRE
+Fgfr3
+/K644EK-Ras
G12D/+ (Fgfr3 K–Ras) cohorts showed accelerated lethality due to 
tumor formation comparing to, UroIICRE
+K-Ras
G12D/+ (K-Ras), and UroIICRE
+Fgfr3
+/K644E 
(Fgfr3). The shorter survival of UroIICRE
+Fgfr3
+/K644EK-Ras
G12D/+ mice compared to control 
cohorts reflects the fact that I have sacrificed the animals when the tumor size reached 1 cm.  
Log rank p<0.001 for Fgfr3 K-Ras vs. Fgfr3/K-Ras cohorts. 
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Figure 5.12 Formation of papilloma lesions in the UroIICRE
+Fgfr3
+/K644EK-Ras
G12D/+ 
model 
H&E  staining  of  papilloma  samples  are  from  12  month-old  of  UroIICRE
+Fgfr3
+/K644EK-
Ras
G12D/+ (A,C) and UroIICRE
+K-Ras
G12D/+Pten
fl/+ mice (B,D). OV100 whole-mouse GFP 
imaging indicated Cre-recombined cells in papilloma (E). 
Red scale bar represents 400 µm and black scale bar represents 200 µm. 
(At least 3 samples from each cohort stained and representative images are shown above). 
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Figure 5.13 Formation of papilloma lesions in the UroIICRE
+Fgfr3
+/K644EK-Ras
G12D/+ 
model 
Papilloma  samples  are  from  12  month-old  of  UroIICRE
+Fgfr3
+/K644EK-Ras
G12D/+ 
(A,C,E,G,I,G,M)  and  UroIICRE
+K-Ras
G12D/+Pten
fl/+  mice  (B,D,F,H,J,L,N).  BrdU 
immunoreactivity  demonstrated  cell  proliferation  (A,B).  Upregulation  of  pERK1/2  was 
observed in UroIICRE
+Fgfr3
+/K644EK-Ras
G12D/+ (C) as observed in the urothelium, and in the 
control UroIICRE
+K-Ras
G12D/+Pten
fl/+ mice (D). However, upregulation of Sprouty2 was not 
present (E). Neither pAKT(Ser473) nor p-mTOR was upregulated in papillomas formed in 
UroIICRE
+Fgfr3
+/K644EK-Ras
G12D/+ mice (G,I). In contrast, in UroIICRE
+K-Ras
G12D/+Pten
fl/+ 
papillomas, Sprouty 2 (F), pAKT(Ser473) (H) and p-mTOR (J) was upregulated. I noticed 
significant upregulation of p21 in the papillomas (K,L), as well as pMEK (M,N) 
Scale bar represents 200 µm in all panels. 
(At least 3 samples from each cohort stained and representative images are shown above). 
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Figure 5.14 Box plots quantifying immunostaining of pERK1/2 and pAKT(Ser473) in 
papillomas of UroIICRE
+Fgfr3
+/K644EK-Ras
G12D/+ and UroIICRE
+K-Ras
G12D/+Pten
fl/+ mice  
For  each  tissue  section  (n=5),  the  percentage  of  immunoreactivities  in  the  nucleus  and 
cytoplasm was evaluated at × 40 magnification. Staining intensity was categorized into the 
percentage of cells with 0, 1, 2 and 3, denoting negative, weak, moderate and strong staining, 
respectively. The final histoscore was calculated from the sum of (1 × % weakly positive 
tumour  cells) + (2 × %  moderately  positive  tumour  cells) + (3 × %  strong  of  experience) 
positive tumour cells with a maximum histoscore of 300.  Statistics were performed using the 
Mann Whitney test. 
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5.3. Discussion 
 
In summary, I have demonstrate here that activating mutations of FGFR3 are unlikely to be 
the sole initiating factor for UCC (Figure 2) and that FGFR3 does not cooperate with either 
Wnt or Ras signaling to drive UCC. Given that FGFR3 mutations are thought to be mutually 
exclusive  with  HRAS  mutations  and  only  rarely  mutated  with  p53  this  suggests  that 
generating mouse models that recapitulate superficial UCC that have FGFR3 mutations will 
be difficult and will require greater knowledge of the genetic changes that accompany FGFR3 
mutations (Puzio-Kuter et al., 2009, Wu, 2005).   
The study showed that somatic FGFR3 mutations caused upregulation of the MAPK pathway 
in  the  urothelium,  which  accompanied  upregulation  of  Sprouty2,  one  of  the  feedback 
inhibitors of the MAPK pathway. I speculate that this may be one of the mechanisms by 
which  UCC  is  normally  prevented.  In  case  of  lung  tumours  in  UroIICRE
+Fgfr3
+/K644Eβ-
catenin
exon3/+ cohort, a strong upregulation of the PI3K-pAkt and Wnt-β-Catenin pathways 
may  underlie  tumourigenesis.  In  contrast,  in  papillomas  in  UroIICRE
+Fgfr3
+/K644EK-
Ras
G12D/+,  no  concomitant  upregulation  of  Sprouty2  had  occurred,  potentially  leading  to 
uncontrolled activation of MAPK pathway in the absence of a negative feedback mechanism. 
It is tempting to propose that these differential downstream signaling profiles are the basis of 
tumourigenesis in the presence of Fgfr3 mutations in a tissue-specific fashion (Figure 5.15). It 
would  be  interesting  to  assess  if  downregulation  of  Sprouty2  in  our  system  resulted  in 
formation  of  UCC.    Using  Oncomine
TM 
(http://www.oncomine.org/geneModule/differential/filterStore.jsp)  Lindgren  and  colleagues 
have demonstrated that in FGFR3 mutant bladder cancer there is a downregulation of Sprouty 
2 at the mRNA level (p=0.015) (Lindgren et al., 2006). In the same study they find that 192 
 
Sprouty2  mRNA  levels  are  downregulated  as  the  disease  progresses  from  Grade  1  to  3 
(p=0.015).  
 
 
 
 
 
 
Figure 5.15 Current model of signaling pathways that could contribute to tumour 
formation in the presence of Fgfr3 mutations in specific organ systems 
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FGFR3  is  a  membrane  tyrosine  kinase  that  is  known  to  mediate  the  effects  of  fibroblast 
growth factors (FGFs). Somatic mutations in FGFR3 have been identified at a high frequency 
in bladder cancer (35-41%) (Cappellen et al., 1999, Sibley et al., 2001a, Sibley et al., 2001b). 
In bladder, the frequency of FGFR3 mutation was higher in superficial tumours than invasive 
ones (Billerey et al., 2001, van Rhijn et al., 2001, Kimura et al., 2001). The mutations found 
in bladder cancer are specific and not found in other primary tumours and tumour cell lines 
(Sibley et al., 2001a, Sibley et al., 2001b, Karoui et al., 2001). However, frequent mutation 
has been detected in seborrhoeic keratoses and epidermal naevi (Hafner et al., 2007a, Hafner 
et al., 2007b, Hafner et al., 2006).   
K652E and K652M (equivalent of murine K644E and K644M respectively) mutations, which 
I described in this thesis, are found in human UCC but are much less frequent (3%) than the 
S249C which account for 67% of the FGFR3 mutations in bladder cancer (Knowles 2008). 
Thus it is possible that S249C mutations are more oncogenic in the bladder. In vitro, both 
S249C and K652E/K652M mutations are shown to constitutively increase the FGFR3 kinase 
activity,  albeit  with  different  mechanisms.  S249C  is  known  to  cause  ligand-independent 
dimerization, while K652E/K652M promotes conformational change that favors the higher 
auto-phosphorylation  and  its  kinase  activity  can  be  further  enhanced  by  additional  ligand 
stimulation (Naski et al., 1996, d'Avis et al., 1998). Upon measuring transcription-inducing 
activity by fos-luciferase reporter assay, K644E mutant protein was actually twice as active as 
S249C  mutant  in  the  absence  of  ligand  (d'Avis  et  al.,  1998).    However  preliminary  data 
suggests that, transgenic mice with human FGFR3IIIb isoform with S249C mutation did not 
show any tumors in the bladder up to 1 year of age (M. Knowles personal communication). 
This  strongly  indicates  that  UCC  formation  requires  an  additional  mutation(s)  to  that  in 
FGFR3.   194 
 
The skin papilloma and lung tumours observed in our study with Fgfr3 mutations are relevant 
in human cancer, as FGFR3 mutations are found in such tumours (Woenckhaus et al., 2006, 
Hafner et al., 2007a, Cortese et al., 2008). Studies by Logie et al showed that the transgenic 
mice, K5-(S249C)FGFR3, that expresses FGFR3 S249C mutation in the basal cells of the 
epidermis driven by bovine keratin 5 promoter, developed benign skin tumours (Logie et al., 
2005). In these mice, the skin tumours are observed from 3-4 months of age and lesions 
enlarged  as  the  animals  aged,  without  showing  regression.  To  further  this  work  we  are 
investigating activation of FGFR3 in the skin using the skin specific K14-Cre ER with and 
without Ras activation (Indra et al., 2000).  We currently have a number of FGFR3 inhibiting 
antibodies in the lab that I would wish to try in these mice to assess tumour response. 
Recent work has elegantly demonstrated knockdown of FGFR3 expression suppressed growth 
of bladder cell lines and mouse xenograft models (Qing et al., 2009). Furthermore, FGFR3-
specific  monoclonal  antibody  (R3Mab)  significantly  inhibited  growth  and  progression  of 
xenograft tumors that harboured the S249C and K650E mutations (Qing et al., 2009).  Further 
studies of the FGFR3 signaling pathway deregulated in UCC is therefore essential, firstly to 
allow one to stratify patients according to risk of progression/recurrence, and secondly to aid 
in patient selection for either single agent or combination therapy with small molecule and 
monoclonal antibody-based treatments in the future (Knowles, 2008, Black et al., 2007, Qing 
et al., 2009).  Moreover identifying the cooperating molecular events that occur alongside 
FGFR3  mutation  to  drive  UCC  will  aid  development  of  genetic  models  of  UCC  to  test 
combinatorial therapies. 
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Chapter 6: Summary and Concluding Remarks 
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6.1. Summary 
 
Manipulation of the mouse genome has allowed researchers to analyse the effect of specific 
genetic alterations on the development of urothelial cell cancer (UCC) in vivo.  We are able to 
analyse  the  molecular  basis  of  initiation,  invasion  and  progression  to  metastatic  disease. 
Transgenic mice had improved the molecular characterisation of the divergent pathways of 
UCC and metastasis and help examine the crosstalk among different genetic mutations.  In the 
future one would hope that they identify new prognostic targets and novel therapeutic agents, 
as well as providing in vivo models to test these treatment regimes.  
In this thesis I hope I have achieved my initial aims and have shown that deregulated Wnt 
signalling plays a critical role in driving UCC both in the mouse (and the human).  I have 
demonstrated that Wnt signaling within the bladder urothelium is a progressor mutation of 
UCC in the background of mutations to other key oncogenic/tumour suppressor genes (PTEN, 
Ras p21, FGFR3).  Finally I have developed better murine models of human UCC that will 
allow pre-clinical trialling of new drug agents and assessment of treatment response. 
I showed that deregulated Wnt signalling on a background of PTEN loss leads to UCC that 
appears  to  be  mTOR  dependent  (regression  with  rapamycin  treatment).  Similarly  in  our 
human UCC cohort we find that those patients that have high levels of Wnt signalling appear 
to correlate with those that have high levels of pAKT (and loss of PTEN). 
I next looked at oncogenic Ras signalling on the background of deregulated Wnt signalling 
and discovered similar results with both H-Ras and K-Ras causing UCC in the β-catenin 
mutant mouse. In our human cohort I demonstrated a correlation between upregulation of β-
catenin and pERK1/2.  However whether the pERK1/2 upregulation is solely due to Ras 
mutation is unlikely, making it interesting to sequence these tumours that upregulate β-catenin 
to assess Ras mutational status. 197 
 
I observed that in our β-catenin urothelial lesions, as well as the H-Ras induced hyperplasia an 
upregulation of the p21 tumour suppressor. Thus, I next decided to knock-out p21 in this 
mouse and demonstrated again that p21 provides an essential block to the progression of 
deregulated Wnt induced tumourigenesis in the urine urothelium.  Although this upregulation 
was not confirmed by our human TMA, this is not unexpected due to the heterogenous grade 
and types of samples I had access to.  As a result I am expanding our cohort to look at early 
neoplastic (CIS) and low-grade tumours, where one would expect upregulation of p21. 
Similarly I attempted to test the functional significance of FGFR3 mutations as a “driver” of 
UCC.  Thus  I  targeted  the  expression  of  mutated  Fgfr3  to  the  murine  urothelium  using 
uroplakin  II  promoter.  These  FGFR3  mutations  had  no  effect  on  bladder  homeostasis  or 
tumourigenesis up to 18 months of ages. Even when these mutations were combined with β-
Catenin  or  Ras  activating  mutations,  no  urothelial  dysplasia  or  UCC  was  observed.  This 
suggests that other alterations are required that can cooperate with FGFR3 activation to cause 
UCC.  To  further  investigate  the  role  of  these  co-operating  mutations  with  FGFR3,  I  am 
currently  breeding  these  mice  with  a  transposon  based  method  that  utilises  the  synthetic 
Tc1/mariner family transposon Sleeping Beauty (SB) to induce tumourigenesis in vivo (Collier 
et al., 2005, Dupuy et al., 2005).  This synthetic SB transposon, called T2/Onc, can both trap 
upstream genes and promote downstream sequences.  This allows both inactivation of tumour 
suppressor genes and activation of oncogenes.  Since it is foreign DNA, the SB insertion sites 
can be readily cloned and rapidly characterised to implicate genes that are co-operating with 
FGFR3 to drive UCC in vivo. 
Interestingly, however, due to sporadic ectopic Cre recombinase expression in the lung and 
skin  of  these  mice,  FGFR3  mutation  caused  skin  papilloma  and  promoted  lung 
tumourigenesis in cooperation with K-Ras and β-Catenin activation, respectively.  198 
 
All these results demonstrate that deregulated Wnt signalling plays a critical role in driving 
bladder cancer formation, in combination with activation of proto-oncogenes such as Ras (but 
not Fgfr3) and loss of tumour suppressor genes such as PTEN and p21. I also demonstrated 
that activation of FGFR3 can cooperate with other mutations to drive tumourigenesis in a 
context  dependent  manner  and  support  the  hypothesis  that  activation  of  FGFR  signaling 
contributes to human cancer. Interestingly there was no single mutation that drove UCC, in 
contrast to the intestine, where mutation to Apc is seen as the key driving tumourigenesis 
(Polakis,  2000a).    It  appears  that  bladder  cancer  is  a  more  progressive  disease,  requiring 
combinations of mutation to drive the neoplastic phenotype. 
Although  these  models  recapitulate  various  aspects  of  UCC,  no  one  model  has  yet 
recapitulated all stages from pre-invasive disease to metastasis.  So we ask ourselves the 
question how we can improve these models and make them more relevant.  One avenue I am 
currently actively pursuing is modeling loss of wildtype p53/mutation of p53 in combination 
with out Wnt based cancer models to observe whether this will drive metastatic disease as in 
other  tumours.    We  are  also  considering  using  intravesical  carcinogen  treatments  to 
investigate whether this will cooperate with the transgenic mutation found in our mice to 
drive muscle invasive UCC. 
Recent sequencing of human UCC by the Sanger Institute in Cambridge is reassuring and 
demonstrates  that  these  mutations  we  are  modelling  in  the  mouse  are  indeed  relevant  in 
human UCC. 
(http://www.sanger.ac.uk/perl/genetics/CGP/cosmic?action=byhist&ss=bladder&sn=urinaryra
ct&s=3).    Indeed  it  has  demonstrated  that  APC  mutations  occur  about  11%  of  tumour 
samples, confirming it is an important mutation in UCC.  Further work must be done, in 
particular  on  the  aggressive  muscle  invasive  tumours  and  their  metastasis  to  properly 199 
 
delineate which mutations are contributing to their malignant phenotype.  Then one can better 
model human conditions in the mouse.  Since bladder tumourigenesis in humans requires 
genetic events in a temporal sequence, the next generation of murine models will be inducible 
systems, allowing us to switch on and off genes in a bladder specific manner at different time 
periods, in different sequences and to different levels, enabling us better understand what is 
occurring in the human.  This in turn will allow us to better target treatment at a molecular 
level, initially in the murine model, and ultimately translatable into man. 
The models I describe will provide ideal platforms for trialling of Wnt pathway inhibitors, 
most likely in combination with MAPK/PI3K inhibitors, to assess tumour response.  This 
makes  it  important  to  be  able  to  identify  the  Wnt  dependents  tumours.    This  type  of 
preclinical trialling is essential, since in the clinic cancer patients are moving towards more 
personalised medicine, where their treatments will be based on the unique molecular signature 
of their tumours. 
In summary murine models will continue to provide us with invaluable information about 
tumour biology, initiation and progression and ultimately identification of molecular markers, 
and  further  elucidation  of  molecular  pathways.    These  models  will  allow  for  preclinical 
studies regarding efficacy and tolerability of various anticancer agents in isolation and in 
combination, as well as assessment of ultimate response.  This will ultimately allows us to 
translate  these  findings  to  the  clinical  setting  allowing  us  to  prognosticate  and  ultimately 
render cancer patients disease free. 
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